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ABSTRACT 
Aderonke Aramide Akinkugbe: Periodontal Origins of Non-alcoholic Fatty Liver Disease 
(Under the direction of Gerardo Heiss and Gary D. Slade) 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease and the 
hepatic component of the metabolic syndrome. Estimated to affect 17-33% of U.S. adults, its risk factors 
include insulin resistance and obesity each putatively acting through chronic low-grade systemic 
inflammation. These risk factors are associated with periodontitis, a chronic oral disease affecting about 
45% of U.S. adults. Periodontitis is reported to cause a state of chronic low-grade systemic inflammation. 
The relationship between periodontitis and NAFLD was investigated using longitudinal data from 2,623 
participants of the Study of Health in Pomerania. Potential effect measure modification of this association 
by inflammatory markers was also assessed. Periodontitis was defined as: 1) proportion of periodontal 
sites with clinical attachment level (CAL) of ≥3mm (0%, <30%, ≥30%); 2) proportion of sites with 
probing pocket depth (PD) of ≥4mm (0%, <30%, ≥30%). Worsening periodontitis was defined as ≥2mm 
increase in mean CAL between study visits. Incident NAFLD was defined as a significant increase in 
liver echogenicity on ultrasound relative to the kidneys, with the diaphragm indistinct OR the echogenic 
walls of the portal veins invisible. Thresholds for elevated alanine aminotransferase indicative of NAFLD 
were >34.2 U/L for men and 24 U/L for women. Serum CRP was used as a proxy for inflammatory 
markers. Single nucleotide polymorphisms previously identified through genome-wide association studies 
as robustly associated with serum CRP were combined into a weighted genetic CRP score (wGSCRP). 
After a median 7.7 years of follow-up, 605 incident cases of NAFLD accrued at a rate of 32.5 cases per 
1,000 person-years. Compared to participants with a healthy periodontium, participants with ≥30% of 
sites with CAL of ≥3mm had multivariable-adjusted incidence rate ratio (IRR) of 1.60; 95% CI, 1.05-
iv 
 
2.43. The corresponding IRR for participants with <30% of sites with PD ≥4mm was 1.53; 95% CI, 1.00-
2.35. Worsening periodontitis was likewise associated with greater NAFLD incidence, although only in 
participants with pre-existing periodontitis. While the wGSCRP was not a modifier (Pinteraction=0.8), serum 
CRP was a significant modifier (Pinteraction=0.01) of the periodontitis-NAFLD association. Consideration 
should be given to periodontitis in the prevention and management of NAFLD. 
 
 
 
 
 
  
v 
 
 
In loving memory of David A. Akinkugbe 
 
 
  
vi 
 
 
ACKNOWLEDGEMENTS 
 
 
I am thankful to my dissertation committee for their help in making this project a reality. To my 
doctoral dissertation chair- Dr. Gerardo Heiss, thank you for your patience and kindness this past 4 years. 
Even when this project was just an idea, you thought it was a good one and encouraged me to pursue it. 
For the numerous emails we exchanged and, meetings we had to discuss this project, thank you. You 
responded to emails very promptly and provided constructive feedback and edits on several drafts of this 
work to make it what it is in its current state.  
To Dr. Gary Slade, thank you for also encouraging me to pursue this project and for supporting 
my decision to write this project to receive funding from the NIH. Thank you for the countless times that 
we met to discuss this project and for your input every step of the way. Throughout the 5 years that I have 
been your mentee, you have allowed me to spread my wings and think for myself. This allowed me to 
pursue other research interests that I had which led to collaborations on projects with you and other 
faculty members.  
To Dr. Stephen Cole, thank you for agreeing to be on my doctoral committee. Having you on my 
committee was invaluable and I thank you for your methodological expertise at every step. You raised 
thought provoking questions that allowed me to think critically about how I was implementing a 
particular method. Your feedbacks were invaluable and they greatly enhanced this work. To Dr. Christy 
Avery, it has always been a pleasure working with you, from been one of your teaching assistants and 
having you on my committee, you provided invaluable insights for my data analysis and, I take this 
knowledge with me for future work.  
To Dr. Sidney Barritt. I knew it would be a great pleasure to work with you right from the time I 
met you. I was just another 2nd year doctoral student looking for a mentor in gastroenterology and you 
vii 
 
stepped up to the plate and showed great excitement when I discussed what I was planning to work on. 
Your comments and input greatly improved this work and I thank you for that. I really do hope there are 
opportunities for us to collaborate on other projects in the future. 
To my general epidemiology methods teachers-Drs. Charles Poole, Steve Marshall, David 
Richardson, Steve Cole and Christy Avery. Thank you for the invaluable knowledge you imparted to me. 
I learned invaluable lessons from sitting in your classrooms. Especially to Dr. Charles Poole, your 
teachings have greatly inspired me to becoming the epidemiologist that I am today. Thank you for 
believing in me and trusting me to be a teaching assistant for your methods course, I do not take this 
opportunity lightly and it was one of the greatest honors of my life to work with you in this capacity. I 
enjoyed every single one of your classes and they greatly enhanced who I am today as an epidemiologist. 
Your thought provoking insights I will carry with me for a long time to come. Thank you! I am thankful 
to the UNC Chapel Hill CVD group for providing me access to CERES remote server, which allowed me 
to run my multiple imputation algorithm with ease and in record time. 
To my family, especially to my mom-Florence Akinkugbe and my grandmother-Felicia Akinsiku, 
thank you for your prayers. I knew I could count on the fact that you were praying for me and that kept 
me going in spite of any odds. And grandma, this is it, no more schooling for me☺.  
To my friends – Gandarvaka (Gigi), Eboneé, Terra, Shelly-Ann and Veeral. Thank you for being 
there every step of the way in the good times and the not so good times. For your encouragements and 
humor thank you. I truly would have struggled without supportive friends like you all. Especially to Gigi, 
you are unarguably one of the wisest people I’ve been fortunate enough to have met. Your wisdom 
surpasses your years and I’m thankful to have known you. 
To Drs. Anne Sanders, Kimon Divaris and Jim Beck, your offices were always open for me to 
pop in and ask questions. I thoroughly enjoyed working on research projects with each one of you. The 
invaluable insights I gleaned from those collaborations will stay with me for a long time. Especially to Dr. 
Anne Sanders, thank you for being my friend this past 5 years and for all of the insights you gave me 
viii 
 
about work-life balance and career development. I cherished all of our time together and hold them dear 
to my heart.  
I am extremely thankful to the National Institute of Health NRSA T90 Training Grant NIH/ 
NIDCR (5T90DE021986) that funded the first three years of my doctoral training and to the National 
Institutes of Health/ National Institute of Dental and Craniofacial Research (Grant number: 
R03DE025652-01A1) that funded my doctoral dissertation. Having these funds allowed me to single- 
mindedly pursue my doctoral dissertation research with little distractions or worrying about funding.  
Finally, I am immensely grateful to the participants of the Study of Health in Pomerania without whose 
participation my doctoral dissertation may not have been possible. 
 
 
  
ix 
 
 
PREFACE 
 
 
Chapter 1 provides relevant background information for the exposure of interest (periodontitis). 
Chapter 2 provides relevant background information for the outcome of interest (non-alcoholic fatty liver 
disease). Chapter 3 describes historic relationships between oral diseases and systemic conditions, while 
Chapter 4 focuses specifically on current evidence (experimental animal and human studies) suggesting 
likely associations between periodontitis and liver diseases. Chapter 5 describes inflammation and the 
hyper-inflammatory processes. Study rationale and specific aims are described in Chapters 6 and 7, 
respectively. Research methods are described in Chapter 8, while Chapter 9 describes the statistical 
analysis methods. Chapters 10 and 11 are the manuscripts produced from this investigation. These two 
chapters are intended to stand alone as manuscripts for submission for peer review publication and thus 
have similarities with earlier chapters. Chapter 12 provides an overall discussion and summary of findings 
from this investigation, with concluding remarks and implications of our findings. 
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE OF PERIODONTITIS 
1.1 Definition and pathophysiology of periodontitis 
Periodontitis is an oral disease recognized as a major cause of tooth loss among adults in the U.S. 
(Burt and Eklund 2005; Eklund and Burt 1994). Estimated to affect 45% of U.S. adults (Eke et al. 2015; 
Eke et al. 2012b; Papapanou 2012), periodontitis is characterized by gingival pockets and periodontal 
attachment loss resulting from gradual destruction by periodontal pathogens of periodontal tissues and 
supporting alveolar structures. 
1.1.1 The oral environment  
The oral cavity is made up of the teeth with its supporting alveolar structures, gingiva attachment, 
the tongue, the soft and hard palate. With a mean surface area of 214.7cm2 (Collins and Dawes 1987), and 
a dentogingival surface area (i.e. sulcular, junctional and pocket epithelial areas) of 1-44cm2 (mean: 8-20 
cm2) (Hujoel et al. 2001), the oral cavity provides a large surface area for microbial colonization with 
majority of species reported to selectively colonize periodontal pockets, dorsum of the tongue and the 
hard palate (Paster et al. 2006). Close to 700 species (Paster et al. 2006) of bacteria identified in the oral 
cavity exist in a relatively stable state of bacterial homeostasis (Marsh 2006) and, about 100-200 different 
combinations of bacteria are present in a person at any given point in time although with wide inter-
individual variation (Paster et al. 2006). Specific to the periodontium, Socransky et al., described clusters 
of bacteria species based on similarities and differences in nutritional and atmospheric environment 
(Figure 23). They described the blue (Actinomyces species); purple (V. parvula, A. odontolyticus);  
yellow (Streptococcus species); green (E. corrodens, C. gingivalis);  orange (P. intermedia, P. nigrescens); 
and red (P. gingivalis, T. forsythia, T. denticola) microbial complexes (Socransky et al. 1998). Members 
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of the red complex in particular are reported to be associated with severity and progression of 
periodontitis (Sekot et al. 2011; Socransky and Haffajee 2005).  
Following tooth brushing, a protein film (i.e. acquired pellicle) selectively binds salivary 
glycoproteins and prevents continuous deposition of salivary calcium phosphate unto the tooth surface to 
protect the tooth from bacterial by-products. Later dental plaque—a structurally and functionally 
organized biofilm (Marsh 2006) begins to form on the pellicle. This ordered community of microbes 
embedded in a glycocalyx and derived from the host and bacteria (Marsh 2004; Socransky and Haffajee 
2002), has a composition that remains relatively stable overtime (Marsh 2006). Because the oral cavity is 
constantly bathed in saliva, it is suitable for biofilm formation and the microbial content of biofilm differ 
in complexity between individuals with respect to location, genetics and environment. Biofilms comprise 
three components, surface to be colonized, the biofilm community (i.e. bacteria) and the bulk fluid which 
bathes the biofilm, provides nutrients, removes waste and transport colonizing microbes (Socransky and 
Haffajee 2005). Pioneer microbes are first to colonize plaque, altering the habitat and making it suitable 
for other microbes to succeed (Ritz 1967; Socransky et al. 1977; Zee et al. 1996). Succession of microbes 
in plaque occurs in two ways: autogenic and allogenic succession. In autogenic succession, the microbial 
environment is altered in such a way that it is no longer suitable for the current species and therefore, has 
to be replaced by species better suited to the modified habitat. Allogenic succession occurs when factors 
other than microbial changes the physical and chemical attributes of the host (Socransky and Haffajee 
2005). 
1.2 Natural history and pathogenesis of Periodontitis 
1.2.1 Periodontal destruction, gingivitis, periodontitis and host response 
The tooth-gingival interface is subject to innate host defense mechanisms including periodic 
shedding of epithelial cells, cleansing brought about by saliva and gingival crevicular fluid as well as 
continuous migration and phagocytic action of neutrophils via the junctional epithelium into the gingival 
sulcus (Genco and Williams 2010). It was previously thought that periodontitis was a consequence of 
aging with level of destruction directly correlated with plaque levels. However, extensive research has 
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shown that plaque initiates periodontitis but its severity and progression is determined mainly by host 
response to plaque bacteria (Genco and Williams 2010; Socransky and Haffajee 2005). This is especially 
the case for aggressive periodontitis where plaque levels correlate poorly with severity of periodontal 
destruction (Armitage 1999; 2004; Lang and Löe 1993). Host response is therefore modified by factors 
such as genetic (familial aggregation of aggressive periodontitis) (Hart and Kornman 1997; Page 1998) 
and environmental/behavioral (diabetes and smoking) factors (Chapple and Genco 2013). 
The relatively large periodontal pocket dentogingival surface area provides abundant habitat for 
bacteria colonization and recolonization. Indeed more than 400 bacteria species have been reported to 
reside in sub-gingival plaque alone (Socransky et al. 1998). Tannerella forsythia, a member of the red 
complex possesses a glycosylated S-layer that delays recognition by the cellular immune response (Sekot 
et al. 2011). Likewise, Porphyromonas gingivalis produces specific proteolytic enzymes that allows for it 
to evade and delay host immune response (Genco et al. 1999), further enhancing destruction of 
periodontal attachment in the susceptible host. The host response to bacteria plaque is essentially 
protective with the potential to become adverse in the susceptible host. This is because cytokines although 
involved in a variety of physiological processes are also able to induce pathology if expressed 
inappropriately (Graves and Cochran 2003). The initial host response starts with the production of pro-
inflammatory cytokines and enzymes. Classic to the inflammatory process, metabolic bacteria products 
(especially bacteria endotoxins) stimulate proliferation of the junctional epithelium, produce tissue 
destructive proteinases and increase permeability of microbes and their byproducts to the sub-epithelial 
connective tissue. This action stimulates the connective tissue to produce inflammatory mediators (IL-1, 
TNF-alpha) leading to an influx of polymorphonuclear leucocytes (PMN). PMN, engulf bacteria and the 
signs of acute gingival inflammation (i.e. gingivitis) become apparent. In the non-susceptible host, this 
primary defense mechanism controls the infection. However, in those susceptible to periodontitis, the 
inflammatory process extends apically and laterally to involve deeper connective tissue structures and the 
alveolar bone. The bacterial endotoxin further facilitates the recruitment of monocytes and lymphocytes 
(Page 1998; Pihlstrom et al. 2005; Yucel-Lindberg and Bage 2013) and, the host in turn produces high 
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levels of prostaglandins (PG), interleukins (IL-1, IL-6), TNF-alpha and, matrix metalloproteinase (MMP). 
MMP breaks down periodontal ligaments, which are collagen fibers, thereby disrupting the normal 
periodontal anatomy. With persistent inflammation, high levels of PGs, ILs and TNF-alpha stimulates 
osteoclasts to resorb the alveolar bone (Graves and Cochran 2003). Elevated levels of pro-inflammatory 
cytokines are counterbalanced by anti-inflammatory mediators (IL-4, IL-10) and tissue inhibitors of 
MMP. Under healthy conditions, the anti-inflammatory and pro-inflammatory mediators are balanced 
thereby controlling tissue destruction. However, in the presence of excessive pro-inflammatory reactions, 
there is loss of periodontal attachment and alveolar bone. In people with periodontitis, the continued 
inflammatory process allows for the inflammatory mediators — cytokines and prostanoids and local oral 
bacteria to enter the systemic circulation, thereby inducing a state of bacteremia (Schenkein and Loos 
2013) characterized by high levels of circulating C-reactive protein, an acute phase reactant reported to be 
associated with cardiovascular diseases and diabetic complications (Schenkein and Loos 2013; Slade et 
al. 2000). In summary, periodontal pathogens invade periodontal tissues causing, loss of epithelial 
integrity within the periodontal pocket which then creates ample opportunity for direct bacterial 
translocation and systemic bacteremia (Beck et al. 1996). 
1.3 Classification of Periodontitis 
Periodontal diseases are chronic infections of the gingiva, periodontal ligament and alveolar bone. 
They include two broad categories based on whether there is associated loss of periodontal attachment 
and alveolar bone: gingivitis and periodontitis. Gingivitis is a reversible plaque-induced inflammation of 
the gingiva characterized by bleeding on probing (BOP), but without a corresponding loss of periodontal 
attachment and/or alveolar bone (Armitage 1995; Page and Eke 2007; Pihlstrom et al. 2005). In contrast, 
periodontitis is a biofilm-initiated infectious disease that induces an inflammatory cascade resulting in 
host-mediated destruction of periodontal tissues (Graves and Cochran 2003; Pihlstrom et al. 2005), which 
manifests clinically as loss of periodontal attachment. 
Various identification methods for periodontitis have been put forth and continue to evolve For 
instance, the classification of periodontal diseases by the American Academy of Periodontology (AAP) 
 5 
 
went from 2 broad categories in 1977 to four in their 1986 classification (Wiebe and Putnins 2000). In 
1989, another classification scheme that added a category for periodontal manifestation of systemic 
diseases was put forth by the AAP (Wiebe and Putnins 2000). At about the same time, a classification 
scheme was also put forth at the first European workshop on periodontology in 1993 (Attstrom and 
Vandervelden 1994). In spite of improvements in terminology and classification schema, inability to 
categorize all affected persons, and the dependence of classification and disease progression on age 
(Armitage 1999; Wiebe and Putnins 2000) made these disease classifications hard to implement for 
research purposes. To this end, an update was developed at the 1999 international workshop for a 
classification of periodontal diseases and conditions (Armitage 1999). The 1999 classification improved 
considerably on terminology and categories for periodontitis. Specifically, measures of severity and 
extent were included and defined as: localized periodontitis - ≤30% of sites affected, and extensive 
periodontitis- >30% of sites affected for extent while severity was classified as slight - 1-2 mm of clinical 
attachment level (CAL), moderate - 3-4 mm CAL and severe ≥5mm CAL (Armitage 1999). Other 
manifestations of periodontitis are used in some classification schemes, including probing pocket depth 
(PD), radiographic pattern and extent of alveolar bone loss, as well as BOP or a combination of these 
measures (Armitage 2004; Page and Eke 2007). However, not all of these measurements can be 
implemented in population-based studies.  
Clinical attachment level provides an indication of lifetime history of periodontitis while PD 
provides an indication of current disease activity (Armitage 2003; Greenstein 1997). Therefore, it has 
been argued that measurement of CAL and PD at different sites and on different teeth are needed to 
classify individuals as having periodontitis (Page and Eke 2007). This is because both gingival recession, 
and PD contribute to measures of CAL (Page and Eke 2007), so when CAL results from greater gingival 
recession than PD (Baelum et al. 1988; Yoneyama et al. 1988), the accuracy of measuring severity and 
extent of periodontitis using CAL only is at best modestly successful (Beck et al. 1997a; Beck et al. 1994; 
Beck et al. 1997b; Page and Eke 2007). Likewise, the use of only measures of PD to characterize 
periodontitis especially in older individuals can be misleading and result in an underestimate of disease 
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severity. Given that CAL progresses with time, as gingival recession occurs, measures of PD fail to keep 
pace with increasing levels of CAL (Albandar et al. 1999; Eke et al. 2012a; Holtfreter et al. 2009; Page 
and Eke 2007). For these reasons, a case definition that incorporates both of these measures may be 
preferred. 
Periodontitis case definitions for U.S. national surveys have progressed from the Russell 
periodontal index that assumes gingivitis progressed to periodontitis and uses a scale ranging from 0 
(healthy gingiva) to 8 (severe attachment loss) to definitions that incorporate quantitative measures of PD 
and CAL such as ≥3mm of CAL and PD of ≥3mm at ≥1 sites (Albandar et al. 1999; Brown et al. 1990; 
Page and Eke 2007) used in NHANESIII. Threshold for defining a case is critical because relatively small 
changes in measures of PD and CAL can adversely affect disease prevalence (Brown et al. 1990). In their 
position paper, the AAP stated “thresholds for CAL, PD or both at a given site should demonstrate 
unequivocal evidence at such sites as well as document the number such sites needed to establish disease” 
(Burt 2005). In 2003, the CDC and AAP appointed a working group to further standardize the clinical 
case definition for periodontitis for surveillance and population-based studies. This classification uses 
thresholds for PD and CAL and takes into account the number of affected sites when determining 
prevalence (Page and Eke 2007). Because the CDC-AAP definition assesses only interproximal sites, it 
takes advantage of the fact that disease begins and is most severe at interproximal sites. It also minimizes 
misclassification of gingival recession due to mechanical factors (e.g., toothbrush abrasion) that do not 
signify periodontitis. The 2003 CDC-AAP case classification for moderate-severe periodontitis was 
updated in 2012 to include a ‘mild category’ (Eke et al. 2012a; Eke et al. 2012b) and uses the following 
taxonomy (Table 16). 
• Severe periodontitis: two or more interproximal sites (not on the same tooth) with CAL of ≥6 mm 
AND one or more interproximal sites with PD ≥5 mm 
• Moderate periodontitis: two or more interproximal sites (not on the same tooth) with CAL of 
≥4mm OR two or more interproximal sites (not on the same tooth) with PD of ≥5mm 
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• Mild periodontitis: two or more interproximal sites (not on the same tooth) with CAL of ≥3mm 
AND [two or more interproximal sites (not on the same tooth) with PD ≥4mm OR ≥1 site with 
PD ≥5mm] 
• Healthy periodontium: individuals not meeting any of the above criteria. 
The CDC-AAP classification assesses the severity of periodontitis by counting the number of 
interproximal sites affected. It however, fails to take into account the fact that the number of teeth at any 
given point in time between individuals are not the same, as this will affect the disease category a person 
is placed in. Therefore, also incorporating classification schema that considers instead the proportion of 
remaining sites affected minimizes this limitation (Carlos et al. 1986).  
In the interest of a well-rounded review of periodontitis case identification methods, competing 
case classifications will be described briefly. First is the two-level periodontitis case definition put forth at 
the 2005, 5th European workshop on periodontology. This definition incorporates both severity and extent 
of sites affected. The first category requires interproximal attachment level of ≥3mm in ≥2 non-adjacent 
teeth and the second requires interproximal attachment level of ≥5mm in ≥30% of teeth present. The first 
category although very sensitive is prone to high false positives while the second category, although 
specific, is subject to high false negatives (Tonetti and Claffey 2005). 
In 2007, the Biofilm Gingival Interface (BGI) was put forth (Offenbacher et al. 2007). This 
classification considers the subclinical biology of the processes involved in the complex interaction of 
biofilm with host inflammatory and immune responses and so uses only PD and BOP measures. The 5-
level BGI classification is thus: 
• BGI-Healthy- all PD ≤3mm and <10% BOP 
• BGI-Gingivitis- all PD ≤3mm and ≥10% BOP 
• BGI-Deep Lesion (DL)/Low Bleeding - ≥1 site with PD ≥4mm and BOP <10% 
• BGI-DL/Moderate Bleeding - ≥1 site with PD ≥4mm and BOP between 10% and <50% 
• BGI-DL/Severe Bleeding - ≥1 site with PD ≥4mm and BOP ≥50% 
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1.4 Epidemiology of Periodontitis 
1.4.1 Person, place and time 
Data from the United States and across the world have used a variety of partial mouth 
examination protocols for the surveillance of periodontitis. Given tooth sites affected by periodontitis are 
not equally distributed in the mouth, these partial mouth protocols have been reported to severely 
underestimate both the prevalence and severity of periodontitis (Beck et al. 2006; Eke et al. 2010; 
Kingman and Albandar 2002; Kingman et al. 2008; Susin et al. 2005). In addition to concerns of 
underestimated prevalence from partial mouth protocols, is the use of different case definitions to identify 
periodontitis. Indeed, prevalence ranging from 14-65% was reported in a population based study using 
different thresholds to define a periodontitis (Costa et al. 2009). With these caveats, the descriptive 
epidemiology of periodontitis is discussed in terms of person, place and time. 
Age reflects biological and social processes of aging internal to the individual and developmental 
changes over the life course. Prevalence of periodontitis has been reported to increase with age both in the 
U.S and elsewhere (Dye et al. 2007; Holtfreter et al. 2009), leveling off at about the 4th and 5th decade of 
life and increasing thereafter (Holtfreter et al. 2009). Although it appears that some form of mild 
attachment loss (at most 2mm) is widely present in the population, in cross-sectional surveys, prevalence 
of moderate-severe periodontitis, with moderate disease defined as attachment level of ≥4mm and severe 
disease as attachment level of ≥ 6mm, has been reported to increase with age while no tangible 
relationship between age and pocket depth has been reported (Albandar et al. 1999; Eke et al. 2012a; 
Holtfreter et al. 2009). This gives credence to the fact that CAL is a measure of cumulative disease while 
PD is a measure of current disease activity and is able to fluctuate over time irrespective of age.  
Women were initially thought to have greater prevalence of periodontitis compared to males but 
this has been attributed to detection bias because of relatively greater dental care seeking behaviors 
among women. Recent prevalence data show greater estimates among males both in the United States 
(Eke et al. 2015; Eke et al. 2012a) and elsewhere (Holtfreter et al. 2009), mostly because females are 
thought to have better oral hygiene practices than males. With regards to race-ethnicity, Blacks and those 
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of Hispanic origin are reported to carry a higher burden of periodontitis. Cautious interpretation of these 
estimates is however warranted given that racial categorization is technically not a biologically 
determined classification (Marshall 1998), but a product of social and political factors (Kaufman and 
Cooper 2001). Thus, higher prevalence of periodontitis among racial-ethnic minorities (Borrell and 
Papapanou 2005; Eke et al. 2012a), is attributed to differential access to dental care, an indication of 
social position in the society. Accordingly, there is socio-economic disparity in periodontitis distribution 
with more affluent and, those with higher education having lower prevalence compared to low income 
and, less educated individuals (Eke et al. 2015; Eke et al. 2012a). The SES disparity and differential 
access to dental care also explains the differing disease burden between high- and low-income countries 
(Burt and Eklund 2005). 
The major person level risk factor for periodontitis that has consistently been identified is 
cigarette smoking (Hujoel 2003; Tomar and Asma 2000). Current smokers have higher prevalence of 
periodontitis compared to former and never smokers with a dose response decrease in prevalence with 
increasing duration of time since smoking cessation. Hujoel et al., projected a 68% (range: 46-81%) 
decrease in incidence of advanced periodontitis by 2020 from its level in 1955 should smoking be 
eliminated (Hujoel et al. 2003) i.e. a preventative fraction. Indeed, the reduction in the gender, SES, and 
country disparities in smoking at the turn of the century due to increasing smoking prevalence among 
females, low income persons and countries, has contributed to the higher prevalence of periodontitis in 
these groups (Hujoel et al. 2003). Smoking (to a large extent) and factors like genetic predisposition (to a 
lesser extent) currently account for major variations in prevalence of periodontitis.  
Although oral hygiene appears to be a person level factor, it has not been consistently reported to 
affect the burden of periodontitis (Amarasena et al. 2002; Merchant et al. 2002). Good oral hygiene 
practices affect dental plaque levels but not host response to plaque bacteria. While dental plaque levels 
correlate positively with gingivitis, it’s in periodontitis is less straightforward. Other location level factors 
besides country relate to policies at the societal level and their effects on periodontitis prevalence over 
time. For example, the ban on smoking practices in public places (the clean indoor air act) and excise tax 
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on tobacco products have been shown to affect prevalence of periodontitis (Sanders and Slade 2013). 
Indeed, non-smokers exposed to environmental tobacco smoke (ETS) have higher prevalence of 
attachment loss compared to non-smokers unexposed to ETS (Akinkugbe et al. 2016b). 
Temporal trends in the epidemiology of periodontitis relate to time period and birth cohort 
effects. Time period effects refer to variation over calendar years that affect all age groups simultaneously 
while birth cohort effects, refer to variation among groups born in different years. Birth cohort effects 
closely align with time period effects and a better understanding of the etiology of periodontitis with the 
passing of time has improved its preventive management and correspondingly affected its prevalence over 
time. In the periodontal literature however there is a dearth of valid secular trend data regarding 
periodontitis prevalence, mostly due to changing examination protocols over time (Demmer and 
Papapanou 2010). Accounting for period and cohort effects, multiple simultaneous population surveys 
showed a declining prevalence of periodontitis in the same age groups with each successive time period, 
even though older individuals were more likely to have the disease than younger individuals (Dye et al. 
2007). Although not directly comparable because of the differing partial examination protocols, data from 
the 1988-1994 and 1999-2004 NHANES, showed a decline in the prevalence of CAL ≥6mm among 20-
64 year olds from 8.4% to 5.3% (Dye et al. 2007). On the other hand, the most recent data from the 
United States (NHANES 2009-2012) based on a full mouth periodontal examination reported a 25.5% 
prevalence of periodontitis based on having CAL of ≥6mm for those ≥30 years (Eke et al. 2012a) and a 
14.7% prevalence of severe CAL of ≥7mm (Eke et al. 2015). Likewise, among U.S. adults 65 years and 
older, prevalence of moderate or severe periodontitis was reported to be 26% and 17% in NHANESIII 
and NHANES 1999-2004 respectively, while the 2009-2010 NHANES estimate in this same age group 
was 64% (Eke et al. 2012a). Thus, cautious interpretation should be given to the previously suggested 
decrease in periodontitis burden with time. Despite the substantial between-study variation in reported 
burden of periodontitis, a systematic review of periodontitis prevalence found that estimated disease 
prevalence across population corroborate the well-established notion in the periodontal literature that men 
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experience more disease than women and, that prevalence increases with age (Demmer and Papapanou 
2010). 
1.5 Public health impacts of Periodontitis 
1.5.1 Impact of periodontitis on quality of life 
Using the oral health impact profile and the oral health quality of life-UK instruments, and self-
reports, studies have reported positive associations between periodontitis and poor oral health related 
quality of life measures (Brennan et al. 2007; Durham et al. 2013; Marino et al. 2008; O'Dowd et al. 
2010) in the functional, physical (pain), psychological, and social (aesthetics, halitosis) (Durham et al. 
2013; Marino et al. 2008) domains. As expected, periodontal therapy was associated with improved 
OHQoL measures (Saito et al. 2011). Poor periodontal health was reported to negatively affect general 
health related quality of life measures in the physical and mental health domains of quality of life 
(Durham et al. 2013; Marino et al. 2008). Likewise, a cross-sectional study of middle aged adults, found 
periodontal disease to be associated with poorer cognitive measures (Naorungroj et al. 2013), while no 
meaningful relationship with 8-year cognitive decline was observed in the same population (Naorungroj 
et al. 2015). Tooth-loss, considered to be the true clinical endpoint of periodontitis (Hujoel 2004), was 
reported to have a modest negative impact on the 8-year change in cognitive health, specifically, word 
fluency and delayed word recall (Naorungroj et al. 2015).  
1.5.2 Impact on systemic health and health outcomes 
Periodontal pockets, harbor endotoxins, lipopolysaccharides and proinflammatory cytokines 
(Gurav and Jadhav 2011; Page 1998; Page and Schroeder 1976; Yucel-Lindberg and Bage 2013), with the 
propensity to induce low-grade systemic inflammation (Chapple and Genco 2013; Daly et al. 2001; 
Kinane et al. 2005; Loos 2005; Loos et al. 2000; Pussinen et al. 2004) when released into the circulation. 
Release of these inflammatory mediators could be in response to periodontal therapy (Daly et al. 2001; 
Kinane et al. 2005), or gentle mastication in the severely affected periodontium (Geerts et al. 2002). 
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However, a recent systematic review of 12 studies found tooth brushing but not chewing to induce 
transient bacteremia (Tomas et al. 2012).  
Periodontitis has been linked to systemic health conditions like cardiovascular diseases (Beck et 
al. 1996; Beck and Offenbacher 2001; Beck et al. 1998). A clinic based study of public and private dental 
practices found individuals with periodontitis to more likely have co-morbid health conditions like 
bronchitis, hepatitis, hypertension and diabetes (Georgiou et al. 2004). A systematic review of the 
association between oral health and systemic health found periodontitis to be related to diabetes, 
cardiovascular diseases, and adverse pregnancy outcomes even after adjustments for age, gender and oral 
hygiene practices (Li et al. 2000). Non-surgical treatment of periodontal disease comprising scaling and 
root-planning, without antibiotic adjuvants was associated with a decrease in elevated white cell count 
(Christan et al. 2002), and proinflammatory cytokines (D'Aiuto et al. 2004), suggesting an association 
between CP and elevated levels of inflammatory mediators. 
1.6 Risk factors for Periodontitis 
Numerous risk factors have been reported for periodontitis, some of which have consistently 
shown strong positive associations. Among factors strongly associated with periodontitis is age. Although 
not strictly a disease of aging, periodontitis more likely affects older compared to younger individuals 
(Albandar et al. 1999; Borrell and Papapanou 2005; Eke et al. 2015). In addition, severity of periodontitis 
is worse among older individuals. The most important risk factors relevant to this project are discussed 
below: 
1.6.1 Smoking  
Smoking is a modifiable lifestyle factor that has been linked both cross-sectionally (Do et al. 
2008; Susin et al. 2004; Tomar and Asma 2000) and longitudinally (Thomson et al. 2007) to periodontitis 
prevalence, severity and progression. Indeed, national surveys from Brazil, Australia and the United 
States have reported smoking population attributable fraction estimates for periodontitis of 12% (Susin et 
al. 2004), 32% (Do et al. 2008) and 42% (Tomar and Asma 2000). And an estimate as high as 67% was 
reported in a follow-up birth cohort in New Zealand (Thomson et al. 2007). These high PAFs have great 
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public health implications and are in line with the well-established biological effects of smoking on the 
periodontium. Specifically, cigarette smoke interferes with vascular and immune reactions, suppressing 
normal gingival inflammatory response and the subtle signs of inflammation. Because gingival reaction 
appears late in the disease process, any associated destruction of the supporting alveolar structure is only 
evident late in the disease process (Bergstrom 2004). Studies have shown that gingival inflammatory 
response among smokers gradually returned to normal levels seen in non-smokers after smoking cessation 
(Morozumi et al. 2004; Nair et al. 2003). Even though no meaningful difference in oral microbial 
composition is apparent for smokers and non-smokers, because smokers are more likely to have deeper 
periodontal pockets and, because deep pockets are more likely to be colonized than shallower ones, 
microbial colonization occurs more frequently and, at greater proportions among smokers than non-
smokers (Bergstrom 2004), thus further aggravating periodontitis in smokers. 
1.6.2 Diabetes  
Diabetes is an established risk factor for periodontitis prevalence, severity and progression 
(Mealey and Oates 2006; Taylor and Borgnakke 2008). Likewise, severity of periodontitis appear to 
influence glycemic control and the development of diabetic complications (Lalla and Papapanou 2011), 
both in cross-sectional (Georgiou et al. 2004) and longitudinal (Demmer et al. 2008; Ide et al. 2011; 
Taylor et al. 1998) studies. In addition, several other studies (Demmer et al. 2008; Georgiou et al. 2004; 
Lalla and Papapanou 2011; Li et al. 2000; Saito et al. 2004; Stewart et al. 2001) have linked periodontitis 
to diabetes and poor glycemic control. In the diabetic state, there is defective neutrophil chemotaxis such 
that accumulation of glucose mediated advanced glycated end-products (AGE) affects migration and, 
phagocytic activity of mononuclear and polymorphonuclear phagocytic cells. This leads to the 
establishment of a more pathogenic sub-gingival flora (Lalla and Papapanou 2011; Li et al. 2000). 
Additionally, impaired gingival collagen and glycosaminoglycan synthesis by fibroblasts enhance 
crevicular fluid collagenolytic activity, which results in destruction of periodontal fibers (Iacono et al. 
1985). Simultaneously, periodontal infection may induce a chronic state of insulin resistance, aggravating 
the cycle of hyperglycemia, nonenzymatic irreversible glycation and AGE-protein binding and 
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accumulation, thereby amplyfying the classical pathway of diabetic connective tissue degradation, 
destruction and proliferation (Li et al. 2000). Hence, the often reported bidirectional relationship between 
diabetes and periodontitis (Chapple and Genco 2013; Demmer et al. 2008; Grossi and Genco 1998; Gurav 
and Jadhav 2011; Kim and Amar 2006; Mealey and Rose 2008; Nishimura et al. 2003; Taylor 2001). This 
bidirectional association potentially induces a vicious cycle through which periodontitis worsens diabetes 
and vice versa (Figure 24). Indeed, there is increased likelihood for impaired glucose tolerance among 
non-diabetics with periodontitis, leading to a state of insulin resistance. 
1.6.3 Insulin resistance  
Insulin resistance is characterized by the inability of organs like the muscles, liver and adipose 
tissues to respond to endogenously produced insulin. Underlying inflammatory mechanisms have been 
reported to contribute to and/or promote insulin resistance. Likewise, insulin resistance may promote 
inflammation by impairing the anti-inflammatory effects of insulin (Dandona et al. 2004; Shoelson et al. 
2006).  Thus, insulin resistance is considered a proinflammatory state (Dandona et al. 2002; Das 2001a; 
Schmidt and Duncan 2003), that is accompanied by elevations in pro-inflammatory cytokines, with TNF-
alpha reported as the most important cytokine involved in the initiation and progression of insulin 
resistance (Dandona et al. 2004; Gurav 2012). Insulin resistance is associated with altered glucose 
tolerance, hypertriglyceridemia, abdominal obesity and coronary heart disease. Because inflammation 
promotes insulin resistance and deregulates glycemia (Hu et al. 2004; King 2008; Pradhan et al. 2001; 
Shoelson et al. 2006), insulin resistance is hypothesized to be a constituent of the causal pathway 
connecting inflammatory mediators to incident diabetes (Dandona et al. 2004; Gurav 2012; Schmidt and 
Duncan 2003). 
The etiology of insulin resistance involves multiple pathways that are crucial to the pathogenesis 
of the metabolic syndrome and type-II diabetes (Gurav 2012). Mouse models (Su et al. 2013; Watanabe et 
al. 2008), have demonstrated causal relations between periodontitis and insulin resistance while 
epidemiologic studies (Allen et al. 2011; Benguigui et al. 2010; Genco et al. 2005; Gurav 2012; Timonen 
et al. 2011) have reported associations linking insulin resistance to prevalent periodontitis. In addition, 
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quartiles of HOMA-IR (a measure of insulin resistance), were reported as associated with both prevalence 
and severity of periodontitis (Benguigui et al. 2010; Genco et al. 2005). In spite of these, it remains 
unclear whether the causal cellular mechanisms linking periodontitis to insulin resistance in animal 
models is also causal in humans.  
1.6.4 Other risk factors  
Others risk factors for periodontitis are obesity, alcohol consumption and oral hygiene practices. 
The etiology of obesity represents a complex interaction of genes, diet, metabolism and physical activity 
(Das 2001b). Obesity is reported to have a weak positive association (Amaral Cda et al. 2009; Palle et al. 
2013; Saito et al. 2001; Saito et al. 1998; Wood et al. 2003) with periodontitis. Systematic reviews and 
meta-analysis report positive associations (Jimenez et al. 2012; Suvan et al. 2011) between BMI and 
periodontitis while a Mendelian randomization of 13 studies reported a weak to no association (Shungin 
et al. 2015). 
Alcohol is documented to have antimicrobial effects and able to confer protections from 
antimicrobial-plaque diseases. As such, invitro (Herrera et al. 2003) and clinical studies (Kongstad et al. 
2008), have reported inverse associations between alcohol consumption and periodontitis. In contrast, 
population based studies have reported both positive and inverse associations with severity and extent of 
periodontitis (Amaral Cda et al. 2009; Jansson 2008; Kongstad et al. 2008; Lages et al. 2012; Nishida et 
al. 2004; Pitiphat et al. 2003; Shimazaki et al. 2005; Tezal et al. 2001; 2004). 
Oral hygiene is reported to be a risk indicator for periodontitis (Amarasena et al. 2002), but this 
finding is not universal (Merchant et al. 2002). While the practice of good oral hygiene affects dental 
plaque levels, good oral hygiene practices does not directly influence person-level response to plaque 
bacteria. An extreme example is localized aggressive periodontitis where good oral hygiene correlates 
poorly with the extent of periodontal destruction. Thus, while dental plaque levels correlates positively 
with gingivitis, its role in periodontitis is less clear (Burt and Eklund 2005). 
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE OF NON-ALCOHOLIC FATTY 
LIVER DISEASE 
 
2.1 Definition and pathophysiology of NAFLD 
Non-alcoholic fatty liver disease (NAFLD) is fatty infiltration in the form of triglycerides into 
hepatocytes exceeding 5-10% of the liver weight (Angulo 2007; Neuschwander-Tetri and Caldwell 2003), 
in the absence of excessive alcohol consumption. Excess hepatic fat is estimated objectively as the 
percentage of fat laden hepatocytes observed under light microscopy (Neuschwander-Tetri and Caldwell 
2003). NAFLD is the most common type of liver disease and the hepatic component of the metabolic 
syndrome (Angulo 2002; Bedogni et al. 2005; Clark et al. 2002; Marchesini et al. 1999). It comprises a 
pathologic spectrum of diseases ranging from simple steatosis, steatosis with lobular inflammation, 
steatosis with lobular inflammation and ballooning degeneration (i.e. Non-alcoholic steatohepatitis 
(NASH) without fibrosis) and steatosis, ballooning degeneration and Mallory bodies with fibrosis (NASH 
with fibrosis) (Farrell et al. 2004). Metabolic conditions like insulin resistance and type-2 diabetes co-
occur in >95% and 85% respectively of individuals who present with NASH (Chitturi et al. 2002; 
Marchesini et al. 2003) and NASH has the potential to progress to cirrhosis and hepatocellular carcinoma 
(Angulo 2002; Clark 2006; Clark et al. 2002; Selmi et al. 2007). 
The National Institutes of Health clinical research network on NAFLD/NASH defines excessive 
alcohol consumption as at most one standard drink per day (70g ethanol/week) for women and 2 standard 
drinks per day (140g ethanol/week) for males (Neuschwander-Tetri et al. 2010). This cut point has been 
widely adopted and was put forth in the first textbook on NAFLD (Farrell et al. 2004). Liberal cut points 
of 30g/day for men and 20g/day for women (Ratziu et al. 2002; Ratziu et al. 2012) have also been used 
although not widely. In addition to this, lifetime alcohol consumption of 100kg, equivalent to 30g/day for 
10 years has also been put forth been relevant to elevations in markers of hepatic inflammation like 
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Figure 1. Increased SOCS proteins induced by proinflammatory 
cytokines can be a common path to components of the metabolic 
syndrome and establish a vicious cycle (Source: Ueki et al. Proc Natl 
Acad Sci 2004) 
  
 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Hayashi et al. 2004). Despite the 
detrimental effects of alcohol when used in excess, low levels of regular alcohol consumption is reported 
to reduce the risk of cardiac events and improve insulin sensitivity in those with type-2 diabetes and the 
metabolic syndrome. And by extension beneficial with respect to delaying NAFLD and, its progression to 
NASH (Farrell and Larter 2006). Given the multifactorial etiology of NAFLD, it has been argued that 
NAFLD might be a non-disease 
(Cassiman and Jaeken 2008) to 
the extent that it does not have a 
single predictable clinical and 
pathologic phenotype or a 
specific therapy. The presence of 
hepatic fat reflects disturbances in 
liver physiology that manifests as 
functional (such as end stage liver 
disease, Hepatocellular 
carcinoma) and structural (fibrosis) complications (Ekstedt et al. 2006; Farrell and Larter 2006; Larter et 
al. 2010; Musso et al. 2010). And while simple steatosis may have a benign course, the mere presence fat 
in the liver, sensitizes the liver to injury from other causes (Neuschwander-Tetri and Caldwell 2003). 
2.2 Natural history and pathogenesis of NAFLD 
The natural history of NAFLD is currently unknown because there have been no longitudinal 
population based studies to elucidate it. Therefore, current knowledge about the initiation and progression 
of NAFLD have mainly been from cross-sectional studies. The pathology of NAFLD progresses from 
simple steatosis, steatosis with lobular inflammation, steatosis with lobular inflammation and ballooning 
degeneration (NASH, without fibrosis) and steatosis, ballooning degeneration and Mallory bodies with 
fibrosis (NASH with fibrosis) (Farrell et al. 2004). Non-alcoholic steatohepatitis is hepatic fat 
accumulation with associated inflammation. It is the pathologic condition that represents the active and 
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progressive form of NAFLD and is not amenable to diagnosis by hepatic ultrasound or elevated 
transaminases but solely by a liver biopsy as of the time of this report. Without a definitive diagnosis 
made by a liver biopsy, all that can be said is that NAFLD is present because, perhaps hepatic fat is 
detected by liver ultrasound and/or elevations in serum transaminase levels after ruling out other causes. 
For this report, reference to NAFLD implies the full spectrum of the disease since biopsies are 
unavailable to definitively stage the condition. Fat accumulation in the liver considered pathologic is a 
weight percentage of 5.5%, based on the 95% percentile of hepatic fat accumulation in a population of 
individuals with normal BMI, glucose tolerance, liver enzymes, physically inactive with excessive 
alcohol intake (Browning et al. 2004). Cross-sectionally, individuals with hepatic fat >5.5% of liver 
weight, had a higher prevalence of metabolic conditions like diabetes, obesity, lipid abnormalities and 
insulin resistance compared to those with hepatic fat ≤ 5.5% (Browning et al. 2004).  
A two-hit theory for the pathogenesis and progression of NAFLD from simple steatosis to NASH 
was proposed by Day et al., (Day and James 1998). The first-hit is steatosis which occurs secondary to 
insulin resistance, leads to increased susceptibility to the second hit comprising of lipid peroxidation, 
inflammation and oxidative stress from reactive oxygen species. Oxidative stress results from either an 
excessive production of ROS or a reduction in antioxidant defenses. Given that approximately 10-20% of 
individuals with hepatic steatosis progresses to NASH (Farrell and Larter 2006; Williams et al. 2011), the 
initial disease process might differ for those who do and do not progress. Likewise, disease progression 
may be enhanced by other factors like worsening severity of insulin resistance, or through pathways 
involving cytokines. To this end, a ‘multiple parallel hits’ hypothesis to NAFLD pathogenesis was 
proposed (Tilg and Moschen 2010). This hypothesis suggests that events leading up to disease occur in 
parallel rather than simultaneously, stating that adipose tissue inflammation precedes liver steatosis, 
resulting in elevations of adipocytokines that subsequently attack the liver and promote the inflammation 
leading up to NASH and progression to more advanced liver diseases. 
One response to inflammation is elevations in circulating levels of pro-inflammatory cytokines. 
Elevated TNF-alpha and IL-6 (Ueki et al. 2004), lipopolysaccharides (Feingold et al. 1992; Tomofuji et 
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al. 2007) and endotoxins (Feingold et al. 1992) have been linked to NAFLD occurrence. This evidence 
linking cytokines to NAFLD comes from both animal and human studies and, the molecular basis has 
been demonstrated in mice models (Figure 1). Specifically, overexpression of suppressors of cytokine 
signaling (SOCS) proteins in insulin sensitive tissues caused insulin resistance and increased the levels of 
the sterol regulatory element binding protein (SREBP)-1c (Farrell 2005; Ueki et al. 2004), a key regulator 
of hepatic lipid synthesis and a positive regulator of lipogenic enzymes. Conversely, inhibition of SOCS 
proteins improved insulin sensitivity and, normalized overexpressed SREBP-1c, leading to amelioration 
of hepatic steatosis (Ueki et al. 2004). In transgenic mice models, overexpression of SREBP-1 was 
associated with severe hepatic steatosis (Shimano et al. 1996) and SREBP-1 knockout mice were found to 
be resistant to fatty liver development even in the presence of obesity and, insulin resistance (Yahagi et al. 
2002). Probiotics and antibodies to TNF-alpha were shown in NAFLD mice models to decrease serum 
ALT levels and resolve hepatic steatosis and inflammation (Li et al. 2003). Among 105 humans with 
ultrasound and/or biopsy confirmed NAFLD, levels of pro-inflammatory cytokines —TNF-alpha, IL-6 — 
were higher compared to levels in 77 non-NAFLD cases. Levels of these cytokines were additionally 
reported to increase with severity of NAFLD (Das and Balakrishnan 2011). In summary, elevated 
cytokine levels have been demonstrated in the pathogenesis of hepatic steatosis while antibodies to these 
cytokines ameliorate it. 
2.3 Classification of Non-alcoholic Fatty Liver Disease 
To date no consensus exists on a non-invasive method for a definitive case definition for NAFLD 
for epidemiologic investigations other than definitions based on histologic findings. Although liver biopsy 
is preferred, it is not without constraints including but not limited to: ethical constraints when not 
medically indicated, safety and, sampling variability of biopsied site. Given many non-hospital based 
studies do not perform liver biopsies, an Asia-Pacific consensus on NAFLD in 2007 published a case 
definition based on findings from hepatic ultrasound (Chitturi et al. 2007). They defined NAFLD as “at 
least two of the following: Increased echogenicity with liver echogenicity greater than the kidney or 
spleen, vascular blurring and, deep attenuation of the ultrasound signal”. A limitation of hepatic 
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ultrasound however, is that upwards of 20-30% of fatty infiltration of the liver is necessary for a positive 
signal to be detected (Hernaez et al. 2011). In the absence of hepatic ultrasound, serum transaminases, 
although non-specific, are commonly used for characterizing NAFLD in epidemiological settings 
(Younossi et al. 2011a). Alanine aminotransferase (ALT) >30 U/L or gamma glutamyltransferase (GGT) 
>35 U/L (Bedogni et al. 2006) or the ratio of ALT: AST of ≥1 or AST: ALT ratio <1 indicates fatty liver. 
These upper limits of normal for serum transaminases were put forth in the 1980s for identifying non-A, 
non- B hepatitis before the introduction of anti-HCV testing, and thus, the reference population at the time 
likely included some with NAFLD (Prati et al. 2002), hence the concerns of misclassification of affected 
individuals as unaffected. To this end, the International Federation of clinical chemistry, proposed less 
stringent values for the upper limits of normal AST as 35 U/L for men and 30 U/L for women. The 
corresponding value for ALT was 19 U/L for women and 30 U/L for men (Angulo et al. 2013; Prati et al. 
2002). These thresholds have higher sensitivities and are able to identify individuals at low risk for 
disease at the expense of incorrectly classifying unaffected individuals as affected.  
Irrespective of cut point, significant liver disease may exist in the presence of normal levels of 
aminotransferases and depending on laboratory cut point, more than half of NAFLD cases may have 
normal liver enzymes. This is due to an upward drift in normal range of aminotransferases or treatment 
with anti-diabetic medications which has the potential to normalize aminotransferase levels in spite of co-
existing liver disease (Neuschwander-Tetri and Caldwell 2003). Therefore, instead of relying on ALT and 
AST levels in identifying NAFLD, a simple algorithm known as the fatty liver index (FLI), with 
estimates ranging from 0-100% can also be used. The FLI utilizes NAFLD risk factors and transaminases 
(Bedogni et al. 2006) in predicting fatty liver in the general population. Although not yet validated, this 
algorithm was developed from variables most predictive of fatty liver: BMI, waist circumference, 
triglycerides and GGT. This combination of variables have an area under the ROC curve of 85% (range: 
81% - 88%). 
 
 
 21 
 
The fatty liver index algorithm is: 
FLI =  𝑒0.953∗loge (triglycerides)+0.139∗BMI + 0.718∗loge (ggt)+0.053∗waist circumference − 15.745) 
      1 + 𝑒0.953∗loge (triglycerides)+0.139∗BMI + 0.718∗loge (ggt)+0.053∗waist circumference − 15.745)  (Bedogni et 
al. 2006). A FLI of <30% (Sensitivity =94%, Specificity=44%) indicates low likelihood of fatty liver, 
while a score of ≥60% (Sensitivity=61%, Specificity=86%) indicates high likelihood of fatty liver 
(Bedogni et al. 2006). Other variations on the theme of the fatty liver index have also been proposed and 
are displayed in Table 17. Indices are used mostly for prediction purposes rather than for etiologic 
modeling and thus inappropriate for outcome characterization in epidemiologic studies. 
Despite these indices, the performance of transaminases especially ALT in detecting fatty liver is 
suboptimal and, there is a need for biomarkers that are able to reliably discriminate steatosis from NASH. 
In an attempt to distinguish steatosis from NASH non-invasively, a study found high sensitivity C-
reactive protein (hs-CRP) capable of discriminating between steatosis and NASH (Park et al. 2004). But 
this finding was not replicated in another study (Hui et al. 2004a). It thus appears that hs-CRP may show 
little promise as a non-invasive marker for NAFLD but serum hemoglobin appears promising as a 
biomarker independent of elevations in serum transaminases and/or the presence of other components of 
the metabolic syndrome. Specifically, serum proteomic analysis conducted in morbidly obese bariatric 
surgery patients identified protein peaks related to alpha and beta hemoglobin subunits. These peaks 
progressively increased in intensity in obese patients without biopsy determined liver abnormality, to 
those with steatosis and, was highest among those with biopsy confirmed NASH (Trak-Smayra et al. 
2009). Also, another study found protein peaks related to alpha subunit of hemoglobin to be related with 
severity of histologically determined fatty liver (Yu et al. 2012). In addition, several population based 
cross-sectional studies, found serum hemoglobin concentration to be related to ultrasound and 
transaminase determined fatty liver disease (Xu et al. 2013; Xu et al. 2009). These same studies also 
reported higher baseline levels of serum hemoglobin to be associated with greater 3- and 5-year 
cumulative incidence of NAFLD (Xu et al. 2013; Yu et al. 2012). These findings suggest that serum 
 22 
 
hemoglobin may be an alternative non-invasive marker of NAFLD that is able to distinguish between 
steatosis and NASH. However, cut point indicating steatosis from NASH is yet to be determined.  
NAFLD patients with fibrosis have greater risk of progression to end stage liver disease and at 
this time, only a liver biopsy can determine disease stage. Additionally, as fibrosis progresses, other 
features of NAFLD like steatosis and/or inflammation may improve or disappear (Adams et al. 2005b) 
and, histological features of fibrosis may be inadequate for predicting long term prognosis. Likewise, 
transaminase levels may normalize spontaneously despite fibrosis progression (Adams et al. 2005b). 
Therefore, non-invasive markers for identifying stage of fibrosis are also needed. Several algorithms have 
been created based on risk factors for progression to fibrosis. Specifically, BMI, insulin resistance, type-2 
diabetes (Adams et al. 2005b; Ekstedt et al. 2006) advancing age, high AST, low ALT and high alkaline 
phosphatase (Shah et al. 2009). The ratio of AST: ALT >1 is one of the simplest algorithms for predicting 
progression to fibrosis. This ratio has been shown to increase with disease progression and advancing 
fibrosis (Angulo 2007). 
A study reviewed 8-indices [Fibrosis-4; NAFLD fibrosis score; Goteborg University Cirrhosis 
Index (GUCI); AST:ALT ratio (AAR); AST: Platelet ratio index (APRI); AST: Platelet ratio; Cirrhosis 
discriminant score (CDS); and BMI, AAR, diabetes (BARD score)], developed for identifying NAFLD 
patients with advanced fibrosis from those without, found the Fibrosis-4 index followed closely by the 
NAFLD fibrosis score to outperform the rest (Shah et al. 2009). In a head to head comparison with the 
fibrosis-4 index, the NAFLD fibrosis score had an AUC of 76% compared to 80% for the fiborosis-4 
index (Shah et al. 2009). None of these indices distinguishes fatty liver from NASH, because they only 
evaluate the likelihood of having advanced versus no fibrosis among those with NAFLD. The NAFLD 
fibrosis score is a validated scoring algorithm (Angulo et al. 2007), developed from clinical and 
laboratory data of individuals with NAFLD to determine extent and stage of fibrosis. This score is 
particularly useful in population based epidemiologic studies as an additional tool to liver ultrasounds and 
serum transaminases because of its high accuracy of about 90% accuracy, which can minimize the need 
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for a biopsy. The NAFLD fibrosis scored distinguishes advanced fibrosis from none using the algorithm 
below:  
NAFLD fibrosis score = -1.675 + 0.037 x age (years) + 0.094 x BMI (kg/m2) + 1.13 x IFG/diabetes (yes 
= 1, no =0) + 0.99 x AST/ALT ratio - 0.013 x platelet (x109/l) - 0.66 x albumin (g/dl). 
Individuals with score >0.676 have significant fibrosis while those with score < -1.455 do not have 
significant fibrosis while scores between these values are indeterminate. The Fibrosis-4 score on the other 
hand was originally developed for predicting fibrosis in HIV patients co-infected with HCV (Sterling et 
al. 2006) but has been validated 
for NAFLD (Shah et al. 2009). 
The Fibrosis-4 score has an AUC 
of 80%, a sensitivity and 
specificity of 74% and 98% for cut 
points of <1.3 and >2.67 
respectively (Shah et al. 2009). 
The fibrosis-4 score is based on 
the following algorithm: age 
([yrs.] * AST [U/L]) / ((PLT [109/L]) * (ALT [U/L]) 1/2). This index produces values ranging from 0.2 to 
10 and scores 1.3 and >2.67 identify Individuals with NAFLD without and with advanced fibrosis 
respectively while values between >1.3 and ≤2.67 were indeterminate (Shah et al. 2009). 
2.4 Epidemiology of NAFLD 
2.4.1 Person, Place and Time 
NAFLD is the most common cause of elevated transaminases and cryptogenic cirrhosis (Clark 
2006), with high prevalence in North and South America, the Asia Pacific region, the Middle East and 
Europe. The incidence of NAFLD is unknown because of a dearth of longitudinal studies, therefore, the 
Figure 2. Prevalence of liver diseases in a representative sample of the 
adult U.S population (Source: Younossi ZM, et al Clin Gastroenterol 
Hepatol.; 2011 
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majority of estimates presented in this report are mostly prevalence measures obtained from cross-
sectional studies. Using a population based registry of Minnesota residents, Adams and colleagues 
reported an adjusted incidence rate for ultrasound, computed tomography or biopsy confirmed NAFLD of 
4.2/100,000 PY between 1980-1985 and 38/100,000 PY from 1995-1999 (Adams et al. 2005a). However, 
this appreciable increase in incidence was attributed to ascertainment bias. Even though no current 
incidence estimates are available for the U.S., estimates of incidence from a Chinese population of non-
obese individuals suggests a 5-year cumulative incidence of 8.9% (Xu et al. 2013) while another study 
reported a 3-year cumulative incidence of 11.4% in the general population (Yu et al. 2012).  
An estimated 20-30% of the world’s population have NAFLD, 10% of whom (or 2 to 3% of 
adults) have NASH (Bedogni et al. 2005; Bellentani et al. 2004; Neuschwander-Tetri and Caldwell 2003; 
Yu and Keeffe 2002) based on autopsy findings and ultrasound. The prevalence of NAFLD is on the rise 
both in the U.S. (Younossi et al. 2011a) and around the world in concert with rising prevalence of 
NAFLD risk factors like obesity and diabetes (Flegal et al. 2012; Flegal et al. 2010; Flegal et al. 2002). 
Depending on diagnostic modality (ALT >30 IU/L, GGT >35 IU/L, or ultrasound findings) and 
race/ethnicity, prevalence ranging from 10-33% (Browning et al. 2004; Clark 2006; Farrell and Larter 
2006; Neuschwander-Tetri et al. 2010) have been reported for the United States. Nationally representative 
data from NHANES reported prevalence of 5.5% from 1988-1994, 9.8% between1999-2004 and 11% 
between 2005 -2008 (Figure 2). During these same periods, 21.7%, 30.2% and 33.2% respectively were 
reported as obese, while 5.6%, 7.9% and 9.1% were diabetic (Younossi et al. 2011a). Indeed 75% of those 
with type-2 diabetes or obesity have NAFLD (Angulo 2002; Farrell et al. 2004), while as high as 20% of 
obese individuals have NASH (Bellentani et al. 2004). Population based surveys from northern Italy 
using ultrasonography, reported NAFLD prevalence of 16% in lean and 76% in obese individuals 
(Bellentani et al. 2000; Bellentani et al. 1994). Recent studies from the United States using proton 
magnetic resonance spectrometry to assess elevations in hepatic triglyceride content reported that 30% of 
U.S adults are affected, with prevalence highest among Hispanics and lowest among African Americans 
relative to non-Hispanic Whites. Specifically, 45% of Hispanics, 33% of non-Hispanic Whites and 24% 
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of African Americans have high hepatic triglyceride content (Browning et al. 2004). Because most of the 
data for NAFLD come from clinic-based studies, the ethnic variation in prevalence may be reflective of 
either limited data among African Americans or differences in physician referral patterns. It has also been 
suggested that this difference may be related to potential genetic differences in body fat distribution or 
metabolic thermogenesis among ethnicities (Caldwell et al. 2002; Weston et al. 2005). Similarly, white 
males are more likely affected than white females (42% vs. 24%) but no gender difference was seen 
among individuals of African American or Hispanic origin (Browning et al. 2004). Gender differences 
have however been inconsistent as other studies have reported higher prevalence among women and 
being female to be a risk factor for disease progression (Angulo et al. 1999).  
NAFLD is often regarded as the hepatic manifestation of the metabolic syndrome and given the 
shared pathogenic factors with certain components of the metabolic syndrome, NAFLD has been 
suggested to be the link between obesity, type-2 diabetes, and cardiovascular diseases (Farrell and Larter 
2006). While NAFLD is sometimes considered a disease of the western world, socioeconomic factors 
associated with diet and physical activity have contributed to its etiology, thereby making NAFLD a 
worldwide phenomenon. Indeed, high levels of saturated fat intake (Musso et al. 2003) and possibly 
carbohydrates (Mager et al. 2015; Solga et al. 2004) promote hepatic fat accumulation and inflammation. 
Although elevations in aminotransferase levels in the absence of secondary liver diseases may point 
towards NAFLD, studies (Hwang et al. 2004; Marcos et al. 2000) have shown that about 20% of liver 
donors with normal aminotransferase levels have some form of hepatic steatosis. Thus, it is likely that 
many cases go undiagnosed early in the disease process with the more severe and progressing cases 
having a higher probability of been diagnosed. Given that the prevalence of obesity and type-2 diabetes 
are on the rise and the increasing diagnosis of childhood NASH (Farrell et al. 2004), the prevalence of 
NAFLD will likely continue to increase and NAFLD will contribute substantially to the burden of chronic 
liver diseases for some time to come. 
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2.5 Public health significance of NAFLD 
Compared to age and sex matched individuals in the general population, those with NAFLD have 
significantly higher morbidity and mortality (Adams et al. 2005a; Angulo 2007). NAFLD is a major cause 
of both chronic liver disease (CLD), the 12th cause of death in the United States (Xu et al. 2010) and 
cryptogenic cirrhosis (liver disease of unknown cause). CLD attributable to NAFLD rose from 47% 
between 1998-1994 to 75% between 2005-2008 (Younossi et al. 2011a). Extrapolating from prevalence 
estimates for NAFLD and proportion who progress to NASH, approximately 70% of cryptogenic chronic 
hepatitis was attributed to NAFLD (Clark et al. 2002), making NAFLD the most common cause of 
cryptogenic cirrhosis (Caldwell et al. 1999). NAFLD also aggravates complications of other kinds of liver 
diseases. Specifically, clinic based studies of biopsy confirmed NAFLD, reported NAFLD to be an 
independent risk factor for cirrhosis in the presence of hepatitis C virus infection (Adinolfi et al. 2001; 
Ong et al. 2001). NASH, has the potential to progress to cirrhosis and hepatocellular carcinoma (Angulo 
2002; Clark 2006; Clark et al. 2002; Selmi et al. 2007) with an estimated 5 and 10 year post-NASH 
survival of 67% and 59% respectively (Neuschwander-Tetri and Caldwell 2003). Among individuals with 
NAFLD, cardiovascular complications (Bhala et al. 2011; Ekstedt et al. 2006; Ong et al. 2008; Soderberg 
et al. 2010) and, liver related mortality (Adams et al. 2005a; Farrell and Larter 2006; Hui et al. 2003; 
Soderberg et al. 2010; Younossi et al. 2011b) are implicated as common causes of death with liver related 
mortality ranking third (Adams et al. 2005a; Angulo et al. 2013; Dunn et al. 2008; Ong et al. 2008).  
Elevated ALT levels and ultrasound confirmed hepatic steatosis were associated with a 14.8% 
increase in the number of outpatients’ visits, a 12.8% increase in outpatient health care costs and 26.0% 
increase in overall health care costs (Baumeister et al. 2008). Individuals with NAFLD as compared to 
other chronic liver diseases were more likely to self-report a physician diagnosis of depression (Weinstein 
et al. 2011), more likely to have poorer health related quality of life scores determined using the chronic 
liver disease questionnaire (Dan et al. 2007) and the physical and mental health short form 36 (SF-36) 
questionnaires (Afendy et al. 2009). In addition, these individuals were also more likely to present with 
autonomic nervous system (ANS) dysfunction (Newton et al. 2009), falls, fractures, cognitive impairment 
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(Newton 2010), and a range of non-specific symptoms like fatigue and day-time sleepiness (Newton 
2010; Newton et al. 2009) all of which can negatively affect quality of life. 
2.6 Risk factors for NAFLD 
2.6.1 Insulin resistance  
Insulin resistance is associated with many cardiovascular and metabolic conditions and reported 
in about 20% of non-diabetic individuals (Alexander et al. 2003; Wilson and Grundy 2003). Insulin 
resistance can be peripheral or hepatic. Peripheral IR is the decrease in insulin-mediated uptake of glucose 
in peripheral tissues like the skeletal muscles and adipocytes. Peripheral IR leads to an influx of free fatty 
acid (FFA) to the liver thereby decreasing lipolysis and increasing de novo lipogenesis in the liver. The 
corresponding fatty acid accumulation in liver cells leads to development of hepatic IR. Associated 
production of FFAs worsens peripheral insulin sensitivity by inhibiting insulin stimulated peripheral 
glucose uptake, thus providing a substrate for oxidative stress and facilitating disease progression from 
bland steatosis to NASH. This is supported by the demonstration that hepatic IR worsens with 
progression of NAFLD from simple steatosis to NASH (Sanyal et al. 2001) and, provides additional 
support that insulin resistance in some instances precedes steatosis (Angelico et al. 2005) rather than be 
an effect of hepatic hyperinsulinaemia. 
Environmental and life-style related factors such as physical inactivity and high fat diet influence 
the development of insulin resistance-associated comorbidities and NAFLD. NAFLD is not only seen in 
obese and diabetic individuals. Indeed, among non-diabetic patients who are insulin resistant, about 45% 
had severe hepatic steatosis (Angelico et al. 2005). Likewise, severe steatosis was reported in 19% of 
non-diabetics with no components of the metabolic syndrome (Expert Panel on Detection 2001), 35% of 
those with 1 or 2 components and 41% of those with 3-5 components of the metabolic syndrome (see 
Table 18 for components of the metabolic syndrome). The corresponding measure of insulin resistance as 
assessed by HOMA-IR was 2.2, 3.6 and 5.2 respectively (Angelico et al. 2005). 
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2.6.2 Type-2 diabetes and hyperglycemia 
Studies have reported prevalence of ultrasound determined NAFLD in apparently healthy 
Japanese workers as high as 29%. This prevalence was 27% in those with normal fasting blood glucose, 
43% among those with impaired fasting glucose and 62% in newly diagnosed type-2 diabetes (Jimba et 
al. 2005). Likewise, levels of triglycerides, AST, ALT, albumin and total protein were significantly higher 
while HDL cholesterol and AST/ALT ratio were significantly lower in those with NAFLD compared to 
those without. 
2.6.3 Abdominal Obesity and dyslipidemia (hypertriglyceridemia) 
Adipose tissue is now recognized as a tissue that secretes physiologically active peptides 
(adipocytokines) that are either proinflammatory (TNF-alpha, IL-6, leptin) or anti-inflammatory 
(adiponectin), hence the chronic low grade inflammatory state causally linked to obesity (Ouchi et al. 
2011; Shoelson et al. 2006). TNF-alpha is derived primarily from adipose tissues in the absence of active 
infections or other inflammatory conditions and its plasma levels are reported to be correlated with body 
fat mass (Neuschwander-Tetri and Caldwell 2003). Levels of the pro-inflammatory adipocytokines are 
higher in those with bland steatosis as opposed to NASH and levels of adiponectin is reduced independent 
of insulin resistance (Hui et al. 2004b). In contrast to overall obesity, central adiposity represents one of 
the more important risk factors for NASH (Chitturi et al. 2002; Park et al. 2007; Thomas et al. 2005) and 
central adiposity correlates positively with insulin resistance as many individuals that are non-obese based 
on BMI have central obesity and NAFLD. 
2.6.4 Hypertension 
The presence of arterial hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg or use of anti-
hypertensive medications) among individuals with normal ALT levels was reported to  be associated with 
greater prevalence of ultrasound determined NAFLD (Donati et al. 2004). These hypertensive individuals 
were also more likely to present with other components of the metabolic syndrome like insulin resistance, 
and high total cholesterol levels. This suggests an insulin resistance mediated association between 
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hypertension and NAFLD. A study among Chinese non-obese individuals found systolic and diastolic BP 
to be significantly associated with the 5-year cumulative incidence of NAFLD in univariate but not 
multivariate analysis (Xu et al. 2013). Many patients with NAFLD have hypertension and a pilot study 
showed that control of hypertension with angiotensin II receptor antagonist improved transaminase levels 
and liver histology (Yokohama et al. 2004). A study also reported that individuals with NAFLD were 
more likely to have systolic and diastolic hypertension (mostly systolic) compared to their counterparts 
with ‘normal’ livers (Bedogni et al. 2005). 
2.6.5 Environmental factors  
Evidence of an association between dietary choice and NAFLD is weak. However, diets high in 
fats and carbohydrates predispose to obesity and IR while total parenteral nutrition and rapid weight loss 
is associated with NASH. Furthermore, important regulatory components of the inflammatory cascade 
(TNF-alpha) mediate diet induced IR (McAvoy et al. 2006). 
2.6.6 Age and gender 
Although fatty liver disease occurs in obese children, advancing age (>45 years) is an established 
risk factor for NAFLD and independently predicts mortality in NAFLD. In addition, Male gender is 
associated with greater prevalence of NAFLD (Hamaguchi et al. 2005), with a reversal in gender 
prevalence post menopause (Lavoie and Pighon 2012). In addition, female gender is reported to be related 
with disease progression.  
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CHAPTER 3: HISTORY OF THE ORAL DISEASES-SYSTEMIC DISEASES 
RELATIONSHIP 
 
Historically, the oral-systemic diseases relationship dates back to early 20th century when the 
theory of focal infection was born (Billings 1912). This theory was based on the premise that, the focus of 
infection in patients presenting with a given systemic infection has to be located and if it seems rationally 
related to the systemic infection, be removed. With regards to oral diseases as the foci of infection, Frank 
Billings stated in his paper “ulcerative gingivitis, small abscesses under the gums and collection of pus in 
the alveoli require vigorous treatment. Ill-fitting crowns on teeth and much bridge-work may harbor 
septic infection in the mouth and produce systemic disease, and when found should be removed” (Billings 
1912). This idea subsequently led to widespread teeth extractions in both Dentistry and Medicine in an 
attempt to control systemic diseases. More than 2 decades passed before the realization that this 
widespread removal of teeth in no way affected systemic diseases attributed to oral infections (Easlick 
1951), hence this theory was discarded. 
The oral diseases-systemic diseases relationship was again thrust into prominence with a 1989 
publication that reported that patients presenting to the emergency department with a heart attack were 
disproportionately affected by oral diseases like periodontitis, independent of other CVD risk factors 
(Mattila et al. 1989). A few years later, DeStefano and colleagues reported that periodontitis was 
associated with greater prevalence of coronary heart disease after adjustment for confounders and CVD 
risk factors (DeStefano et al. 1993). In spite of these findings, a biologic rationale for this relationship was 
lacking but a working theory was put forth by Beck et al., stating that the association may be due to an 
underlying inflammatory response trait (which is now attributed to genetic differences in the innate 
immune response) that increases the risk for developing both periodontitis and CVD outcomes (Beck et 
al. 1996). Also put forth was the concept that systemic bacteria dissemination from established 
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periodontitis lesions lead to the activation of hepatic acute phase response that acts as inflammatory 
triggers for CVD events (Beck et al. 1996). Subsequent studies supported these working theories with 
findings of oral bacterial DNA and live oral bacteria in atheroma lesions, and increase circulating CRP 
levels in both animal and human studies. Refer to commentary (Offenbacher and Beck 2014) for 
additional information. 
Many studies report associations between periodontitis and systemic diseases, especially CVD 
events, diabetes, chronic kidney disease, and adverse birth outcomes (Ide and Papapanou 2013; Ide et al. 
2011) (Figure 3). However, a causal explanation for the association appears tenuous based on the few 
intervention studies that have evaluated systemic health benefits of treating periodontal infections 
(Kapellas et al. 2014). This has especially been the case for adverse birth outcomes where periodontitis is 
associated with adverse pregnancy outcomes (Ide and Papapanou 2013), while evidence of a beneficial 
effect of periodontal treatment on prevention of adverse birth outcomes is still in question (Michalowicz 
et al. 2013). Hence, the ongoing controversy that periodontal diseases might not be associated with 
systemic diseases because of some treatment failure.  
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CHAPTER 4: EVIDENCE LINKING PERIODONTITIS TO LIVER DISEASES 
 Hospital based studies investigating liver diseases and periodontal health suggest duration (3 or 
more years) of liver cirrhosis (determined histologically) to be related to poor periodontal health –high 
attachment level 
measures (Movin 1981) 
and alveolar bone loss 
(Oettinger-Barak et al. 
2002) while another 
(Novacek et al. 1995) 
found no difference in 
the periodontal health of 
liver cirrhosis cases 
compared to a control 
group. These studies were clinic based with sample sizes of not more than 100 individuals. In addition, 
periodontal status and liver cirrhosis were assessed concurrently and thus also subject to incidence-
prevalence bias. A cross-sectional study of 172 middle aged Japanese women found levels of serum 
transaminases (ALT, AST and AST: ALT) to be greater among those with periodontitis- defined as 
having PD ≥4mm (Saito et al. 2006). Similar conclusions were reported among young adult males but not 
females for ALT levels (Furuta et al. 2010). This relationship has also been reported in non-human 
primates (DeBowes et al. 1996).  
Compelling new data exists linking CP to NAFLD in both mice models (Tomofuji et al. 2007; 
Yoneda et al. 2012) and a human study (Yoneda et al. 2012). Oral administration of P. gingivalis to mice 
 
Figure 3. Remote effects of periodontal disease on systemic health (Source: 
Saito and Shimazaki Periodontol 2000, 2007) 
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increased hepatic fat and triglyceride levels compared to levels in sham administered mice models 
(Tomofuji et al. 2007). Mice models randomized to receive high fat diet and Porphyromonas gingivalis (a 
key periodontal pathogen)(Darveau et al. 2012) showed significant increases in body weight (45g vs. 
38g), liver weight (2.5g vs. 1.5g) and elevated ALT levels (98 IU/L vs. 47 IU/L) compared to mice 
models randomized to receive high fat diet alone (Yoneda et al. 2012). On the contrary, when the bacteria 
administered was Streptococcus mutans –the dental caries pathogen or certain less-virulent oral microbes 
like Streptococcus sanguinis or Streptococcus salivalius, authors reported no corresponding increase in 
either the body or liver weight of the mice models. Others have reported an up-regulation of 
proinflammatory genes and down regulation of insulin sensitivity genes (Arimatsu et al. 2014), and have 
found hepatic steatosis to be associated with increased production of proinflammatory cytokines 
specifically IL-6, a significant predictor of progression from steatosis to NASH (Wieckowska et al. 2008).  
Among 150 biopsy-confirmed NAFLD cases, detection frequency for P. gingivalis in salivary 
samples was 46.7% compared to 21.7% among non-NAFLD controls with a detection odds ratio of 3.16. 
A 3-month non-surgical periodontitis (having ≥5 sites with PD of ≥5mm) therapy comprising of scaling 
and root planning with the application of minocycline microspheres in periodontal pockets decreased 
previously elevated serum transaminases among biopsy-confirmed NAFLD cases thus implicating 
periodontal pathogen as contributing to the etiopathogenesis of NAFLD (Yoneda et al. 2012). Another 
cross-sectional study of factory workers found periodontal pocket depth (based on the community 
periodontal index of treatment needs) to be related with elevated GGT levels independent of alcohol 
consumption, and stated that no association was found with respect to levels of AST and ALT, although 
these estimates were not reported (Morita et al. 2014).  
Current evidence in humans came mostly from cross-sectional studies making causal relations 
questionable. However, taken together, evidence from animal and human studies suggest a plausible role 
of periodontitis in the etiopathogenesis of NAFLD. Thus, periodontitis potentially represents a modifiable 
risk factor for non-alcoholic fatty liver disease (NAFLD) —through its association with both insulin 
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resistance and inflammatory mediators—for which early treatment/intervention could mitigate the 
systemic inflammatory response that aggravates NAFLD and enhances its progression.   
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CHAPTER 5: INFLAMMATION AND HYPER-INFLAMMATORY PROCESSES 
Inflammation is a complex series of events that occur in response to infections and injury. It is 
accompanied by local tissue damage presenting with symptoms like swelling and pain that ultimately 
resolves as inflammation abates, leaving little to no permanent damage (Kumar et al. 2014). The process 
to control inflammation is regulated primarily by the innate immune system (Kumar et al. 2014; 
Takashiba and Naruishi 2006) and involves a coordinated cascade of biological events regulated by 
specific cells and molecular signals (Naitza et al. 2012). The innate immune system is made up of pattern 
recognition receptors that recognize molecular components of foreign microorganisms as well as 
molecules released by damaged cells or produced by host cells during an inflammatory response. This 
system activates and instructs the adaptive immune system for antigen specific T and B lymphocytes 
responses and the development of immunologic memory. In other words, the innate immune system has 
sentinel and first-responder status, activates and instructs the adaptive immune response, regulates 
inflammation and maintains an efficient homeostasis compatible with life. Just as the innate immune 
system has protective effects, allergic sensitization, inflammation and disease may originate during 
aberrant innate immune development (Adkinson et al. 2013). 
Hyper-inflammatory trait also known as hyper-responsive trait refers to an excessive 
inflammatory response upon stimulation of the innate immune system (Shaddox et al. 2010). In essence, 
certain individuals because of this hyper-responsive trait may respond to a given microbial challenge with 
an abnormally high inflammatory response as reflected by the release of high levels of circulating 
proinflammatory cytokines. This trait was suggested as a plausible rationale for the periodontitis-CVD 
events relationship (Beck et al. 1996) and possibly also responsible for the increased expression of 
CRP—an acute phase reactant—in edentulous individuals with no identifiable underlying cause of this 
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elevation (Slade et al. 2000). Indeed, this hyper-inflammatory trait has been linked to multiple 
inflammatory processes like localized aggressive periodontitis where the phenotype has been described as 
an increased inflammatory response upon stimulation by Toll like receptors (Shaddox et al. 2010). 
Because the innate immunity is central to inflammation, genetic variations that disrupt this system could 
explain inter-individual differences in the ability to respond to injury, diversity in clinical presentation of 
inflammatory reactions to the same stimuli and response to therapy. Such genetic variations may identify 
persons more or less likely to respond excessively to an inflammatory response. For instance, bacteria 
pathogen is necessary for the initiation and progression of periodontitis, however, a susceptible host is 
also required. Host response to bacteria toxins in periodontitis is protective, however, an abnormal host 
response (say due to a hyper-responsive trait) results in an exacerbation of periodontitis leading to greater 
tissue destruction. This heightened inflammatory response occurs concurrently with an exaggeration of 
the innate immune response (Southerland et al. 2006) and presents systemically as heightened expression 
of systemic markers of inflammation. Because of wide inter-individual variability in response to 
inflammation, with certain individuals exhibiting a heightened response more so than others even with 
similar bacterial challenge, it has been suggested that genes regulating the inflammatory processes as well 
as environmental factors may be responsible for the expression of this trait (Beck et al. 1996).  
5.1 Genome-wide association scans for genetic markers of inflammation 
Genetic determinants of inflammatory biomarkers can more accurately indicate lifelong 
inflammatory status (Raman et al. 2013) compared to biomarker concentrations at a given point in time 
because level of these markers varies within individuals for various reasons. Likewise, recent population-
based genetic studies suggest that natural selection has shaped the evolution of the innate immunity with 
specific focus on inflammatory genes that are pivotal in host-pathogen interactions (Barreiro and 
Quintana-Murci 2010). Therefore, individuals with certain polymorphisms in genes regulating the 
inflammatory process may differ in their expression of periodontitis and NAFLD and in the magnitude of 
association between periodontitis and NAFLD. Gene polymorphisms are locations within the genome that 
vary in sequence between individuals (Nielsen 2004). The most common are the single nucleotide 
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polymorphisms (SNP), which are DNA sequence variation occurring in at least 1% of the population and 
characterized by changes in a single base pair of the genomic DNA with the ability to affect gene function 
(Nielsen 2004).  
Inflammatory markers appear to have high heritability as suggested by several studies among 
ethnically homogenous groups and twins reporting that about half of inter-individual variability in 
markers of inflammation are genetically determined. For instance, the Framingham heart study reported 
age and gender adjusted heritability estimates of 25.3%, 25.4%, 45.2% and 32.5% for CRP, IL-6, MCP-1 
and sICAM-1 respectively (Dupuis et al. 2005) and the NHBLI family heart study reported heritability 
ranging from 35-40% for CRP, WBC and albumin levels (Pankow et al. 2001). These high heritability 
values suggest that genetic variation as opposed to environmental factors are major determinants of levels 
of inflammatory markers. However, currently identified genetic loci account for <5-10% of this variation 
(Dehghan et al. 2011; Lange et al. 2006; Raman et al. 2013) and this is still an active area of research. 
Identifying specific genes/markers of inflammatory response can be challenging, often necessitating 
GWAS studies. Several GWAS studies have identified SNPs in certain genes that regulate levels of these 
inflammatory markers (Dehghan et al. 2011; Naitza et al. 2012; Raman et al. 2013). The specific 
inflammatory SNPS listed in Table 13 attained genome-wide significance and are explored in this report. 
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CHAPTER 6: STUDY RATIONALE 
Periodontal pockets, harbor bacteria endotoxins, lipopolysaccharides and proinflammatory 
cytokines (Gurav and Jadhav 2011; Page 1998; Page and Schroeder 1976; Yucel-Lindberg and Bage 
2013), with the propensity to induce low-grade systemic inflammation (Chapple and Genco 2013; Daly et 
al. 2001; Kinane et al. 2005; Loos 2005; Loos et al. 2000; Pussinen et al. 2004) when released into the 
systemic circulation. Release of these inflammatory mediators could be in response to periodontal therapy 
(Daly et al. 2001; Kinane et al. 2005), or gentle mastication in the severely affected periodontium (Geerts 
et al. 2002). Non-surgical treatment of periodontal disease without antibiotic adjuvants was associated 
with a decrease in elevated white cell count (Christan et al. 2002), and increased circulating levels of 
proinflammatory cytokines (D'Aiuto et al. 2004), suggesting an association between CP and elevated 
levels of inflammatory mediators. Elevated cytokines have been demonstrated in the pathogenesis of 
hepatic steatosis while antibodies against these cytokines have been shown to ameliorate it. CP potentially 
represents a modifiable risk factor for NAFLD —through its association with both insulin resistance and 
inflammatory mediators—for which early treatment/intervention could mitigate the systemic 
inflammatory response that potentially aggravates NAFLD and enhances its progression. 
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CHAPTER 7: SPECIFIC AIMS 
 Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic 
syndrome and the most common type of liver disease. It comprises a spectrum of diseases ranging 
from simple steatosis through non-alcoholic steatohepatitis (NASH) to cirrhosis and hepatocellular 
carcinoma (Clark 2006; Clark et al. 2002; Selmi et al. 2007). Estimated to affect 17-33% of the adult 
U.S. population (Angulo 2002; Erbey et al. 2000), NAFLD incurs substantial health care costs 
(Baumeister et al. 2008) and mortality (Musso et al. 2011). Established risk factors are limited to 
insulin resistance and obesity (Clark 2006; Marchesini et al. 1999). A few studies implicate 
proinflammatory cytokines (Haukeland et al. 2006; Targher 2006) and other components of the 
metabolic syndrome (Grundy et al. 2004) in NAFLD etiology (Hui et al. 2004b; Kugelmas et al. 
2003). To date, less attention has been paid to other chronic health conditions that elicit systemic 
inflammatory response that might represent unrecognized but modifiable risk factors for NAFLD. 
 The central hypothesis for this project is that systemic inflammatory burden associated with 
chronic periodontitis contributes to the risk of NAFLD. Periodontitis affects about 45% of the adult 
U.S. population (Eke et al. 2015; Eke et al. 2012a) and based on evidence from experimental animal 
models and epidemiologic studies, it contributes to low-grade systemic inflammation. Furthermore, 
given the evidence from experimental animal and human studies that endogenous estrogens in pre-
menopausal women (Gutierrez-Grobe et al. 2010; Lavoie and Pighon 2012; Lonardo et al. 2006) and 
exogenous estrogens in post-menopausal women (Clark et al. 2002; Hagymási et al. 2009) exert 
protective effects against NAFLD occurrence, the potential association between periodontitis and 
NAFLD likely vary according to gender. An opportunity now exists to explore these associations 
using data from a prospective cohort study that is the first to have made detailed measurements of 
 40 
 
NAFLD, periodontitis, systemic inflammatory burden and, targeted SNPs likely to influence this 
relationship. 
7.1 Aim #1: Evaluate the longitudinal association between periodontitis and NAFLD 
 Periodontal probing measurements were used to classify periodontitis at baseline, 5 and 10-
years of follow-up, while serum transaminases and liver ultrasound were used to classify NAFLD at 
baseline, 5 and 10-years follow-up. 
  7.1.1 Hypothesis #1 
 Extent of sites with periodontitis and the CDC-AAP classification of periodontitis assessed at 
baseline is positively associated with the 10-year cumulative risk and rate of NAFLD among those 
free of NAFLD at baseline  
  7.1.2 Hypothesis #2 
 Increase in clinical attachment level (i.e. ALOSS) from baseline level is associated with 
increased rate of NAFLD occurrence at follow-up. 
7.2 Aim #2: Assess if the association between periodontitis and NAFLD is modified by 
systemic markers of inflammation.  
 Existing genotype data from a pre-selected group of SNPs that regulate the inflammatory 
pathways: IL-6, hs-CRP, ESR, MCP-1 were used to generate a genetic score (Kathiresan et al. 2008; 
Labos et al. 2014; Pharoah et al. 2008) for inflammation burden. 
  7.2.1 Hypothesis #3 
 The periodontitis-NAFLD association differs according to categories of the GS of SNPs 
previously identified to be associated with inflammatory markers. 
7.3 Aim #3: Evaluate predictors of follow-up and the impact of losses to follow up on the 
association between periodontitis and NAFLD. 
Close to half (40%) of the sample became lost to follow-up by the 2nd follow-up visit, 11 years 
after baseline. This extent of attrition could result in bias if not taken into consideration especially if 
losses to follow-up did not occur completely at random or if there are differential losses to follow-up with 
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respect to the exposure or outcome. To address this, inverse probability of censoring weights (Pearl 2012; 
VanderWeele 2015; VanderWeele 2009) were created to minimize potential bias from losses to follow-
up. 
 
Significance statement: Periodontitis represents a modifiable, common risk factor for components of 
the metabolic syndrome and for the expression of NAFLD. This investigation addresses an important 
gap in literature by quantifying for the first time the association between periodontitis and objectively 
measured NAFLD. 
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CHAPTER 8: RESEARCH DESIGN AND METHODS 
8.1 Study Overview 
This dissertation uses data from a population based prospective cohort study, the Study of Health 
in Pomerania (SHIP) to investigate likely association between chronic periodontitis and non-alcoholic 
fatty liver disease (NAFLD). The goals were to 1) estimate the prevalence of NAFLD according to the 
different methods used in evaluating NAFLD in this study (serum transaminases, liver ultrasound). In 
addition, to estimate prevalence of NAFLD using the FLI, determine the extent of fibrosis among those 
identified as having NAFLD using the NAFLD fibrosis score and the fibrosis-4 score. 2) evaluate the 
periodontitis-NAFLD association (cross-sectionally at baseline and longitudinally over follow-up), 3) 
assess effect measure modification of the association between periodontitis and NAFLD by systemic 
markers of inflammation and 4) assess the impact of losses to follow-up on study findings. To facilitate 
answering these study aims, cases of periodontitis were identified using the CDC-AAP case classification, 
predetermined groupings of extent of sites with CAL ≥3mm and PD ≥4mm and mean CAL and mean PD 
at baseline. Serum transaminases, and hepatic ultrasound were used in characterizing NAFLD while 
genomic data were used in identifying SNPs, previously reported in GWAS to be related with systemic 
markers of inflammation. 
8.2 Study design and Population 
The Study of Health in Pomerania is a population-based cohort of the western Pomeranian region 
of northeastern Germany (John et al. 2001; Volzke et al. 2011). The SHIP was designed to provide 
prevalence estimates for various diseases and disease risk factors, incidence of common risk factors, 
subclinical disorders, and clinical diseases and evaluate associations among these factors. From 213,057 
eligible inhabitants of west Pomerania in 1996, 6,265 adults aged 20-79 years were drawn using a two-
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stage stratified cluster sampling design. Twenty-nine communities representing the clusters i.e. the 
primary sampling units (PSU) were first drawn. PSUs with more than 1,500 inhabitants were sampled 
with a probability equal to one while smaller PSUs were selected at random. The second stage of 
sampling was stratified according to age and sex and study participants were sampled proportional to the 
size of the PSU they belonged to (John et al. 2001). Selected persons received up to 3 invitational letters 
followed by telephone calls in the case of non-response. Baseline examination (SHIP-0), took place 
between 1997 and 2002. Follow-up occurred every 5 years with the first installment conducted between 
2003 and 2007 (SHIP-1) and the second installment between 2008 and 2012 (SHIP-2). Study participants 
underwent rigorous clinical and laboratory examinations to determine baseline risk factors for major 
chronic health conditions and similarly at each follow-up visit. Interviewer-administered questionnaires 
were used to collect information on socio-demographic factors including but not limited to age, alcohol 
use, smoking, blood pressure, medical history and oral health. 
8.2.1 Recruitment, data collection, management, quality control and retention 
All data collection instruments and examination protocols were developed in collaboration with 
an independent panel of experts and were all pilot tested before implementation in the SHIP study. For all 
examinations, standard operating procedures were available for mandatory review by all examiners. 
Quality reports for all examinations were discussed semi-annually with a board of independent scientists. 
For continuously distributed variables, the mean bias for intra and inter observer variability was ≤5% and 
2 standard deviations of this bias was ≤25%. For categorical variables, kappa statistics were all >80%. 
Examiner(s) who did not fulfill quality criteria were subjected to individualized calibration and without 
subsequent improvement replaced. All interviewers and examiners were certified prior to start of study 
and recertification was repeated every 6-12 months. To maximize response, participants were sent 3 
invitational letters; repeated telephone calls and in-person contacts at home. All participants were given a 
€30 expense allowance or offered free transportation to and from the examination site plus a €20 expense 
allowance. Of the 7,008 eligible persons invited to participate, 615 (8.8%) had moved to a different area 
and 126 (1.8%) died before they could participate. A total of 4,308 participated in SHIP-0, with overall 
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response rate of 68.8% with slightly more female than male responders (69.4% vs. 68.2%). For SHIP-1, 
130 migrated and 231 died. Of the remaining subjects, 3,300 participated in follow-up examinations 
indicating a response rate of 83.6%. A morbidity follow-up (response rate 88.6%) was conducted between 
June and December 2006 by postal questionnaires and non-responders were contacted by telephone 
(Volzke et al. 2011). For SHIP-2 data collection that took place between 2008 and 2012, 29% of SHIP-1 
participants had been lost to follow-up, resulting in an effective sample size of 2,333 individuals who 
participated in the 2nd follow-up visit. 
Interview: Trained and certified interviewers conducted computer-assisted personal interviews. About 
10% of this data were reviewed semi-annually by a group of independent auditors. 
Laboratory samples: Blood and urine samples were collected according to standardized procedures. 
Likewise, saliva samples and swabs of the nose, throat, tongue and tooth pockets were also collected. 
Blood aliquots were immediately placed on ice after collection. Blood and urine samples were stored at -
800C in a bio-bank. All assays were calibrated against the international reference parameters when 
available and a bank of dummy samples were used to standardize the different laboratory methods (John 
et al. 2001). 
Prevalence of periodontitis and NAFLD are comparable to U.S. benchmarks. Specifically, the 
population of western Pomerania experience high levels of abdominal obesity and other cardio-metabolic 
risk factors (Volzke et al. 2011), with hepatic steatosis affecting approximately 30% of this population 
(Volzke et al. 2005; Volzke et al. 2007) and more than 25% are affected by periodontitis (Holtfreter et al. 
2009). This secondary data analysis is a cost-efficient use of resources because exposure, outcome and 
confounder data have been previously enumerated. 
8.3 Exposure assessment 
Study participants with no medical contraindication requiring antibiotic prophylaxis received a 
partial-mouth periodontal examination at SHIP-0 and at subsequent follow-up visits (SHIP-1 and SHIP-
2). Measurements of PD and CAL were obtained by trained dental examiners at 4 sites distobuccal, 
mesiobuccal, midbuccal and midlingual or midpalatal per tooth (except the 3rd molars) on 2 randomly 
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selected quadrants (quadrants 1 and 4 or quadrants 2 and 3). PD is the distance from the free gingival 
margin to the base of the periodontal pocket while CAL is the difference between PD and gingival 
recession (defined as the distance from the free gingival margin to the cemento-enamel junction). Oral 
examinations were performed in a dental examination room with adequate lighting, without the use of 
saliva ejector or air jet using the PCP11, PCP-2 and UNC15 (Hu-Friedy, Chicago, IL) periodontal probes 
for periodontal measurements at baseline, first and second follow-up visits respectively. The same 
quadrants examined at baseline were also examined at follow-up. Examiners underwent a rigorous 4-8 
weeks training and calibration to a gold standard examiner was done with reported intra-class correlation 
of 0.82 to 0.91 per examiner and inter-rater correlation of 0.84 (Hensel et al. 2003; Volzke et al. 2011).  
8.3.1 Exposure definition 
For this investigation, periodontitis was characterized using the CDC-AAP case classification, 
mean CAL, mean PD at baseline and the extent of sites exhibiting signs of periodontal destruction. Extent 
of periodontitis was defined as the proportion of periodontal sites with PD of ≥4 mm and separately as 
proportion of periodontal sites with CAL of ≥3 mm. These were categorized into: 0% (no site affected), 
<30% (moderate), ≥30% (extensive) for the purposes of dose-response assessment. Clinical attachment 
loss between study visits was defined as mean change in CAL of ≥1mm and ≥2mm. 
8.4 Covariate Assessment 
Information on covariates were collected at baseline and during each follow-up visit using either 
structured interviewer administered questionnaires or clinical/laboratory assessments. The most relevant 
phenotypic covariates for this investigation were age, gender, BMI, hypertension, smoking, diabetes, 
alcohol, waist and hip circumference, physical activity, medications, smoking, total cholesterol, 
triglycerides, high density lipoprotein cholesterol (HDL-C), HRT-use, CRP, and Inflammatory mediators 
like: TNF-alpha, IL-6. Age and gender were self-reported. Trained examiners performed anthropometric 
measurements of weight, height, waist and hip circumference on study participants. After a 5-minute rest, 
systolic and diastolic blood pressure measurements were taken thrice on the right arm of seated study 
participants using the HEM-705CP, Omron Corporation, Tokyo, Japan, that meets the association for the 
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advancement of medical instrumentation and British hypertension society criteria (John et al. 2001). 
Alcohol consumption was recorded as self-reported number of drinks/week. An oral glucose tolerance test 
was used to determine plasma glucose levels. Specifically, non-fasting venous blood was first collected 
and 75g of anhydrous glucose was given orally. Another sample of venous blood was then taken 2-hours 
later to characterize post-prandial glucose clearance. Smokers were identified from response to smoking 
at least 100 cigarettes in a lifetime. Serology for hepatitis A, B and C as well as type of medication is 
important for ruling out other causes of liver diseases. Serum insulin (if available) and blood glucose 
levels will be used to assess HOMA-IR, while the ratio of TGs to HDL-C will be explored as another 
measure of insulin resistance. HOMA-IR will be estimated as [(fasting blood glucose levels*serum 
insulin levels)/22.5)] (Matthews et al. 1985; Neuschwander-Tetri et al. 2010) while a ratio of TG/HDL-C 
>3 will characterize the threshold for insulin resistance (McLaughlin et al. 2003). Genotypes were 
determined at baseline with genomic DNA from blood samples. A total of 4,096 samples were genotyped 
using the Human SNP 6.0 Array (Affymetrix, Santa Clara, CA) with an overall genotyping efficiency of 
98.6% (Volzke et al. 2011). For this project, the focus was on polymorphisms in the inflammatory genes 
and SNPs previously identified in GWAS to be related to markers of inflammation.  
 Levels of inflammatory biomarkers appear to rise following periodontitis and also increase the 
likelihood for NAFLD occurrence. However, due to within person fluctuations over time in levels of 
these markers resulting from factors like acute infections (Hardikar et al. 2014; McDade et al. 2012; Nash 
et al. 2013; Sjöberg et al. 2014), the potential for measurement error and misclassification in marker 
levels exist. Therefore, to accurately identify those with “hyper-inflammatory traits”, genetic variants 
associated with these inflammatory markers were first identified under the premise that they represent a 
better indicator of lifelong inflammatory status because they are not subject to environmental or other 
factors that could affect their levels.  
Several studies among ethnically homogenous groups and twins show that close to half of inter-
individual variability in markers of inflammation is genetically determined (Dupuis et al. 2005; Pankow 
et al. 2001). However, currently identified loci account for <5-10% of variation in the levels of these 
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markers (Raman et al. 2013). Identifying these markers are amenable to GWAS or sequencing techniques 
which are beyond the scope of this dissertation. However, several SNPs have been reported to be related 
to the inflammatory process from which those reported to have genome-wide significance were chosen. 
While there are several potentially relevant inflammatory markers that could be explored, this 
investigation focuses on the following: IL-6, MCP-1, ESR and hs-CRP. These inflammatory markers are 
present on different pathways and stages of inflammation and their levels differ during both acute and 
chronic inflammatory processes. To identify the respective genetic variants, genome-wide association 
scans of inflammatory markers among a population of Sardinians (Naitza et al. 2012), a meta-analysis of 
GWAS for serum CRP (Dehghan et al. 2011) and a systematic review on genetic markers of 
inflammation related to CVD outcomes (Raman et al. 2013) provided the necessary information. The 
resulting inflammatory markers, genes and selected SNPS are presented in Table 13. This genotyped 
cohort provides a unique opportunity for an assessment of the impact of polymorphisms in the 
inflammatory genes and their respective SNPs on the periodontitis-NAFLD association. 
8.5 Outcome Assessment 
Markers of hepatic inflammation were assessed using serum transaminases (ALT, AST and 
GGT), and hepatic ultrasound at baseline; serum transaminases at SHIP-1 and serum transaminases, 
hepatic ultrasound at SHIP-2. Trained physicians performed liver ultrasound on study participants using a 
7.5-MHz transducer (John et al. 2001; Volzke et al. 2011). All ultrasound measurements were based on a 
standardized scanning protocol and done in two examination centers but all readings were done at a 
central location (John et al. 2001). Blood drawn from the cubital vein in the supine position was analyzed 
using standardized procedures for blood cell counts, electrolytes, clotting factors, lipid enzymes, 
hormones and transaminases. 
8.5.1 Outcome definition 
In addition to transaminases and hepatic ultrasound, the fatty liver index (FLI) previously 
described was used to determine those with a high versus low likelihood of having NAFLD. Although 
serum transaminases are non-specific, they are commonly used for characterizing NAFLD in 
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epidemiological settings after ruling out competing causes of liver diseases (Younossi et al. 2011a). To 
evaluate the periodontitis-NAFLD association at baseline (specific aim 1), a clinical diagnosis of NAFLD 
was defined as ALT/AST ratio ≥1 (or AST/ALT ≤1) as well as a high vs. low-likelihood of NAFLD 
based on a FLI of ≥60%. In other words, a clinical diagnosis of NAFLD was based on abnormal liver 
function tests, and fatty liver on ultrasound readings in the absence of other known causes of liver 
diseases. A positive finding on ultrasound was defined as significant increase in liver echogenicity (bright 
liver) relative to the kidneys, with the diaphragm indistinct OR the echogenic walls of the portal veins 
invisible (Baumeister et al. 2008; Williams et al. 2011). 
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CHAPTER 9: STATISTICAL ANALYSIS 
Aim1 assesses the relationship between extent and severity of periodontitis on NAFLD 
occurrence; aim 2 assesses effect measure modification of the periodontitis-NAFLD association by a 
panel of genetic markers of inflammation; and aim 3 assesses the impact of losses to follow-up on study 
findings. Individuals meeting any of the following criteria reported at baseline were excluded: number of 
alcoholic beverages of ≥70g of ethanol/week for women and ≥140g of ethanol/week for males 
(Neuschwander-Tetri et al. 2010), reported use of the following medications: tamoxifen, amiodarone, and 
methotrexate, self-reported doctors diagnosis of chronic or autoimmune viral hepatitis in the past year, 
detection of hepatitis B surface antigen (HbS), hepatitis C antibodies (HbC) in blood samples and 
transferrin saturation <50%. 
9.1 Descriptive analysis 
Data analysis began with an examination of data distributions for exposure, outcome and 
covariates. Specifically, the frequency (n) and relative frequency (%) of periodontitis (extent and 
severity), NAFLD status (yes/no) based on serum transaminase, hepatic ultrasound, and FLI and mean 
(SD) and median (IQR) for ALT, AST and GGT. In addition, the distribution of covariates were reported 
according to extent of sites with periodontitis (0%, <30%, and ≥30%). For continuous covariates like age, 
BMI, waist and hip circumference, their distributions were assessed graphically using histograms and 
descriptively using medians and interquartile ranges (IQR). 
9.2 Data Analysis of Specific aim 1 
To estimate the total effect of baseline periodontitis status on the 11-year cumulative risk and rate 
of NAFLD, NAFLD measured with serum transaminases (ALT) was modeled continuously while 
NAFLD defined as ALT/AST ratio ≥1 and NAFLD assessed via ultrasound were modeled as binary. 
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Control for confounding was accomplished using weighted propensity scores (PS). The 
corresponding predicted probabilities (i.e. propensity scores) were outputted and inverse probability of 
exposure weights created. The inverse probability of exposure weights were stabilized by multiplying by 
the marginal probability of exposure (periodontitis) for the exposed and 1 minus this probability for the 
unexposed.  
The model form for the PS score model follows below. For extent measures of periodontitis 
defined as the proportion of sites with PD of ≥4mm and separately as proportion of sites with CAL of 
≥3mm, a quantile binning of exposure was done and predicted probabilities estimated using a cumulative 
logit model (Naimi et al. 2014). 
PS model: E[X|C] =α0+α1C+ε (where ε, mean ~ 0, σ2=1) 
PS model: Logit[P(X=1| C)] =α0+α1C 
Stabilized inverse probability weight for the exposed was calculated as Pe/PS and (1-Pe)/(1-PS) 
for the unexposed. Where Pe=marginal probability of the exposure. C-vector of baseline covariates. The 
final outcome model included only the exposure as a covariate but weighted by the previously described 
exposure weight. The numerator of the stabilized inverse probability weight for the cumulative logit 
model was calculated as the inverse of the bin number an individual fell into. For example, say we created 
j=1,2,3….10 quantiles, the numerator for the weight i.e. the marginal probability of falling into category j 
equals 1/j (Naimi et al. 2014). 
9.2.1 Specific aim 1, Hypothesis #1 
The total effect of periodontitis on NAFLD risk was investigated after restricting to participants 
free of NAFLD at baseline. To investigate baseline periodontitis status on the 11 year rate of NAFLD, 
occurrence, the following Poisson regression model was fit to estimate rate ratios and 95% confidence 
interval. 
Log(Y=1|X) =α0+α1X+Logti 
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where Y-NAFLD; X-periodontitis; Logti –log of person-time or offset. Extent of periodontitis was 
modeled separately as the proportion of sites exhibiting PD of ≥4mm, and the proportion of sites 
exhibiting CAL of ≥3mm. Control for confounding was accomplished as previously described using 
inverse probability of exposure weights. 
9.2.2 Specific aim 1, Hypothesis #2 
 Change in periodontal attachment level (i.e. ALOSS) from baseline is associated with poorer 
measures of NAFLD (transaminases, ultrasound) at follow-up. This analysis was based on CAL measures 
only and not PD because loss 
of clinical attachment over 
follow-up is considered the 
cardinal sign of periodontal 
destruction. Therefore, mean 
CAL at baseline was 
subtracted from mean CAL at 
first follow-up to determine 
the mean change in CAL or 
mean clinical attachment loss. 
This calculation was restricted only to periodontal sites that were present at baseline and first follow-up 
visits. Because of the different periodontal probes used at each study visit,  and to minimize biases from 
digit preferences, mean CAL values SHIP-1 were adjusted to the values it would have been had the 
PCP11 probe instead of PCP-2 periodontal probe been used as previously described.(Holtfreter et al. 
2012). Using this exposure specification, the relationship between periodontitis and NAFLD incidence 
was assessed also with a Poisson regression model that estimated rate ratios and 95% C.I. 
For all models, adjustment for confounding was achieved using inverse probability of exposure 
weights derived from propensity score models. Variables included in the propensity score models were 
Figure 4. Directed Acyclic Graph 
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confounders and outcome risk factors (Rosenbaum and Rubin 1983). For continuous and ordinal 
variables, the linearity assumption with NAFLD on the natural log scale was assessed (Figure 25). When 
the linearity assumption was violated, continuous variables were modeled with flexible splines while 
ordinal variables were modeled with indicator terms. A sufficient set of confounders were identified after 
analyzing a directed acyclic graph (Figure 4) (Greenland et al. 1999). Baseline confounders and outcome 
risk factors included: age, gender, BMI, smoking, diabetes, socio-economic status, physical activity, waist 
circumference, educational attainment and alcohol consumption. Given difference measures of 
association have inherent public health relevance, incidence rate differences and 95% CI for the analyses 
described above were also estimated. 
9.3 Data analysis of Specific aim 2 
To assess potential effect measure modification of the periodontitis-NAFLD association 
according to categories defined by an inflammatory biomarker specific genetic score. 
9.3.1 Specific aim #2 hypothesis #3 
For common complex diseases, multiple gene loci as opposed to a single locus are responsible for 
their expression (Risch 2000). For instance, among participants of the cardiovascular heart health study 
aged ≥65years, a single CRP SNP accounted for <2% of variation in plasma CRP levels while 5 SNPs 
cumulatively explained 6.4% of variation in CRP (Lange et al. 2006). Thus, it was hypothesized that the 
effect from multiple gene loci will be associated with stronger effects than the effect from a single locus. 
To investigate the contribution of multiple gene loci, a genetic score (GS) as described by Pharoah et al 
(Pharoah et al. 2008) and implemented by (Kader et al. 2012; Mavaddat et al. 2015; Thanassoulis et al. 
2012; Xiao et al. 2015) was created. The GS was estimated for each individual under the assumption that 
the respective effect measure for each SNP combine additively using the formula: 
GS = α  x α  x        α k x k  α n x n  
Where α k is the per-allele beta estimate for the inflammatory marker associated with the risk allele for 
SNP k, and xk the number of alleles for the same SNP (0, 1 or 2), and n=total of SNPs used in creating 
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the GS. In other words, a weighted genetic risk score was calculated for each individual based on 
his/her genotype for each inflammatory SNP(s) and weighted by effect estimate reported for each 
SNP in the original study. Quality control (QC) assessments at the SNP level included: call rate, 
minor allele frequency (MAF), and deviation from Hardy Weinberg equilibrium (HWE), while the 
call rate, gender and relatedness assessed quality at the sample level. QC checks were performed 
using PLINK (Purcell et al. 2007). 
9.4 Data analysis of Specific aim 3 
Inverse probability of censoring weights (Cole and Hernan 2008; Howe et al. 2016) were created 
to evaluate the impact of losses to follow-up on the association between periodontitis and NAFLD.  
By the time of the second follow-up visit close to half (45%) of the baseline study participants had 
become lost to follow-up. This is problematic if for instance, participants who remained under study 
are not representative of those who were lost to follow-up thus making these losses informative and a 
source of threat to the internal validity of study findings. 
9.4.1 Specific aim#3, hypothesis 4 
Inverse probability of censoring weights (IPCW) 
The inverse probability of censoring weight is the probability that a given participant was not lost 
to follow-up through time t conditional on exposure (if exposure is associated with loss to follow-up) 
divided by the probability that the participant remained on study through time t conditional on measured 
determinants of the outcome and loss to follow-up including exposure (if exposure is associated with loss 
to follow-up). At each follow-up visit, study participants were assigned this weight. To estimate the 
numerator and denominator probabilities, a pooled logistic regression, modeling as the outcome the log 
odds of remaining on study conditional on the exposure and determinants of loss to follow-up was fit. 
 Logit P[D(t)=0|D(t-1)=0, Y(t-1)=0, X]=α0t+α1X –numerator of stabilized weight 
 Logit P[D(t)=0|D(t-1)=0, Y(t-1)=0, X,Z]=β0t+β1X+ β2Z –denominator of stabilized weight 
α0t and β0t are time the specific intercepts; P[D(t)=0] is the probability of remaining on study at time t; 
P[Y(t)=0] is the probability of not developing the outcome at time t. 
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To fit these models, data were first transformed from a person level to a person-period data 
structure with multiple records per person. A binary indicator for censoring was created and assigned a 
value of 0 until the date of the last observation, at which point censored individuals are assigned a value 
of 1. The respective predicted probabilities were estimated from the pooled logistic regression models and 
IPCWs created  
  𝑠𝑤(𝑡) = ∏
𝑃[𝐷(𝑡)=0|𝐷(𝑡−1)=0,𝑌(𝑡−1),𝑋
𝑃[𝐷(𝑡)=0|𝐷(𝑡−1)=0,𝑌(𝑡−1),𝑋,𝑍
𝑡
𝑢=1  ; where(𝑡 − 1) = 0 𝑎𝑛𝑑 𝑌(𝑡 − 1) = 0, 
respectively indicate that the participant was not lost to follow-up and did not develop the outcome 
prior to time t; u=1,2. zi(t), and x are respectively the actual values of any time-varying, baseline 
predictors of loss to follow-up and the exposure. To allow participants who were lost to follow-up to 
receive a non-zero weight when they exit the risk set and in turn be able to calculate the number of 
losses in the pseudo-population weighted by SW(t), the stabilized SW(t)=0 only for times after loss to 
follow-up occurred (Howe et al. 2016). Bootstrapping (Nevitt and Hancock 2001) was used to obtain 
appropriate standard errors for the estimation of confidence intervals, recalculating the weights on 
each resample (Cole et al. 2015; Howe et al. 2016).  
The IPCW in essence, creates a pseudopopulation that would have been observed had losses to 
follow-up occurred randomly (i.e. uninformatively) conditional on measured exposure and covariates 
(Howe et al. 2016). This pseudopopulation was created by reweighting the contribution of each study 
participant who was not lost to follow-up at a given study visit (Howe et al. 2016). This technique 
assumes the outcome in those who remained on study is a true reflection of the unobserved outcomes of 
those lost to follow-up with similar exposure and covariate values (Hernán et al. 2004), making the 
exposure effect the same as in the original population. Thus, the pseudopopulation effect measure is in 
expectation, equivalent to the effect measure had nobody been lost to follow-up. This assumption cannot 
be tested empirically, but bounds can be created for worst and best case scenarios where everyone 
exposed is lost to follow-up to no one exposed is lost to follow-up respectively. IPCW estimates marginal 
as opposed to covariate conditional estimates corrected for selection bias with estimates that are more 
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easily displayed graphically (Cole et al. 2015). As with methods applying inverse probability weights, the 
assumptions of conditional exchangeability, positivity and correct model specification of both the weight 
and outcome models are required for any resulting estimates to be valid. In addition, the exposure and 
censoring mechanism must also be well defined (Hernán and Robins 2016; Hernán et al. 2004; Howe et 
al. 2011). 
Multiple imputation using chained equations (MICE) for variables with missing values 
 Multiple imputation is a missing data technique for data assumed to be missing at random 
(MAR). This process essentially uses the distribution of non-missing data to estimate a set of 
plausible values for missing data points. Given a range of values are plausible for a particular data 
point, uncertainties in terms of random components are incorporated into the imputation to create 
multiple datasets that are analyzed individually and combined to into an overall estimate, variance 
and confidence interval. When correctly implemented multiple imputation estimates are 
asymptotically unbiased and the standard errors and confidence intervals asymptotically efficient 
(White et al. 2011). Three stages are involved in conducting the multiple imputation: 
1. Generate multiply imputed datasets. This stage involves replacing missing data points with m 
independent simulated sets of values drawn from the posterior predictive distribution of the 
missing data conditional on observed data. For instance, say variable c1 has missing 
observations, c1 is regressed on a set of variables c2, c3, c4…ck with non-missing data points 
among those with non-missing values of c1 (White et al. 2011). Next, the second variable 
with missing values say c2, is regressed on all other variables c1, c3, c4. . . , ck , restricted to 
individuals with observed c2, and using the imputed values of c1. Missing values in c2 are 
replaced by draws from the posterior predictive distribution of c2. The process is repeated for 
all other variables with missing values in turn. In order to stabilize results, the procedure is 
repeated for several cycles (e.g. 10 or 20) to produce a single imputed data set, and the whole 
procedure is repeated m times to give m imputed data sets (White et al. 2011). The choice of 
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regression model for c1 depends on the type of variable c1 is and can range from linear if c1 
is continuous to logistic regression if c1 is categorical. 
2. Once multiple imputations have been generated, each imputed dataset is analyzed separately, 
outputting the estimates and covariance matrix. In general, it is expected that the estimates 
from each dataset will differ because missing values have been replaced by different imputed 
values. 
3. Lastly, the m estimates and the variance-covariance matrix are combined into an overall 
value using Rubin’s rules based on asymptotic theory in a Bayesian framework. The 
combined variance-covariance matrix accounts for both within and between imputation 
variability. 
 When there are several variables with missing data points MICE, is a practical approach to 
generating imputations based on a set of imputation models, one for each variable with missing 
values. Variables included in the imputation models are all variables included in the final outcome 
models, predictors of missing data/censoring. This is important for 2 reasons: 1) doing this makes the 
MAR assumption more plausible; 2) it improves imputation and reduces standard errors of estimates 
for the final outcome model. In contrast, variable selection could also be based on univariate or 
multivariate associations in complete cases or a provisional imputation scheme with a small number 
of imputations applying a model selection procedure. Thus, it is possible that the MI model to contain 
more variables than the final outcome model. This approach might be problematic from the 
standpoint of precision as bias is seldom encountered. In addition to including all necessary variables 
in the imputation model, they must also be correctly specified, including adding any necessary 
product interaction terms to the imputation model to preserve any underlying data structure. 
 The MICE method uses a fully conditional specification when imputing data. This method 
does not assume a joint distribution among variables to be imputed nor does it assume a common 
multivariate normal distribution for variables to be imputed. Rather, it uses a separate conditional 
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distribution for each imputed variable (UCLA). Trace plots are used in model diagnostics to assess 
how well the imputations performed. The number of imputed datasets is based on the largest fraction 
of missing information (FMI) for variables to be imputed (White et al. 2011). Such that if the variable 
with the most missing data is missing 20% of its data points, then at least 20 datasets must be 
imputed. This is important because it ensures reproducibility of estimates using the same data sets. 
Additionally, variance and covariance estimates are more stable. Lastly, multiple imputation is not 
synonymous with making up data because several data points are imputed and uncertainties in 
imputed quantities are incorporated at each stage of the imputation procedure. The goal is not 
necessarily to impute the correct covariate value but to obtain unbiased estimates of the exposure-
outcome association. 
9.5 Bias Analysis 
9.5.1 Sensitivity analysis to unmeasured confounding of the total effect 
Sensitivity analysis on the Multiplicative scale 
For the total effect of chronic periodontitis on NAFLD as proposed in specific aim 1, the 
robustness of study findings to potential unmeasured confounding U was investigated by defining the bias 
factor Bmult(c) on the multiplicative scale as the ratio of: 
• The odds ratio (rare outcome) comparing X=1 (moderate/severe periodontitis) to X=0 (none/mild 
periodontitis) conditional on the vector of measured covariates C (exposure-outcome 
confounders) and 
• What would have been obtained as the odds ratio had the vector of covariates C and U been 
conditioned upon.  
Assuming a binary U and no interactions between X and U i.e. the effect of U on Y is the same for all 
strata of X, the effect of U on Y conditional on X and C is given by: 
𝛾 =
𝑃(𝑌 = 1|𝑥, 𝑐, 𝑈 = 1)
𝑃(𝑌 = 1|𝑥, 𝑐, 𝑈 = 0)
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This is the effect of U on Y conditional on C i.e. U’s effect on Y not through C. The bias factor on the 
multiplicative scale is thus given by: 
Bmult(c) =
1+(𝛾−1)𝑃(𝑈=1|𝑥=1,𝑐)
1+(𝛾−1)𝑃(𝑈=1|𝑥=0,𝑐)
 
To get the corrected estimate i.e. effect estimate conditional on both the vector of measured covariates C 
and unmeasured confounder U, observed estimates and both limits of the confidence intervals were 
divided by Bmult(c) to get the corresponding corrected point estimates and confidence intervals. Because 
of the subjectivity of this approach, a wide range of values for 𝛾, and the prevalence of U among the 
exposed and unexposed from highly plausible to unreasonably large values that would explain away any 
observed effect were specified and results tabulated.  
9.6 Statistical power 
 For specific aim1, 
the following assumptions 
were made: prevalence of 
periodontitis of 33% —
conservative, given 
prevalence can be as high 
as 53% in this population 
(Holtfreter et al. 2009), 
constant hazard, and 25% 
of total person-years is 
exposed PYs, a cumulative NAFLD incidence of 12% by 10 years, 40% loss to follow-up by 10 years and 
a 2-sided alpha of 0.05. With baseline sample size of 4,308, an HR of at least 1.3 can be detected with 
80% power (Figure 5). 
 
 
Figure 5. Power to detect main effects 
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For specific aim 2, given a MAF of 0.2, NAFLD prevalence among unexposed of 35%, a main-effects 
OR of 1.1 for SNP effect, OR 
of 1.4 for periodontitis, a 
sample size of 4,000, 
assuming a log additive model 
and a 2-sided alpha of 0.05, a 
gene*environment interaction 
OR of 1.3 can be detected 
with 55% power (Figure 6). 
For these same specifications, 
power to detect an effect 
increases with increasing 
frequency of the minor allele. Power analyses were conducted using SAS version 9.4 (SAS Institute, 
Cary, NC) and the Dartmouth power calculator (Demidenko 2007; 2008). 
 
 
 
  
Figure 6. Power to detect gene x environment interaction 
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CHAPTER 10: MANUSCRIPT 1 
10.1 Study Highlights 
10.1.1 Current knowledge 
 
Non-alcoholic Fatty Liver Disease is common and it is associated with high health care costs. 
Periodontitis is associated with Non-alcoholic Fatty Liver Disease risk factors like obesity and insulin 
resistance while the evidence linking periodontitis to Non-alcoholic Fatty Liver Disease comes from one 
cross-sectional clinic based study in humans and several experimental mice models. 
10.1.2 New information 
 
This investigation provides new information of a longitudinal nature, specifically, the first 
longitudinal epidemiologic investigation linking periodontitis to NAFLD. Also, history of periodontitis as 
opposed to active periodontitis at the time of examination plays a bigger role in NAFLD occurrence. 
Loosing additional periodontal attachment among participants with pre-existing periodontitis at baseline 
was associated with the subsequent occurrence of NAFLD. 
10.2 Introduction  
Non-alcoholic fatty liver disease (NAFLD), the excessive infiltration of triglycerides into 
hepatocytes in the absence of excessive alcohol consumption (Neuschwander-Tetri and Caldwell 2003) is 
the most common type of liver disease and the hepatic component of the metabolic syndrome (Kotronen 
and Yki-Järvinen 2008; Lazo et al. 2013). It comprises a spectrum of conditions ranging from steatosis, to 
non-alcoholic steatohepatitis (NASH) with or without fibrosis, to liver cirrhosis and hepatocellular 
carcinoma (Farrell et al. 2004). Depending on race/ethnicity and diagnostic modality, NAFLD is 
estimated to affect 17-33% of adults in the U.S. (Angulo 2002; Clark et al. 2002; Erbey et al. 2000; Lazo 
et al. 2013) and 20-30% worldwide (Bedogni et al. 2005; Bellentani et al. 2004; Neuschwander-Tetri and 
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Caldwell 2003; Yu and Keeffe 2002). NAFLD is associated with higher health care costs (Baumeister et 
al. 2008) and mortality (Baumeister et al. 2008; Musso et al. 2011), the latter attributed to cardiovascular 
and other liver diseases related complications (Adams et al. 2005a; Ong et al. 2008; Soderberg et al. 
2010).  
Risk factors include obesity and insulin resistance (Angulo 2002; Neuschwander-Tetri and 
Caldwell 2003), the effects of which are thought to be mediated via oxidative stress which contributes to 
NAFLD initiation (Tilg and Moschen 2010) and progression (Day and James 1998; Tilg and Moschen 
2010). Other conditions eliciting systemic inflammatory responses likely contribute to NAFLD 
occurrence. Specifically, periodontitis, a chronic oral disease affecting 45% of adults in the U.S. (Eke et 
al. 2015; Eke et al. 2012b). Periodontitis manifests as inflammation of the gums and formation of 
periodontal pockets in response to pathogenic bacteria that colonizes the tooth surface. Host response 
include localized production of endotoxins, lipopolysaccharides (LPS) and proinflammatory cytokines 
(Gurav and Jadhav 2011; Page 1998; Page and Schroeder 1976; Yucel-Lindberg and Bage 2013). When 
host response is unfavorable, the inflammatory process causes gradual periodontal destruction and loss of 
attachment between periodontal tissues and the tooth. Bacteremia occurs frequently in individuals with 
periodontitis (Schenkein and Loos 2013). Furthermore, sera from individuals affected by periodontitis 
contain elevated levels of LPS which promotes systemic inflammatory response. In addition to the 
systemic inflammatory response elicited, periodontitis also worsens glycemic control among diabetics, 
can impair glucose tolerance among non-diabetics and is linked to insulin resistance (Benguigui et al. 
2010; Chapple and Genco 2013; Demmer et al. 2008; Lalla and Papapanou 2011; Saito et al. 2004; 
Stewart et al. 2001; Timonen et al. 2011).  
Our objectives were to 1) investigate the relationship between clinical periodontitis at baseline 
and 2) progression of periodontitis on the subsequent development of NAFLD. 
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10.3 Methods 
10.3.1 Data Source and study population 
The Study of Health in Pomerania (SHIP) is a population-based cohort sampled from the Western 
Pomeranian region of Northeastern Germany. Details of the study design and data collection have been 
described (Hensel et al. 2003; John et al. 2001; Volzke et al. 2011). Briefly, residents of West Pomerania 
aged 20-79 years in 1996 were sampled using a two-stage stratified cluster design. Communities were 
selected as part of the first stage and individuals were selected in the second stage after stratifying by age 
and gender. Baseline examinations (SHIP-0), were conducted between 1997 and 2001. Of 6,265 eligible 
persons invited, 4,308 participated in SHIP-0 (response rate: 68.8%). Follow-up examinations occurred at 
approximate 5-year intervals, with the first follow-up (SHIP-1) conducted between 2002 and 2006 and the 
second (SHIP-2) between 2008 and 2010. A total of 3,300 participated in SHIP-1 and 2,333 participated 
in SHIP-2. Re-examination participation rates were 76.6% and 70.7% respectively. 
10.3.2 Exposure assessment and characterization 
Dental examiners determined periodontitis status at each study visit using measures of probing 
pocket depth (PD) and clinical attachment level (CAL). PD, defined as the distance from the free gingival 
margin to the base of the periodontal pocket, is an indicator of active periodontitis at the time of the 
examination.  CAL, defined as the distance from the cemento-enamel junction (a fixed landmark on the 
tooth) to the base of the periodontal pocket, signifies the lifetime history of periodontitis up until the time 
of the examination. These measurements were made around teeth other than 3rd molars in two dental 
quadrants (a selected quadrant and its ipsilateral quadrant). PD and CAL were recorded at four sites per 
tooth: the mesio-buccal, mid-buccal, disto-buccal and mid-lingual or mid-palatal. Measurements were not 
made when teeth were missing or landmarks could not be determined. The maximum number of sites was 
56 per study participant. 
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To characterize periodontitis at baseline, two person-level classifications were created: 1) the 
proportion of sites with CAL ≥3mm (0%, <30%, ≥30%); 2) the proportion of sites with PD ≥4mm (0%, 
<30%, ≥30%). Participants with no teeth (i.e. edentulous) were included as a separate exposure category, 
under the premise that reasons for tooth-loss probably included some prior experience of periodontitis 
(Burt and Eklund 2005). In addition, participants’ mean CAL and mean PD at baseline were also modeled 
separately. Progression of periodontitis was computed as the 5-year change in mean CAL between SHIP-
0 and SHIP-1. This calculation used only those periodontal sites that were present at both visits. The 
PCP11 periodontal probe was used for periodontal measurements at SHIP-0, while the PCP2 probe was 
used at SHIP-1. Thus, mean CAL values were adjusted to minimize biases from digit preferences as 
described elsewhere (Holtfreter et al. 2012). Because it is measured longitudinally, change in CAL is 
regarded as the cardinal sign of destructive periodontitis (Beck and Elter 2000). 
10.3.3 Outcome assessment and characterization 
Abdominal sonography was performed by trained physicians using a 7.5 MHz transducer 
(Vingmed VST Gateway, Santa Clara CA). Levels of serum transaminases i.e. markers of hepatic 
inflammation were determined by analyzing blood samples stored at -80C using standardized procedures 
(Hitachi 704; Roche, Mannheim, Germany). The presence of fatty liver was assessed using hepatic 
ultrasound and serum transaminase- alanine aminotransferase (ALT) at baseline (SHIP-0); ALT at SHIP-
1; ALT and hepatic ultrasound at SHIP-2. A positive finding on ultrasound was defined as a significant 
increase in liver echogenicity relative to the kidneys, with the diaphragm indistinct OR the echogenic 
walls of the portal veins invisible (Baumeister et al. 2008; Williams et al. 2011). NAFLD case-
classification was based on a combination of ultrasound findings and ALT levels in the absence of other 
causes of liver diseases as previously described (Clark et al. 2003). NAFLD cases were those with a 
positive finding on ultrasound or ALT above the sex-specific upper threshold of normal defined for this 
study population i.e. >0.57 µmol/sl for men and >0.4 µmol/sl for women (equivalent to >34.2 U/L for 
men and 24 U/L for women). For SHIP-1, only ALT values identified incident NAFLD, thus 
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necessitating a strong reliance on the exclusion criteria described below in identifying ‘true’ cases (Clark 
et al. 2003). ALT instead of AST was chosen because ALT is primarily found in the liver, it is a more 
specific marker of hepatocellular injury with levels persisting longer than those of AST after an injury. 
10.3.4 Study exclusions 
At baseline, participants (n=604) who reported excessive alcohol consumption (see 10.8.1 
Materials and Methods) were excluded. Also excluded were participants self-reporting the following 
hepatic steatosis-promoting medications: tamoxifen, amiodarone or methotrexate (n=18) (Angulo 2002; 
Osman et al. 2007); participants with a doctor’s diagnosis of hepatitis B or C in the past year (n=17), or 
detectable levels of the corresponding antigen (n=15) or antibody (n=22) in blood samples. Participants 
with steatosis on ultrasound with or without elevated ALT levels (n=1,265) were excluded as prevalent 
NAFLD cases. Lastly, individuals (n=14) with missing dental examination data were excluded. Some 
participants were ineligible for multiple reasons. 
10.3.5 Covariates 
Baseline covariates included confounders identified after analyzing a directed acyclic graph 
(Greenland et al. 1999) and risk factors for NAFLD. Age was self-reported and was modeled using 
restricted quadratic splines. Gender was reported as male or female. Alcohol was adjusted for to minimize 
any residual effect of alcohol and was modeled using restricted quadratic splines. Waist circumference 
was measured in centimeters and modeled using restricted quadratic splines. BMI was categorized into 
underweight/normal (<25 kg/m2), overweight (25-30 kg/m2) and obese (>30 kg/m2). Education was used 
as a marker of socio-economic position and was categorized into <10, 10 and >10 years of formal 
education. Diabetes was based on self-reported physician’s diagnosis or the study’s measurement of 
HbA1c ≥6.5%. Self-reported smoking was categorized as never, former and current. Physical activity was 
based on self-reported number of hours per week of moderate activity. 
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10.4 Statistical Analysis 
10.4.1 Control of confounding  
Confounding control was accomplished by inverse probability of exposure weights (IPEW) (Cole 
and Hernan 2008) that included the following confounders and NAFLD risk factors as variables: age, 
waist circumference, BMI, alcohol, education, smoking, diabetes and physical activity (see 10.8.1 
Materials and Methods). 
10.4.2 Controlling for censoring due to Loss-to-Follow-up (LTFU) 
The overall LTFU was 40%. Given this magnitude, LTFU may be informative to the extent of 
biasing study findings if there are differential losses between exposure groups or with respect to the 
outcome. To minimize potential biases from LTFU, inverse probability of censoring weights (Howe et al. 
2016) were created with the following variables that predicted dropping out of study with p <0.05: age, 
gender, smoking, alcohol, PD ≥4mm, and ALT (see 10.8.1 Materials and Methods).  
10.4.3 Outcome models 
Weighted Poisson regression estimated incidence rate (IR), incidence rate ratio (IRR) and 
incidence rate difference (IRD) of NAFLD occurrence while 200 bootstrap resamples (Nevitt and 
Hancock 2001) estimated the corresponding standard errors and 95% confidence intervals. In addition, 
confounding and censoring due LTFU adjusted cumulative risk of NAFLD for each exposure groups were 
estimated and results are presented graphically (see Figure 7 and Figure 8). 
10.4.4 Multiple imputation 
Multiple imputation was performed for missing data using chained equations (White et al. 2011). 
The following variables were imputed: transaminases (ALT, AST, GGT), alcohol, smoking, BMI and 
waist circumference. Because approximately 40% of transaminase values were missing at SHIP-1 (Table 
5), a total of 40 datasets were imputed using 500 between imputation iterations. Trace plots (Figure 10) 
assessed how the imputation algorithm performed, while kernel density plots (Figure 11) assessed 
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deviation of imputed values from observed. Statistical tests were 2-sided and p <0.05 was considered 
nominally statistically significant. Analyses (including multiple imputation) were conducted in SAS v.9.4 
(SAS Institute, Cary NC), across 40 imputed datasets. The results from each imputed dataset were 
summarized using Rubin’s rule (Rubin 1987) into an overall estimate accounting for both within and 
between imputation variances. 
10.5 Results 
Of the 2,330 participants with baseline PD measurements, 766 (32.8%) had no sites with PD 
≥4mm (periodontally-healthy), 1,293 (49.3%) had up to 30% of sites affected (moderate PD-
periodontitis) and 271 (10.3%) had ≥30% sites affected (extensive PD-periodontitis). Of the 2,233 
participants with baseline CAL measurements, 258 (11.6%) were periodontally-healthy, 767 (34.3%) had 
moderate CAL-periodontitis and 1,208 (54.1%) had extensive CAL-periodontitis. There were slightly 
more female than male participants (59% vs. 41%). The median age at baseline was 46 years (IQR: 33-
62) and the 293 edentulous participants were on average older than participants in the other exposure 
groups (Table 1). 
After a median follow-up of 7.7 years (IQR: 2.5-10.6), 588 NAFLD cases were identified during 17,973.2 
person-years of follow-up among the edentulous and participants with baseline CAL measurements. 
While 605 NAFLD cases accrued during 18,595.1 person-years of follow-up among the edentulous and 
participants with baseline PD measurements. Approximately 40% of study participants were lost to 
follow-up with edentulous participants having the highest proportion of losses at 74% (Table 2). 
The unadjusted incidence rate of NAFLD was slightly elevated in the two CAL-periodontitis 
groups compared to periodontally-healthy participants (Table 3), although the IRRs were imprecisely 
estimated. However, upon adjusting for confounders and censoring, there was a dose-response 
relationship in the respective IRRs and IRDs. For instance, the IRR comparing participants with moderate 
CAL-periodontitis to periodontally-healthy participants was 1.28; 95% CI, 0.84-1.95, while for extensive 
CAL-periodontitis the estimate was 1.60; 95% CI, 1.05-2.43. The corresponding IRDs were 5.49 
additional cases per 1,000 person-years; 95% CI, -2.53-13.5 and 11.9 additional cases per 1,000 person-
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years; 95%CI, 4.09-19.6 respectively (Table 3). NAFLD rate was also elevated among edentulous 
participants relative to the periodontally-healthy, although the increase was not significantly different 
from the null, adjusted IRR= 1.37; 95%CI, 0.26-7.15. Similar tendencies were seen for PD-periodontitis, 
although there was no dose-response relationship in the fully-adjusted analysis (Table 3). Qualitatively, 
similar inferences for CAL and PD were obtained from complete case analysis (no data imputation), 
although the corresponding NAFLD rates were smaller (Table 6).  
To ensure adequate control for smoking, data analysis was restricted to non-smokers; the results 
were consistent with those above. For instance, the confounding and censoring-adjusted IRR comparing 
participants with moderate and extensive CAL-periodontitis to periodontally-healthy participants were 
1.11; 95% CI, 0.56-2.21 and 1.72; 95% CI, 0.92-3.21 respectively (Table 20). 
Irrespective of the extent of sites affected, having periodontitis increased the cumulative risk of NAFLD 
(Figure 7). For PD classification, the edentulous group had a greater risk earlier during follow-up, 
however, the risk among participants with PD-periodontitis rose sharply over the follow-up period 
(Figure 8). 
The mean CAL at baseline was 2.4 (SD: 1.8) per participant while the corresponding mean PD 
was 2.5 (SD: 0.7) per participant. The adjusted IRR of NALFD for each 3mm increase in mean CAL, was 
1.11; 95% CI, 0.92-1.34, and 1.28; 95% CI, 0.63-2.57 for each 4mm increase in mean PD (Table 4). 
Among 1,463 eligible participants, progression of periodontitis between SHIP-0 and SHIP-1, was 
observed for 253 (17.3%) participants at a threshold of ≥1mm increase in mean CAL, and for 69 (4.7%) 
participants at a threshold of ≥2mm increase in mean CAL. There was no meaningful difference in the IR 
of NAFLD according to periodontitis progression using either threshold. However, there was a significant 
statistical interaction between CAL at baseline and periodontitis progression (P=0.05).  That is, among 
participants with CAL ≥3mm at baseline, the adjusted IRR of NAFLD comparing participants with mean 
change in CAL of  ≥2mm to participants with <2mm was of 2.07; 95% CI, 0.96-4.58 (Table 4). 
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10.6 Discussion 
10.6.1 Summary of current findings 
Findings of the current study were consistent with a greater incidence rate of NAFLD among 
participants with a history of periodontitis (i.e. CAL-periodontitis) compared to participants with a 
healthy periodontium. In contrast, the PD-periodontitis was not credibly associated with NAFLD. 
Progression of periodontitis measured over five years was also associated with greater incidence of 
NAFLD, although confined only to participants with a relatively extensive history of periodontitis at 
baseline. 
10.6.2 Summary of previous findings 
Evidence to date of an association between periodontitis and NAFLD comes from experimental 
animal models (Tomofuji et al. 2007; Yoneda et al. 2012) and a cross-sectional clinic-based study 
(Yoneda et al. 2012). Mice randomized to a high fat diet and Porphyromonas gingivalis (a potent 
periodontal pathogen) compared to those randomized to a high fat diet alone (Tomofuji et al. 2007; 
Yoneda et al. 2012), had significant increase in body and liver weight, and elevated ALT (Yoneda et al. 
2012). Substituting P. gingivalis with Streptococcus mutans (a dental caries pathogen), had no effect on 
mice body or liver weight. A clinic based study of biopsy-confirmed NAFLD found more NAFLD cases 
than non-cases to have detectable P. gingivalis levels and a 3-month periodontal therapy led to subsequent 
reductions in elevated transaminases (Yoneda et al. 2012). A plausible relationship between periodontitis 
and NAFLD is suggested by these results. 
10.6.3 Possible biologic mechanisms 
The greater NAFLD occurrence among participants with a history of periodontitis could be 
attributed to an underlying hyper-inflammatory trait (Shaddox et al. 2010), that increases the risk of 
initiation and progression of periodontitis and subsequently to a heightened inflammatory response. In 
addition, an increased permeability in gut epithelia induced by swallowed P. gingivalis, potentially leads 
to an alteration in the gut microbial composition (Arimatsu et al. 2014). Given that the liver is constantly 
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exposed to gut-derived factors through the portal vein, resident liver cells become activated by 
proinflammatory factors like LPS with subsequent production of cytokines and, reactive oxygen species 
(ROS) that contribute to liver injury (Imajo et al. 2014). Regarding NAFLD pathogenesis, the ‘two-hits’ 
(Day and James 1998) theory attributes the ‘first-hit’ to steatosis secondary to insulin resistance and, the 
‘second-hit’ to gut derived bacteria endotoxins which promote the inflammation that enhances disease 
progression. A likely source of gut-derived bacterial endotoxin is periodontal pathogen derived LPS given 
that an average 107 copies of periodontal bacteria are found in a mL of saliva (Saygun et al. 2011). In 
experimental animal models, oral administration of P. gingivalis led to changes in the gut microbiota 
leading to metabolic endotoxemia, a precursor for metabolic disorders (Arimatsu et al. 2014). While the 
current study lacked microbiologic data, it is worth mentioning that progression of periodontitis was 
associated with NAFLD only among participants with relatively extensive history of periodontitis. One 
possible explanation is that progressive loss of periodontal attachment elicits systemic responses only 
when progression is occurring at deep periodontal sites that are more likely anaerobic and capable of 
eliciting systemic inflammation. 
Acute inflammation hallmarks tissue injury and is characterized by short term adaptive responses 
vital to tissue repair. In contrast, sustained ‘low-grade’ or chronic inflammation (Hotamisligil 2006), is 
non-beneficial although it engages similar sets of molecules and signaling pathways. This ‘low-grade’ 
inflammation is central to the pathogenesis of obesity related insulin resistance, an NAFLD precursor 
(Hotamisligil 2006). Increased serum levels of LPS and TNF-α associated with P. gingivalis infection can 
demonstrably initiate and worsen insulin resistance (Santos Tunes et al. 2010). Therefore, ‘low-grade’ 
inflammation and exacerbation of insulin resistance likely also links periodontitis to NAFLD. 
10.6.4 Clinical and Public Health implications 
The adjusted 10-year NAFLD cumulative risk difference comparing participants with CAL 
≥3mm to periodontally-healthy participants was 11% (Figure 7). This corresponds to a NNTRD(t=10) of 9, 
interpreted as on average, 9 individuals will need to receive effective periodontal treatments to observe 
one fewer case of NAFLD among those with CAL ≥3mm at 10 years. Replication and experimental proof 
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of efficacy are required to gauge the clinical and population-wide implications of periodontitis as a 
modifiable risk factor for NAFLD. 
10.6.5 Strengths and Limitations 
Study limitations include potential misclassification of NAFLD status. While ultrasound is used 
to assess liver diseases in epidemiologic settings with reported sensitivity of 85% (95% CI: 80%-89%) 
and specificity of 93% (95% CI: 87%-97%), it is only able to detect disease if upwards of 20% of liver 
cells are affected (Hernaez et al. 2011). Another limitation is the reliance on ALT for identifying NAFLD 
at SHIP-1 given ALT is not always elevated when NAFLD is present. Therefore, if ALT is differentially 
under or overestimated according to periodontitis status then estimates are likely biased but the direction 
of bias is hard to predict. If non-differential, then estimates are likely biased towards the null. There is 
also the possibility for residual confounding given the lack of randomization and extensive losses to 
follow-up.  
Strengths include the prospective design and the ability to minimize temporal ambiguity by 
ensuring exposure preceded outcome. The in-depth characterization of the cohort enabled an extensive 
assessment of relevant confounding variables, which permitted adjustments not only for confounders but 
also an assessment of the impact of censoring due to loss to follow-up on study findings. 
10.7 Conclusions 
NAFLD prevalence is on the rise both in the U.S. and around the world. This investigation 
addresses an important gap in literature by characterizing for the first time, an association between 
periodontitis and incidence of objectively measured NAFLD. Periodontitis represents a modifiable risk 
factor for a disease state (NAFLD) where there are no approved pharmacologic interventions and other 
lifestyle modifications are more difficult to attain. 
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Figure Legend 
 
Figure 7. Confounding and censoring adjusted cumulative NAFLD risk for participants of the Study of 
Health in Pomerania according to the proportion of sites with CAL ≥3mm at baseline 
 
Figure 8. Confounding and censoring adjusted cumulative NAFLD risk for participants of the Study of 
Health in Pomerania according to the proportion of sites with PD ≥4mm at baseline 
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Table 1. Baseline characteristics according to the proportion of periodontal sites exhibiting clinical attachment level ≥3mm or probing pocket depth ≥4mm 
among NAFLD free adults in the Study of Health in Pomerania, 1997-2012 
     Proportion of sites with CAL ≥3mm 
(n=2,233) 
 Proportion of sites with PD ≥4mm  
(n=2,330) 
 Overall 
(n=2,623) 
 Edentulous 
(n=293) 
 No site 
(n=258) 
<30% 
(n=767) 
≥30% 
(n=1,208) 
P 
Value 
 No site 
(n=766) 
<30% 
(n=1,293) 
≥30% 
(n=271) 
P 
Value 
Age (yrs.)  46 (33, 62)  71 (65, 76)  26 (23, 31) 34 (27, 42) 54 (42, 63) <.001  34 (27, 52) 45 (34, 58) 54 (44, 64) <.001 
Male sex 1,074 (41)  145 (49)  94 (36) 259 (34) 531 (44) .9  272 (36) 524 (41) 133 (49) .5 
Smoking              
Non-smoker 1,002 (38)  108 (37)  101 (39) 291 (38) 460 (38) 
.02 
 313 (41) 489 (38) 92 (34) 
<.001 Former  809 (31)  125 (43)  69 (27) 213 (28) 372 (31)  214 (28) 403 (31) 67 (25) 
Current  801 (31)  58 (20)  88 (34) 263 (34) 367 (31)  239 (31) 394 (31) 110 (41) 
missing 11  2    9    7 2  
BMI (Kg/m2)              
Normal 1,152 (44)  86 (29)  176 (68) 430 (56) 423 (35) 
.003 
 417 (55) 565 (44) 84 (31) 
.2 Overweight 1,020 (39)  138 (47)  61 (24) 238 (31) 546 (45)  260 (34) 500 (39) 122 (45) 
Obese 445 (17)  69 (24)  21 (8) 97 (13) 235 (20)  88 (12) 223 (17) 65 (24) 
missing 6     2 4   1 5   
Diabetes mellitus 392 (15)  88 (30)  15 (6) 60 (8) 205 (17) .001  82 (11) 168 (13) 54 (20) .001 
Waist cir. a (cm) 85 (75, 94)  91 (83, 98)  75 (69, 85) 79 (72, 89) 88 (79, 96) <.001  80 (71, 89) 84 (76, 94) 91 (80, 99) <.001 
Education (yrs.)              
<10 260 (10)  245 (84)  17 (7) 94 (12) 514 (43) 
<.001 
 143 (19) 393 (31) 146 (55) 
<.001 10 578 (22)  34 (12)  172 (67) 486 (64) 501 (42)  419 (55) 663 (52) 105 (39) 
>10 1,768 (68)  12 (4)  69 (27) 184 (24) 178 (15)  204 (27) 223 (17) 16 (6) 
missing 17  2   3 15    14 4  
Standard drinks b 4 (1, 10)  1 (0, 5)   5 (1, 10) 5 (2, 11) 4 (1, 10) <.001   5 (2, 10)  5 (1, 10) 3 (0, 9) <.001 
Physical activity c 3 (2, 5)  4 (3, 6)  3 (2, 5) 3 (2, 5) 4 (2,5) <.001  3 (2, 5) 3 (2, 5) 4 (2, 5) <.001 
Data are presented as No. (%) or Median (lower quartile, upper quartile) 
a waist circumference 
b Number of standard drinks (beer, wine or liquor) in the past 30 days 
c Number of hours of moderate physical activity in the past week 
P-values for continuous variables are based on the Kruskal-Wallis test (the non-parametric equivalent of the one-way Anova) that tests if the distribution of 
each variable is similar against the alternative that they differ only with respect to the median. And the chi square test for differences in proportions of 
categorical variables 
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Table 2. Disposition of 2,623 NAFLD free adults with measured periodontal status at baseline, followed for a 
median of 7.7 years in the Study of Health in Pomerania, 1997-2012 
   Proportion of sites with CAL ≥3mm 
(n=2,233) 
 Proportion of sites with PD ≥4mm  
(n=2,330) 
 Edentulous 
(n=293) 
 No site 
(n=258) 
<30% 
(n=767) 
≥30% 
(n=1,208) 
 No site 
(n=766) 
<30% 
(n=1,293) 
≥30% 
(n=271) 
 No. (%)  No. (%) No. (%) No. (%)  No. (%) No. (%) No. (%) 
Total PY 1,716.3  1,942.0 5,715.3 8,599.6  5,687.1 9,466.2 1,725.5 
NAFLD 
cases 
30 (10.4)  
57 (21.9) 203 (26.5) 298 (24.6)  182 (23.8) 335 (25.9) 58 (21.5) 
Dropout  216 (73.7)  93 (36.1) 226 (29.5) 457 (37.8)  255 (33.3) 433 (33.5) 142 (52.3) 
Number of cases and person-years were the averages from 40 rounds of multiple imputation 
PY-person-years 
CAL-clinical attachment level; PD-probing pocket depth 
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Table 3. Relationship between baseline periodontitis status and NAFLD incidence after a median 7.7 years of follow-up among participants of the Study of 
Health in Pomerania, 1997-2012 
 Proportion of sites with clinical attachment level (CAL) ≥3mm 
(n=2,526) 
 Proportion of sites with Probing pocket depth ≥4mm 
(n=2,623) 
 Rate IRR (95% C.I) P 
Value 
IRD (95% C.I) P 
Value 
 Rate IRR (95% C.I) P 
Value 
IRD (95% C.I) P 
Value 
Unadjusted            
Edentulous 17.6 0.61 (0.36, 1.02) .1 -11.4 (-21.3, -1.59) .02  17.6 0.55 (0.34, 0.87) .02 -14.5 (-22.3, -6.65) .0003 
No site 29.0 1 [Reference] NA 0 [Reference] NA  32.1 1 [Reference] NA 0 [Reference] NA 
<30% of sites 35.5 1.22 (0.88, 1.70) .2 6.46 (-2.56, 15.5) .2  35.3 1.10 (0.90, 1.35) .3 3.28 (-2.72, 9.28) .3 
≥30% of sites 34.6 1.19 (0.86, 1.65) .3 5.56 (-2.98, 14.1) .2  33.7 1.05 (0.75, 1.47) .8 1.64 (-8.20, 11.5) .7 
Adjusted a            
Edentulous 29.0 1.31 (0.27, 6.39) .7 6.81 (-4.36, 18.0) .2  28.7 0.92 (0.23, 3.64) .9 -2.58 (-12.0, 6.89) .6 
No site 22.1 1 [Reference] NA 0 [Reference]   31.3 1 [Reference] NA 0 [Reference]  
<30% of sites 31.4 1.42 (0.96, 2.10) .1 9.23 (0.45, 18.0) .04  33.2 1.06 (0.86, 1.31) .6 1.90 (-4.04, 7.83) .5 
≥30% of sites 30.8 1.39 (0.94, 2.06) .1 8.68 (0.38, 17.0) .04  22.3 0.71 (0.49, 1.04) .1 -8.97 (-16.7, -1.22) .02 
Adjusted b            
Edentulous 23.1 1.36 (0.33, 5.56) .6 6.12 (-3.37, 15.6) .2  23.0 0.89 (0.27, 2.97) .8 -2.72 (-11.1, 5.69) .5 
No site 17.0 1 [Reference] NA 0 [Reference]   25.7 1 [Reference] NA 0 [Reference]  
<30% of sites 24.5 1.45 (0.92, 2.27) .1 7.59 (0.26, 14.9) .04  34.9 1.36 (1.01, 1.83) .05 9.15 (3.59, 14.7) .001 
≥30% of sites 29.4 1.74 (1.10, 2.74) .02 12.5 (5.47, 19.5) .0005  18.6 0.72 (0.48, 1.09) .1 -7.13 (-14.1, -0.12) .05 
Adjusted c            
Edentulous 27.2 1.37 (0.26, 7.15) .7 7.32 (-3.31, 17.9) .2  25.2 0.91 (0.25, 3.34) .9 -2.47 (-11.3, 6.39) .6 
No site 19.9 1 [Reference] NA 0 [Reference]   27.6 1 [Reference] NA 0 [Reference]  
<30% of sites 25.4 1.28 (0.84, 1.95) .2 5.49 (-2.53, 13.5) .2  42.3 1.53 (1.00, 2.35) .05 14.6 (8.87, 20.4) <.0001 
≥30% of sites 31.8 1.60 (1.05, 2.43) .03 11.9 (4.09, 19.6) .003  21.3 0.77 (0.44, 1.33) .3 -6.34 (-13.7, 1.02) .1 
All estimates were averages from 40 rounds of multiple imputation combined using Rubin’s rule and the variance a function of the within and between 
completed dataset variances. 
IRR-Incidence rate ratio; IRD-incidence rate difference 
Rates and IRD are expressed per 1,000 person-years 
Adjustment variables:  age, sex, waist circumference, BMI, physical activity, alcohol consumption, education, smoking and diabetes 
a Adjusted for confounders only, using Inverse probability of exposure weights 
b Adjusted for confounders and censoring due to loss-to-follow-up (LTFU) 
c Adjusted for confounders and censoring from any reason (including LTFU, end of follow-up, excessive alcohol consumption, hepatitis diagnosis in past year, 
use of hepatotoxic medications) 
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Table 4. Relationship between mean CAL, mean PD at baseline and mean change in CAL with NAFLD incidence 
among participants of the Study of Health in Pomerania, 1997-2012 
 Incidence Rate Ratio IRR (95% CI) 
 Unadjusted P Value  Adjusted a P Value 
Baseline periodontitis      
Mean CAL 0.99 (0.85, 1.16) .9  1.11 (0.92, 1.34) .3 
Mean PD 1.02 (0.58, 1.80) .9  1.28 (0.63, 2.57) .5 
Progression of periodontitis      
Participant with baseline CAL <3mm (n=1,091)     
≥2mm (Yes v. No) 0.72 (0.32, 1.63) .5  0.44 (0.15, 1.30) .1 
≥1mm (Yes v. No) 0.95 (0.63, 1.42) .6  0.88 (0.61, 1.28) .5 
Participants with baseline CAL ≥3mm (n=372)     
≥2mm (Yes v. No) 2.32 (1.00, 5.37) .05  2.07 (0.96, 4.58) .06 
≥1mm (Yes v. No) 1.78 (1.02, 3.11) .04  1.55 (0.90, 2.65) .1 
All estimates were averages from 40 rounds of multiple imputation combined using Rubin’s rule and the 
variance a function of the within and between completed dataset variances   
Estimates are for each 3mm increase in mean CAL at baseline, or 4mm increase in mean PD at baseline 
Progression of periodontitis is the mean difference in CAL between baseline and first follow-up visits 
Adjustment variables:  age, sex, waist circumference, BMI, physical activity, alcohol consumption, education, 
smoking and diabetes. Interaction P=.05 
a Confounders and censoring-adjusted estimates  
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Figure 7. Confounding and censoring adjusted cumulative NAFLD risk for participants of the Study of Health 
in Pomerania according to the proportion of sites with CAL ≥3mm at baseline 
Figure 8. Confounding and censoring adjusted cumulative NAFLD risk for participants of the Study of Health in 
Pomerania according to the proportion of sites with PD ≥4mm at baseline 
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10.8 Supplementary material  
10.8.1 Materials and Methods 
10.8.2 Alcohol consumption 
Study participants who responded ‘Yes’ to the question of ever consuming alcohol also reported 
the number of small and large glasses of alcoholic beverages consumed on average each day in the past 
month. This value was used to estimate the number of standard drinks consumed using the reference 
values provided by the NIAAA/NIH (http://www.niaaa.nih.gov/alcohol-health/overview-alcohol-
consumption/what-standard-drink and http://alcohol.org.nz/help-advice/standard-drinks/whats-a-standard-
drink). Assuming 5% alcohol by volume for beer, 12% for wine and 40% for liquor, the number of 
standard drinks was calculated as the volume of alcohol consumed in liters multiplied by the percent 
volume of alcohol multiplied 0.789 (density of ethanol at room temperature). Volumes (in liters) were 
0.2-0.33 for a small beer bottle, 0.4-0.5 for a large beer bottle, 0.2-0.25 for a wine glass, and 0.02 and 
0.04 for small and large liquor glasses respectively. For each type of alcoholic beverage, the average of 
the range represented the respective volume. In other words, 0.265 liters for a small beer bottle, 0.45 for a 
large beer bottle, and 0.225 liters for a glass of wine. To estimate the total number of standard drinks 
consumed in the past 30 days, the formula for standard drinks was applied to each alcohol type and 
summed across alcohol category reported by each participant. Women were categorized as excessive 
alcohol consumers if they self-reported alcohol consumption for ≥30 days and drank at least 1 standard 
drink a day based on our calculations. The same criterion applied to males but requiring 2 standard drinks 
per day (Neuschwander-Tetri et al. 2010). 
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10.8.3 Statistical analysis 
10.8.4 Person-time assignment, censoring and loss-to-follow-up  
 For aim 1, outcome ascertainment was possible at SHIP-1 and SHIP-2. Those who attended only 
SHIP-0 were censored without the event and assigned a total time on study of 2.5 years, corresponding to 
the mid-point between baseline and, anticipated first follow-up visits. Likewise, those who attended 
SHIP-0 and SHIP-1 without the event at SHIP-1 but missed SHIP-2 were censored without the event mid-
way between SHIP-1 and SHIP-2 and the total time on study assigned as the sum of the interval between 
SHIP-0 and SHIP-1 plus 3 years. There were 72 eligible participants who attended SHIP-0 and SHIP-2 
visits but missed SHIP-1 visit. For the subset identified with NAFLD at SHIP-2 (n=11), event was 
assumed to have occurred mid-way between SHIP-0 and SHIP-2 visits and this formed their total time on 
study. In addition to censoring due to loss-to-follow-up, participants who came to SHIP-1 without the 
event but reported excessive alcohol use in the past 30-days (n=69), hepatitis diagnosis in the past year, 
and use of hepatic steatosis-promoting medications (n=1) were also censored. For participants who never 
became cases or lost to follow-up, total time on study was assigned as the difference between the dates of 
Figure 9. Exposure, covariate and outcome characterization at each study visit 
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SHIP-0 and SHIP-2 visits. Study participants were followed up until NAFLD event, censoring event, 
dropout or end of study in 2010.  
For aim 2, outcome ascertainment was possible only at SHIP-2 to ensure temporality (i.e. 
exposure preceding the outcome). Thus, NAFLD cases at baseline and first follow-up visits were 
excluded. Those who were lost to follow-up after SHIP-1 were censored without the event mid-way 
between SHIP-1 and SHIP-2, and assigned a total time on study as the difference between SHIP-1 and 
SHIP-0 visits plus 3 years. For those who were not lost to follow-up, total time on study corresponded to 
the difference between SHIP-0 and SHIP-2 visits. 
10.8.5 Sensitivity analysis 
To assess study robustness to the person-time allocation described above, bounds were created 
(Figure 12). For the lower bound, event or censoring was assumed to have occurred the day after the 
cohort member was last seen. With respect to aim 1, those who only attended SHIP-0 were censored the 
day after SHIP-0 visit instead of mid-way between SHIP-0 and SHIP-1. Likewise, those who attended 
SHIP-0 and SHIP-1 and identified with NAFLD at SHIP-1 were assumed to have developed the event the 
day after SHIP-0 visit. For the upper bound, event or censoring were assumed to have occurred the day 
before the next anticipated follow-up visit. For example, those who only attended SHIP-0 were censored 
the day before their anticipated SHIP-1 visit. Likewise, those who attended SHIP-0 and SHIP-1 and 
identified with NAFLD at SHIP-1 were assumed to have developed the event the day before SHIP-1 visit. 
10.8.6 Control of confounding 
Confounding control was accomplished by inverse probability of exposure weights (IPEW) (Cole 
and Hernan 2008). A multinomial logistic regression estimated the predicted probability of the exposure 
group (for example: edentulous, no site affected, <30% of sites with ≥3mm, ≥30% of sites with CAL 
≥3mm) an individual fell into, conditional on their baseline covariates. For continuous exposures (mean 
CAL, mean PD at baseline), quantile binning based on exposure ranks was used to create exposure 
weights using a cumulative logit model (Naimi et al. 2014). To ensure correct specification of the 
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exposure weight models, an exploratory analysis was conducted to assess the distributional relationship 
between each potential confounder determined after analyzing a directed acyclic graph (Greenland et al. 
1999) and outcome risk factor with the outcome. Based on the results, waist circumference, alcohol and 
age were specified using restricted quadratic splines with 3 knots at the 5th, 50th and 95th percentiles. 
Education, smoking and diabetes were modeled using categories previously described under covariate 
assessment. Insulin resistance and serum lipids (based on experimental evidence that infection with 
Porphyromonas gingivalis affects lipid profile (Maekawa et al. 2011)) and hypertension were causal 
intermediates and were not included as confounders. Number of remaining teeth was also not included as 
a confounder because it is a consequence as opposed to a cause of periodontitis. Stabilized exposure 
weights were created as the inverse of the estimated probabilities, substituting the numerator with the 
marginal probability of each exposure category. These weights represent the number of additional copies 
of each study participant that would be created to form a pseudo-population in which the exposure is no 
longer associated with any of the confounders used in creating the weights. 
10.8.7 Controlling for censoring due to Loss-to-Follow-up (LTFU) 
Between baseline (SHIP-0) and SHIP-1 visits, 22% were LTFU while 30% were lost between 
SHIP-1 and SHIP-2 visits for an overall LTFU of approximately 40%. Due to this magnitude of loss, 
LTFU may be informative and, could possibly lead to bias if for instance, there were differential losses 
between exposure groups or with respect to the outcome. To account for LTFU, a binary variable 
indexing whether a study participant was lost or remained under study at each study visit was created. 
Next, factors that predicted losses to follow-up were determined using a logistic regression model 
conditional on exposure, outcome and several variables including age, hypertension, waist and hip 
circumference, waist-to hip-ratio, triglyceride and cholesterol levels, transaminases (ALT, AST, GGT), 
alcohol consumption, smoking, BMI, gender, extent of deep periodontal pockets, and time on study. P 
<0.05 was deemed statistically significant. Variables that emerged as associated with been lost to follow-
up were time on study, age (SHIP-0 and SHIP-1), gender, smoking, alcohol consumption at SHIP-1, PD 
≥4mm, and ALT at SHIP-1. To ensure proper characterization, a distributional exploration of each 
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variable with the log-risk of dropping out (Figure 26) was conducted which led to continuous variables 
been modeled with restricted quadratic splines with knots at the 5th, 50th and 95th percentiles and 
categorical variables modeled with indicator terms. A binary logistic regression estimated the predicted 
probability of dropping out conditional on aforementioned variables. Stabilized dropout weights were 
created as the inverse of the corresponding probabilities substituting the numerator with the marginal 
probability of dropping out conditional on time. These weights represent the number of copies of each 
study participants to be created for a pseudo-population that would be observed had losses-to-follow-up 
occurred randomly (i.e. uninformatively) (Howe et al. 2016). 
10.8.8 Outcome model Assumptions 
For the results of the weighted Poisson model to be valid, the following assumptions were made: 
correct specification of both the exposure and dropout weight models, conditional exchangeability (no 
unmeasured confounding or selection bias given measured covariates), positivity, and no measurement 
error. 
10.8.9 Multiple imputation 
Multiple imputation was performed for missing data using chained equations (MICE). This 
method was chosen because it uses a separate conditional distribution for each imputed variable and 
unlike the multivariate normal method, does not assume a joint multivariate normal distribution between 
variables to be imputed. Covariates with missing values at baseline, first and second follow-up visits for 
those who came to those respective visits were imputed. Also imputed were transaminase (ALT, AST, 
GGT) values for those who came to visit 1 but did not have this test done and/or recorded. 
The following variables: transaminases (ALT, AST, GGT), alcohol, smoking, BMI and waist 
circumference were imputed. The proportion of missing values for these variables are shown in Table 5. 
In addition to the variables that were imputed, the following were added to the imputation model: 
exposure, outcome and time on study as well as the following confounders: age, gender, education and 
diabetes. While certain variables were not strictly confounders, to ensure plausibility of the missing at 
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random (MAR) given measured covariates assumption, variables that independently predicted the 
exposure and outcome (missing transaminases) with p < 0.05 were added to the imputation model as 
auxiliaries. These variables were: frequency of dental visits in the past year, having any form of 
periodontal therapy in the past 5 years, total cholesterol, triglyceride at all 3 visits and hip circumference. 
To ensure correct specification of variables in the imputation model, continuous variables that were not 
normally distributed were log transformed. Because the MICE method uses a separate conditional 
distribution for each imputed variable, a logistic specification was used to impute missing categorical 
variables and the predictive mean matching which imputes values consistent with observed values, was 
specified for imputing missing continuous variables (UCLA ; White et al. 2011). 
Trace plots for the means and standard deviations of each imputed variable were created to assess 
how well the imputation algorithm performed. Trace plots assess whether the multiple imputation 
algorithm reached a stable posterior distribution by assessing if imputed values were relatively constant 
over iterations. In other words, they check for the presence or lack of a trend in imputed values between 
iterations and assesses the how long it took for the imputation algorithm to reach a stationary phase, an 
indication of model convergence (Figure 10). Kernel density plots of observed and imputed values 
assessed how imputed values deviated from observed (Figure 11). A total of 40 datasets were imputed 
using 500 between imputation iterations. Multiple imputation was conducted in SAS v.9.4 (SAS Institute, 
Cary NC). 
 
  
 83 
 
Supplementary Figure Legend 
Figure 9. Exposure, covariate and outcome characterization at each study visit 
 
Figure 10. Trace plots for the means of selected imputed variables in the Study of Health in Pomerania, 
1997-2012. Trace plots shows whether the multiple imputation algorithm reached a stable posterior 
distribution by assessing if imputed values were relatively constant over iterations. These plots check for 
the presence or lack of a trend in imputed values between iterations and assesses the length of time it 
takes for the imputation algorithm to reach a stationary phase, an indication of model convergence 
 
Figure 11. Kernel density plots of observed and imputed values for selected imputed variables in the 
Study of Health in Pomerania, 1997-2012. Kernel density plots showing the performance of multiple 
imputation by assessing how imputed values deviated from observed, an assessment of the quality of data 
imputation 
 
Figure 12. Upper and lower sensitivity bounds of person-time specification on the reported unadjusted 
and censoring adjusted estimates of the relationship between periodontitis and NAFLD in the Study of 
Health in Pomerania, 1997-2012. Panel A. unadjusted and censoring adjusted estimates for categories of 
clinical attachment level ≥3mm (edentulous, no site, <30%, ≥30%) at baseline. Panel B. unadjusted and 
censoring adjusted estimates for categories of probing pocket depth ≥4mm (edentulous, no site, <30%, 
≥30%) at baseline 
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Table 5. Proportion of missing observations for imputed variables according to study visit among eligible 
participants of the Study of Health in Pomerania, 1997-2012 
 
Variables 
% missing among those 
who came to SHIP-0 
visit 
% missing among those 
who came to SHIP-1 
visit 
% missing among those 
who came to SHIP-2 
visit 
ALT 0.76% 47.0% 0.28% 
AST 0.50% 47.0% 0.41% 
GGT 1.41% 47.0% 0.21% 
Alcohol 6.82% 7.60% 15.5% 
Waist circumference 0.19% 0.20% 0.21% 
Smoking  0.42% 0% 0.28% 
BMI 0.23% 0.35% 0.07% 
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Figure 10. Trace plots for the means of selected imputed variables in the Study of Health in Pomerania, 1997-2012 
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Figure 11. Kernel density plots of observed and imputed values for selected imputed variables in the Study of Health in Pomerania, 1997-2012 
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Table 6. Relationship between baseline periodontitis status and NAFLD incidence after a median 7.7 years of follow-up in the Study of Health in Pomerania, 
1997-2012 (complete case analysis) 
 Proportion of sites with clinical attachment level (CAL) ≥3mm  Proportion of sites with Probing pocket depth (PD) ≥4mm 
 
Rate IRR (95% C.I) 
P 
Value 
IRD (95% 
C.I) 
P 
Value 
 Rate IRR (95% C.I) 
P 
Value 
IRD (95% C.I) P Value 
Unadjusted (n=2,526)     (n=2,623)   
Edentulous 10.9 0.57 (0.33, 0.97) .04 -8.32 (-15.9, -0.71) .03  10.9 0.53 (0.33, 0.85) .01 -9.64 (-15.6, -3.69) .002 
No site 19.2 1 [Reference] NA 0 [Reference] NA  20.5 1 [Reference] NA 0 [Reference] NA 
<30% of sites 24.0 1.25 (0.88, 1.77) .2 4.80 (-2.28, 11.9) .2  25.2 1.23 (1.00, 1.52) .05 4.74 (0.03, 9.45) .05 
≥30% of sites 24.1 1.26 (0.90, 1.76) .2 4.92 (-1.81, 11.6) .2  24.1 1.18 (0.84, 1.65) .4 3.60 (-4.29, 11.5) .4 
 
Adjusted a 
 
(n=1,669) 
     
(n=1,669) 
   
Edentulous 5.67 0.65 (0.28, 1.51) .3 -3.04 (-9.24, 3.16) .3  6.61 0.37 (0.19, 0.70) .002 -11.3 (-16.8, -5.79) <.0001 
No site 8.71 1 [Reference] NA 0 [Reference] NA  17.9 1 [Reference] NA 0 [Reference] NA 
<30% of sites 15.1 1.73 (0.91, 3.27) .1 6.35 (0.13, 12.6) .05  22.6 1.26 (0.97, 1.63) .08 4.67 (-0.40, 9.74) .1 
≥30% of sites 18.4 2.11 (1.14, 3.93) .02 9.68 (3.63, 15.7) .002  8.36 0.47 (0.28, 0.79) .004 -9.57 (-15.1, -4.03) .001 
IRR-Incidence rate ratio; IRD-incidence rate difference 
Rates and IRD are expressed as rates per 1,000 person-years 
Adjustment variables:  age, sex, waist circumference, BMI, physical activity, alcohol consumption, education, smoking and diabetes 
a Adjusted for confounders (using inverse probability of exposure weights and censoring from any reason (including loss-to-follow-up, end of follow-up, 
excessive alcohol consumption, hepatitis diagnosis in past year, use of hepatotoxic medications) 
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Figure 12. Upper and lower sensitivity bounds of person-time specification on the reported unadjusted and censoring 
adjusted estimates of the relationship between periodontitis and NAFLD in the Study of Health in Pomerania, 1997-
2012 
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CHAPTER 11: MANUSCRIPT 2 
11.1 Study Highlights 
11.1.1 Current knowledge 
 
Current knowledge is limited to periodontitis’ association with Non-alcoholic Fatty Liver Disease 
in experimental animal and human studies while the mechanism linking these two conditions is thought to 
involve inflammatory markers. 
11.1.2 New information 
 
This investigation provides new information indicating that periodontitis is associated with 
NAFLD independent of markers of inflammation and that serum C-reactive protein is a significant effect 
measure modifier of the association between periodontitis and Non-alcoholic Fatty Liver Disease while 
genetic markers of inflammatory markers was not a significant effect measure modifier of this 
association. 
11.2 Introduction 
In response to an injury or infection, inflammation occurs as a complex series of short-term 
adaptive responses accompanied by local tissue damage with manifestations that gradually resolves as 
inflammation abates, leaving little to no permanent damage (Kumar et al. 2014). Inflammation is 
regulated primarily by the innate immune system (Kumar et al. 2014; Takashiba and Naruishi 2006), and 
it involves a coordinated cascade of biological events regulated by specific cells and molecular signals 
(Naitza et al. 2012). 
An excessive inflammatory response upon stimulation of the innate immune system has been 
described as a hyper-inflammatory, or hyper-responsive trait (Shaddox et al. 2010) that presents 
systemically as heightened expression of systemic markers of inflammation (Southerland et al. 2006). 
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Population based genetic studies suggest that natural selection has shaped the evolution of the innate 
immunity with specific focus on inflammatory genes that are pivotal in host-pathogen interactions 
(Barreiro and Quintana-Murci 2010). Inflammatory biomarkers are reported to be highly heritable with 
studies among ethnically homogenous groups and twins indicating that about half of inter-individual 
variability in markers of inflammation is genetically determined (Dupuis et al. 2005; Pankow et al. 2001). 
In the Framingham Heart Study cohort, age and gender adjusted heritability was estimated to be 25.3%, 
25.4%, and 45.2% for C-reactive protein (CRP), interleukin-6 (IL-6), and monocyte chemoattractant 
protein (MCP-1), respectively (Dupuis et al. 2005), while the NHLBI Family Heart Study reported 
heritability estimates ranging from 35-40% for CRP, white blood cells and albumin (Pankow et al. 2001). 
Findings among humans and from mice models (Yoneda et al. 2012), suggest a relationship 
between periodontitis and non-alcoholic fatty liver disease both of which are chronic health conditions 
characterized by a heightened inflammatory burden (Day and James 1998; Gocke et al. 2014; Haukeland 
et al. 2006; Schenkein and Loos 2013; Targher 2006; Tilg and Moschen 2008; 2010). Indeed, individuals 
with periodontitis present with frequent bacteremia (Schenkein and Loos 2013) that promotes a pro-
inflammatory state while obesity, a precursor for NAFLD, is characterized by a state of chronic low grade 
systemic inflammation (Ouchi et al. 2011; Shoelson et al. 2006).  
Genome-wide association studies (GWAS) have identified 19 independent loci that are robustly 
associated with levels of C-reactive protein (CRP) (Dehghan et al. 2011; Naitza et al. 2012), an acute 
phase reactant and a marker of systemic inflammation (Pearson et al. 2003; Raman et al. 2013). Because 
genetic determinants of inflammatory biomarkers can more accurately indicate lifelong inflammatory 
status (Raman et al. 2013) compared to biomarker concentrations obtained at a given point in time, 
polymorphisms in genes regulating inflammatory processes may influence the expression of periodontitis 
and NAFLD, as well as modify the relationship between these two conditions. The purpose of this 
investigation was to determine whether CRP-associated genetic loci and serum CRP levels modify the 
association between periodontitis and NAFLD. Furthermore, previously reported associations between 
periodontitis and NAFLD was explored in additional depth by using loci suggestive of having 
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periodontitis  (Divaris et al. 2013; Shaffer et al. 2014) as instrumental variables (IVs) (Greenland 2000), 
to investigate the relationship between periodontitis and NAFLD. This method that uses genetic variants 
robustly associated with modifiable exposures as proxy indicators (i.e. IVs) of these exposures is termed 
Mendelian Randomization (Davey Smith and Hemani 2014; Smith and Ebrahim 2003) and is analogous 
to treatment arms in a randomized controlled trial where treatment (in this case genetic variants) are 
randomly allocated and thus un-confounded. 
11.3 Methods 
11.3.2 Data source and study population 
The Study of Health in Pomerania (SHIP) is a population-based cohort sampled from the Western 
Pomeranian region of northeastern Germany (John et al. 2001; Volzke et al. 2011). The SHIP was 
designed to provide prevalence estimates for various diseases and disease risk factors, incidence of 
common risk factors, subclinical disorders, clinical diseases and evaluate associations among these 
factors. From eligible inhabitants of West Pomerania in 1996, 6,265 adults aged 20-79 years were invited 
to participate. A total 4,308 participated in baseline examination conducted between 1997 and 2002. 
Study participants underwent rigorous examinations and Interviewer-administered questionnaires were 
used to collect information on relevant covariates. 
11.3.2 Exposure assessment and characterization 
Dental examiners performed periodontal examination on study participants with no medical 
contraindication. Measurements of probing pocket depth (PD) and clinical attachment level (CAL) were 
obtained on 4 sites per tooth: distobuccal, mesiobuccal, midbuccal and midlingual or midpalatal (except 
the 3rd molars) on 2 quadrants (quadrants 1 and 4 OR quadrants 2 and 3)(Hensel et al. 2003; Volzke et al. 
2011). For this investigation, periodontitis was defined as the proportion of periodontal sites with PD 
≥4mm categorized as none (0%), moderate (<30%) and extensive (≥30%) and according to the Centers 
for Disease Control and Prevention-American Association for Periodontology (CDC-AAP) criteria that 
defines severe periodontitis as ≥2 interproximal sites with CAL of ≥6mm (not on the same tooth) AND 
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≥1 interproximal sites with PD of ≥5mm, and moderate periodontitis as ≥2 interproximal sites (not on the 
same tooth) with CAL of ≥4mm OR ≥ 2 interproximal sites (not on the same tooth) with PD of ≥5mm 
(Eke et al. 2012b; Page and Eke 2007). Individuals with moderate or severe periodontitis were 
categorized as having periodontitis, while others not meeting these criteria were categorized as 
healthy/mild. In a secondary analysis, periodontitis was characterized as the proportion of sites with CAL 
≥3mm (none, moderate, and extensive). 
11.3.3 Outcome assessment and characterization 
Trained physicians performed liver ultrasound on study participants using a 7.5-MHz transducer 
(John et al. 2001; Volzke et al. 2011). A positive finding on ultrasound was defined as a significant 
increase in liver echogenicity (brightness) relative to the kidneys, with the diaphragm indistinct OR the 
echogenic walls of the portal veins invisible (Baumeister et al. 2008; Williams et al. 2011). 
11.3.4 Covariates 
Covariates identified as confounders were determined after analyzing a Directed acyclic graph 
(Akinkugbe et al. 2016a; Greenland et al. 1999) and included age, modeled with a quadratic term, gender, 
alcohol consumption, waist circumference-dichotomized at ≥88cm for women and ≥102cm for men 
indicative of abdominal obesity (Grundy et al. 2005). Diabetes was based on self-reported physician’s 
diagnosis or study’s measurement of HbA1c ≥6.5%. Self-reported smoking status was categorized as 
never, former and current. Physical activity was based on self-report of the number of hours per week of 
moderate physical activity. 
11.3.5 Laboratory measurements 
Non-fasting blood samples were drawn from the cubital vein in the supine position. HbA1c was 
measured by high performance liquid chromatography (ClinRep HbA1C, Recipe Chemicals Instruments 
GmbH, Munich, Germany). While serum levels of high-sensitivity C-reactive protein (hs-CRP) were 
estimated with the Behring Nephelometer II (Dade Behring Inc., Eschborn, Germany)(Gocke et al. 2014). 
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11.3.6 Genotyping 
Genomic DNA from blood samples was collected using standardized procedures. Blood aliquots 
were immediately placed on ice after collection and stored at -800C in a bio-bank (John et al. 2001). A 
total of 4,096 samples were genotyped using the Human SNP 6.0 Array (Affymetrix, Santa Clara, CA) 
with overall genotyping efficiency of 98.6% and imputed to the 1000 Genomes v3 reference panel 
released March 2012 (ALL ancestries panel, build 37) (Teumer et al. 2013; Volzke et al. 2011). 
A total of 19 CRP SNPs from 19 loci, 1 IL-6 SNP, 2 MCP-1 SNPs and 2 ESR SNPs were identified as 
genetic markers of inflammation for this investigation. After quality control checks, genotype data were 
available for 4,070 participants. None of the SNPs deviated significantly from Hardy Weinberg 
equilibrium (P >0.003) and call rates were >95% for all SNPs. 
11.3.7 CRP-specific weighted genetic score (wGSCRP) 
To study the cumulative effect of multiple gene loci, a weighted genetic score for CRP was 
computed for each study participant. A risk allele was defined as the allele associated with a unit increase 
in log-transformed serum CRP level. The corresponding effect sizes from previous GWAS of 
inflammatory mediators (Naitza et al. 2012) and a meta-analysis of GWAS of CRP-levels (Dehghan et al. 
2011), were used to weigh the contribution of each risk allele within the wGSCRP as previously described 
(Pharoah et al. 2008) and implemented (Kader et al. 2012; Mavaddat et al. 2015; Thanassoulis et al. 2012; 
Xiao et al. 2015). The lead SNPs in each identified locus were used in creating the weighted risk score. 
The list of SNPs and effect sizes are presented in Table 13. The weighted risk score for CRP was 
calculated as indicated below: 
wGSCRP = α  x α  x        α k x k  α n x n  
Where αk is the per-allele beta estimate associated with the risk allele for CRP SNP k, and xk the number 
of risk alleles for the same SNP, and n=total number of SNPs used in creating the score. In addition to 
CRP, weighted genetic risk scores were also created for IL-6, MCP-1, and ESR. 
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11.3.8 Instrumental variable (Mendelian Randomization) analysis 
While no single SNP with genome-wide significant threshold (p<5x10-8) has been identified for 
periodontitis, several suggestive loci have been reported (Divaris et al. 2013; Sanders et al. 2017; Shaffer 
et al. 2014; Teumer et al. 2013). One in particular is the NIN locus with SNP (rs12883458), first reported 
by (Divaris et al. 2013) to increase the odds of CDC-AAP severe periodontitis by 1.89 (95% CI: 1.48, 
2.41), and replicated by (Shaffer et al. 2014) by a different SNP (rs3783412) in the same NIN gene region 
(Odds ratio=1.85). Given genetic variants are fixed and randomly allocated during conception, they are 
inherited independent of any confounding factors (Smith and Ebrahim 2003). This method seeks to 
eliminate potential reverse causality and minimize confounding bias (Davey Smith and Hemani 2014; 
Greenland 2000; Palmer et al. 2011; Smith and Ebrahim 2003). For these SNPs to be good instruments, 
they must be associated with periodontitis, be independent of any of the cofounders and be associated 
with the outcome (NAFLD) only through their effects on the exposure (periodontitis) (Greenland 2000). 
The IV model is shown in the directed acyclic graph (Greenland et al. 1999) in Figure 29. 
11.3.9 Study exclusions 
From 4,308 eligible participants at baseline, participants with no genotype data (n=238) were 
excluded. Also excluded were participants who reported excessive alcohol consumption defined as 70g of 
ethanol/week (equivalent to 1 standard drinks/week) for females and 140g of ethanol/week (equivalent to 
2 standard drinks/week) for males (n=970). Participants with no liver ultrasound reading (n=48), as well 
as those with no periodontal examination (n=14), edentulous or with less than 2 interproximal sites 
measured (n=565) were also excluded. The resulting analytic sample size was 2,481 noting that some 
participants were ineligible for multiple reasons. 
11.4 Statistical analysis 
The respective genetic risk scores including the wGSCRP and log transformed serum CRP levels 
were modeled as continuous traits in separate linear regression models investigating whether these traits 
independently predicted periodontitis and NAFLD. Logistic regression models stratified according to 
wGSCRP (<1.98 vs. ≥1.98) assessed the relationship between periodontitis and NAFLD. In separate 
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stratified analyses, a similar association was investigated within strata of low (<1mg/L), intermediate (1-3 
mg/L) and high (>3mg/L) (Pearson et al. 2003) serum CRP groups. Statistical tests were 2-sided and test 
for statistical significant interaction was set apriori at p <0.1. 
11.4.1 Mendelian Randomization (IV) analysis 
IV analysis was conducted using the multiplicative generalized method of moments (MGMM) 
estimator that assumes that the structural model for the outcome is log-linear with respect to the exposure 
and confounders (Palmer et al. 2011). Unlike the ratio estimators that requires the exposure and outcome 
to be continuous (Pierce and Burgess 2013), and 2-stage IV estimator that requires the exposure to be 
continuous (Burgess and Collaboration 2013; Palmer et al. 2008), the MGMM method allows for the 
exposure to be binary. The MGMM estimation was implemented in Stata with the IVPOIS command 
(Nichols 2007). Data analyses were conducted with SAS v.9.4 (SAS Institute, Cary, NC) and Stata v. 11 
(Stata Corporation, College Station, TX). 
11.4.2 Assessment of IV assumptions 
The extent to which the NIN genotype was associated with periodontitis (assumption 1) was first 
investigated. Each additional risk allele was associated with a 0.21 increase odds of moderate-severe 
periodontitis POR=1.21 (95% CI: 0.98, 1.50) (Table 22). While strictly not possible to test assumptions 2 
and 3, violation of assumption 2 was tested by assessing whether the respective NIN SNPs were 
independent of measured covariates that might confound the association between periodontitis and 
NAFLD. This investigation supports no association with these variables (Table 23). 
11.5 Results 
The prevalence of NAFLD was 26.4% (95% CI: 24.6, 28.1) and 54.3% (95% CI: 52.3, 56.3) of 
the SHIP examinees had moderate-severe periodontitis. Slightly more than half, 52.7% (95% CI: 50.5, 
54.8) had <30% of sites with PD ≥4mm while 17.8% (95% CI: 16.0, 19.6) of the SHIP examinees had 
≥30% of sites with PD ≥4mm. Participants with periodontitis and those with NAFLD had higher serum 
CRP levels compared to their counterparts with a healthy periodontium and without NAFLD. The median 
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serum CRP participants with <30% of sites with PD ≥4mm was 1.48 mg/L (IQR: 0.68-3.01) while those 
with ≥30% of sites with PD ≥4mm had median serum CRP levels of 1.82 mg/L (IQR: 0.82- 3.90) 
compared to 1.11 mg/L (IQR: 0.51-2.95) for participants with no site with PD ≥4mm (Table 7). Similarly, 
participants with moderate-severe periodontitis had median serum CRP levels of 1.51mg/L (IQR: 0.73-
3.67) and 1.08mg/L (IQR: 0.50-2.67) for participants with no periodontitis (Table 8). Participants with 
NAFLD were less likely to report physical activity (33% vs. 49%), equally as likely to consume alcohol 
and more likely to be males (58% vs. 41%) than participants without NAFLD (Table 7). 
Table 13 shows the full list of SNPs with the corresponding effect sizes used in creating the 
respective weighted genetic CRP scores. Most of the CRP SNPs were positively associated with serum 
CRP levels in this study population (Figure 18) and the wGSCRP aligns well with serum CRP levels such 
that participants with low genetic CRP score had lower mean serum CRP levels compared to participants 
with high genetic CRP score (Figure 13). The median value for the wGSCRP was 1.98 (IQR: 1.82-2.14). 
Participants with wGSCRP above the median had mean serum CRP of 3.24 (SD: 4.72) mg/L while 
participants with wGSCRP at or below the median had mean serum CRP of 2.65 (SD: 6.62) mg/L. 
As expected, serum CRP was associated with having PD ≥4mm. Specifically, each unit increase 
in log-transformed serum CRP was associated with a 23% increase in adjusted prevalence odds of having 
≥30% sites with PD ≥4mm, POR=1.23 (95% CI: 1.09, 1.39), while the corresponding estimate for having 
<30% of sites with PD ≥4mm was POR=1.16 (95% CI: 1.06, 1.26) (Table 9). There was no meaningful 
association between individual CRP SNPs and PD ≥4mm (Figure 19). Even after combining into a score, 
the wGSCRP not associated with odds of having <30% sites or ≥30% sites with PD ≥4mm, POR= 1.02 
(95% CI: 0.69, 1.51) and 1.01 (95% CI: 0.61, 1.69) respectively (Table 9). 
Similar trend was observed for periodontitis defined using the CDC-AAP criteria, specifically, each unit 
increase in log-transformed serum CRP was associated with a 14% increase in adjusted prevalence odds 
of moderate-severe periodontitis, POR=1.14 (95% CI: 1.05, 1.24) (Table 10). There was also no 
meaningful association between individual CRP SNPs and moderate-severe periodontitis (Figure 21), 
however when combined into a score, the wGSCRP was associated with a marginal but imprecise increase 
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in the prevalence odds of moderate-severe periodontitis, POR= 1.08 (95% CI: 0.77, 1.52) (Table 10). As 
was observed for periodontitis, each unit increase in log-transformed serum CRP was associated with 
higher prevalence odds of NAFLD, with adjusted POR=1.26 (95% CI: 1.14, 1.39) (Table 9). Likewise, 
most of the individual CRP SNPs had no meaningful effect on the odds of NAFLD (Figure 22), while 
each unit increase in the wGSCRP was associated with 21% increase in the odds of NAFLD; POR=1.20 
(95% CI: 0.82, 1.77) (Table 9). 
Although participants with periodontitis, irrespective of case definition had a higher predicted 
probability of NAFLD compared to participants with a healthy periodontium, there was no significant 
statistical interaction according to tertile of the wGSCRP (Pinteraction =0.8) (Figure 14 and Figure 16). In spite 
of this, estimates stratified at the median value for wGSCRP are presented in Table 11. Participants in the 
stratum of wGSCRP at or below the median had slightly higher unadjusted and covariate adjusted odd ratios 
for the relationship between periodontitis and NAFLD compared to participants in the wGSCRP stratum 
above the median (Table 11). In contrast, the higher predicted probability of NAFLD for participants with 
PD ≥4mm or with moderate-severe periodontitis differs according to serum CRP groups (Pinteraction=0.01) 
(Figure 15 and Figure 17). Similarly, stratified analyses show the magnitude of unadjusted and covariate 
adjusted odds of NAFLD comparing participants with periodontitis to those without to be highest in the 
low (CRP <1mg/L) serum CRP stratum. For instance, the unadjusted and covariate adjusted NAFLD 
prevalence odds ratio comparing participants with ≥30% sites with PD ≥4mm to those with no sites 
affected in the low serum CRP (<1mg/L) stratum were 5.34 (95% CI: 3.18, 8.97) and 2.39 (95% CI: 1.32, 
4.31) respectively while the corresponding estimates for participants in the intermediate serum CRP (1-3 
mg/L) stratum were 2.23 (95% CI: 1.42, 3.50) and 0.97 (95% CI: 0.57, 1.66) respectively and 1.66 (95% 
CI: 1.04, 2.65) and 1.12 (95% CI: 0.65, 1.93) respectively for CRP stratum >3mg/L (Table 11).  
Contrary to the findings of a significant statistical interaction between serum CRP and PD ≥4mm, 
there was no significant interaction with CAL ≥3mm (Pinteraction=0.2). This suggests that, the significant 
interaction observed with the CDC-AAP periodontitis classification (Pinteraction=0.014) appears to have 
been driven mostly by PD instead of CAL. Stratified estimates for periodontitis based on the CDC-AAP 
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criteria and as the proportion of sites with CAL ≥3mm and are presented in Table 12 and Table 15 
respectively. 
11.6 Discussion 
Findings from this investigation aimed at assessing whether inflammatory markers (of which 
CRP was used as a proxy) independently predicted and/or modified the association between periodontitis 
and NAFLD, were consistent with a positive association between serum CRP and NAFLD as well as 
serum CRP and periodontitis. Under the premise that genetic determinants of inflammatory markers are 
better able to indicate lifelong inflammatory status, genetic variants robustly associated with CRP levels 
were combined into a genetic score that was substituted for serum CRP in this study. In line with the 
findings for serum CRP, the wGSCRP, predicted NAFLD to a greater extent than it did for periodontitis. 
However, contrary to findings for serum CRP, the wGSCRP was not a modifier of the association between 
periodontitis and NAFLD. 
NAFLD has a multifactorial etiology with conditions like insulin resistance and obesity identified 
as risk factors (Angulo 2007; Farrell and Larter 2006). Increased levels of inflammatory mediators have 
also been reported in individuals with NAFLD (Haukeland et al. 2006; Targher 2006). While a formal 
mediation analysis was beyond the scope of this study, investigating the periodontitis-NAFLD association 
among individuals with ‘similar inflammatory burden’, while adjusting for confounders and NAFLD risk 
factors attempts at teasing out the potential contribution of other factors besides those of inflammation in 
NAFLD etiology. In spite of the high heritability of CRP (Dupuis et al. 2005; Pankow et al. 2001), 
currently identified genetic loci explain ~5% of the variation in CRP levels (Dehghan et al. 2011). Thus, 
currently identified loci may not be sufficiently robust to characterize associations or detect gene-
environment interactions, even after combining the lead SNPs into a score as was done in this study. This 
may in part explain why no significant effect measure modification within strata of the genetic CRP score 
was detected.  
Serum CRP represents a systemic marker of an inflammatory response, and can be instrumental 
in detecting effect measure modification. The greater magnitude of association between periodontitis and 
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NAFLD in the stratum of study participants with serum CRP <1mg/L suggests a contribution of 
periodontitis to NAFLD risk independent of chronic low-grade systemic inflammation. Furthermore, 
participants with serum CRP <1mg/L were less likely to have established NAFLD risk factors like 
abdominal obesity, and diabetes (Table 14), consistent with an association of periodontitis with NAFLD 
independent of these NAFLD risk factors. While periodontitis may also contribute to NAFLD burden in 
the intermediate and high serum CRP strata, its effects might have been overshadowed by the presence to 
a larger extent of more proximal NAFLD risk factors, hence the seeming appearance of a reverse dose 
response relationship between periodontitis and NAFLD, whereby participants in the high serum CRP 
stratum have the lowest and those in the low serum CRP stratum have the largest measure of association 
for the relationship between periodontitis and NAFLD. 
While polymorphisms robustly associated with serum CRP levels in theory predict an increase in 
the risk of coronary heart disease (CHD) and other cardiovascular diseases (CVD) related events, these 
polymorphisms are not in themselves associated with an increased risk of CHD (Dehghan et al. 2011; 
Elliott et al. 2009; Wensley et al. 2011; Zacho et al. 2008) although serum CRP levels were reported in 
several longitudinal studies to be associated with increased risk of CHD and myocardial infarction 
(Danesh et al. 2004; Lange et al. 2006). The SNPs used in creating the genetic CRP score in this study 
were robustly associated with CRP levels (Figure 18). However, these SNPs did not independently 
predict periodontitis (Figure 19, Figure 20 and Figure 21) or NAFLD risk (Figure 22). While the findings 
for the genetic CRP score are not entirely surprising, it is also likely that the inability to detect effect 
measure modification by the genetic CRP score was due to the relatively small effect of individual SNPs 
even after combining them into a score. 
11.6.1 Strengths and limitations 
Given the modest size, this study may be insufficiently powered to detect effect measure 
modification, especially for the genetic CRP score. In addition, the cross-sectional design makes it 
difficult to infer how the modification by serum CRP levels might impact the periodontitis-NAFLD 
association over time. Lastly, due to the homogeneous study population, findings may not generalize to 
 100 
 
other racial/ethnic groups given that the genetic architecture of CRP differs by ethnicity (Carlson et al. 
2005). Study strengths include a good characterization of the cohort that enabled the implementation of 
relevant exclusions of factors like alcohol consumption that might bias findings. Also, the availability of 
genotype and phenotype data for CRP allowed an investigation of this factor as a potential effect measure 
modifier. 
11.7 Conclusions 
Serum CRP was a significant modifier of the relationship between periodontitis and NAFLD and 
there was a discordance of effect measure modification of this association by serum CRP and the 
weighted genetic CRP score. Given that only a fraction of the variability in CRP is explained by currently 
identified genetic loci, more research may be needed to identify missing CRP heritability that could 
provide a more robust picture of genetic loci predictive of CRP levels and inflammatory markers in 
general.  
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Figure Legend 
 
Figure 13. Mean serum CPR level (right vertical axis) shown as solid black line for categories of the 
weighted CRP risk score. The shaded bars show the distribution of the weighted CRP risk score in the 
study population (left vertical axis) 
 
Figure 14. Predicted probability of NAFLD according to tertile of the weighted genetic CRP score for 
study participants with no site (square), <30% of sites (circle) and ≥30% of sites (diamond) with PD 
≥4mm 
 
Figure 15. Predicted probability of NAFLD according to serum CRP groups- low (CRP <1mg/L), 
intermediate (CRP 1-3mg/L) and high (CRP >3mg/L) for study participants with no site (square), <30% 
of sites (circle) and ≥30% of sites (diamond) with PD ≥4mm 
 
Figure 16. Predicted probability of NAFLD by tertile of the weighted genetic CRP score for study 
participants with (grey) and without (black) CDC-AAP moderate-severe periodontitis 
 
Figure 17. Predicted probability of NAFLD by serum CRP groups- low (CRP <1mg/L), average (CRP 1-
3mg/L) and high (CRP >3mg/L) for study participants with (grey) and without (black) CDC-AAP 
moderate-severe periodontitis 
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Table 7. Distribution of baseline factors according to PD ≥4mm periodontitis and Non-alcoholic Fatty Liver Disease status among participants of the Study of 
Health in Pomerania, 1997-2002 
  Proportion of sites with PD ≥4mm  NAFLD 
 Total  
(n=2,481) 
None (0%) 
(n=733) 
Moderate (<30%)  
(n=1,307) 
Extensive (≥30%) 
(n=441) 
 No  
(n=1,827) 
Yes  
(n=654) 
CRP, mg/L  1.42 (0.64, 3.01) 1.11 (0.51, 2.95) 1.48 (0.68, 3.01) 1.82 (0.82, 3.90)  1.20 (0.55, 2.95) 2.16 (0.99, 4.41) 
Age, yrs. 47.0 (34.0, 60.0) 36.0 (27.0, 56.0) 47.0 (35.0, 60.0) 55.0 (46.0, 65.0)  42.0 (31.0, 57.0) 56.0 (46.0, 65.0) 
Waist circumference (cm) 88.0 (77.2, 98.1) 83.0 (73.0, 94.0) 89.0 (78.0, 98.0) 94.0 (84.5, 103)  84.0 (74.3, 93.8) 98.5 (90.8, 106) 
Alcohol* 4.10 (1.31, 6.86) 4.56 (1.39, 6.71) 4.09 (1.31, 7.17) 3.92 (0.65, 6.41)  4.08 (1.31, 6.86) 4.28 (0.83, 6.86) 
Abdominal obesity** 747 (30.1) 170 (23.2) 389 (29.8) 188 (42.6)  383 (21.0) 364 (55.7) 
Physical activity 1,099 (44.5) 388 (53.0) 586 (45.0) 125 (28.5)  881 (48.5) 218 (33.3) 
Male gender  1,116(45.0) 281 (38.3) 592 (45.3) 243 (55.1)  740 (40.5) 376 (57.5) 
Smoking        
Never 966 (39.1) 323 (44.1) 515 (39.6) 128 (29.2)  717 (39.4) 249 (38.1) 
Former 780 (31.6) 203 (27.7) 434 (33.4) 143 (32.7)  527 (29.0) 253 (38.7) 
Current 726 (29.4) 207 (28.2) 352 (27.1) 167 (38.1)  574 (31.6) 152 (23.2) 
Diabetes mellitus 465 (18.7) 98 (13.4) 248 (19.0) 119 (27.0)  226 (12.4) 239 (36.5) 
Data are presented as No. (%) or Median (lower quartile, upper quartile) 
CDC-AAP- Centers for Disease Control and Prevention-American Academy of Periodontology 
*Number of standard drinks in the past 30 days 
**Sex-specific weight circumference defined as ≥88cm for women and ≥102cm for men (Grundy et al. 2005) 
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Table 8. Distribution of baseline factors according to CDC-AAP Periodontitis and Non-alcoholic Fatty Liver Disease status among participants of the Study of 
Health in Pomerania, 1997-2002 
   CDC-AAP  NAFLD 
 Total  
(n=2,479) 
 None/mild 
(n=1,133) 
Moderate/Severe 
(n=1,346) 
 No  
(n=1,825) 
Yes  
(n=654) 
CRP, mg/L  1.42 (0.64, 3.01)  1.08 (0.50, 2.67) 1.51 (0.73, 3.67)  1.10 (0.53, 2.71) 2.02 (0.95, 4.59) 
Age, yrs. 47.0 (34.0, 60.0)  35.0 (27.0, 49.0) 55.0 (44.0, 64.0)  42.0 (31.0, 57.0) 56.0 (46.0, 65.0) 
Waist circumference (cm) 88.0 (77.2, 98.1)  82.8 (73.0, 93.5) 92.4 (81.5, 101)  84.0 (74.2, 93.8) 98.5 (90.8, 106) 
Alcohol* 4.10 (1.31, 6.86)  4.35 (1.31, 7.17) 3.95 (1.01, 6.71)  4.08 (1.31, 6.86) 4.28 (0.83, 6.86) 
Abdominal obesity** 747 (30.2)  256 (22.6) 491 (36.5)  383 (21.0) 364 (55.7) 
Physical activity 1,099 (44.5)  584 (51.6) 515 (38.5)  881 (48.5) 218 (33.3) 
Male gender  1,115 (45.0)  445 (39.3) 670 (49.8)  739 (40.5) 376 (57.5) 
Smoking        
Non-smoker 966 (39.1)  451 (39.8) 515 (38.5)  717 (39.5) 249 (38.1) 
Former 780 (31.6)  322 (28.5) 458 (34.2)  527 (29.0) 253 (38.7) 
Current 724 (29.3)  359 (31.7) 365 (37.3)  572 (31.5) 152 (23.2) 
missing 9  1 8  1 8 
Diabetes mellitus 465 (30.2)  134 (11.8) 331 (24.6)  226 (12.4) 239 (36.5) 
Data are presented as No. (%) or Median (lower quartile, upper quartile) 
CDC-AAP- Centers for Disease Control and Prevention-American Academy of Periodontology 
*Number of standard drinks in the past 30 days 
**Sex-specific weight circumference defined as ≥88cm for women and ≥102cm for men (Grundy et al. 2005) 
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Table 9. Association between serum CRP and genetic determinants of inflammatory mediators with proportion of 
sites with PD ≥4mm and NAFLD in the Study of Health in Pomerania, 1997-2002 
 Prevalence Odds Ratio (95% CI) for the proportion of 
sites with PD ≥4mm (ref=0%) 
 Prevalence Odds Ratio (95% CI) 
for NAFLD 
 PD ≥4mm 
groups 
Crude Adjusted** 
 
Crude Adjusted** 
Serum CRP* <30% 1.19 (1.10, 1.29)  1.16 (1.06, 1.26)  
1.49 (1.37, 1.61) 1.26 (1.14, 1.39) 
 ≥30% 1.40 (1.26, 1.56) 1.23 (1.09, 1.39)  
Genetic scores*      
wGS CRP <30% 1.02 (0.69, 1.51)  
1.21 (0.82, 1.78) 
 ≥30% 1.01 (0.61, 1.69)  
wGS IL-6 <30% 0.83 (0.49, 1.40)  
0.54 (0.32, 0.90) 
 ≥30% 0.60 (0.31, 1.19)  
wGS ESR <30% 1.24 (0.53, 2.91)  
1.61 (0.69, 3.76) 
 ≥30% 0.99 (0.33, 3.04)  
wGS MCP <30% 0.88 (0.60 1.29)  
1.07 (0.73, 1.57) 
 ≥30% 1.09 (0.66, 1.80)  
*Estimate is for each unit increase in the respective genetic scores or log transformed CRP  
**Adjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption and diabetes 
 
 
Table 10. Association between serum CRP and genetic determinants of inflammatory mediators with CDC-AAP 
periodontitis and NAFLD in the Study of Health in Pomerania, 1997-2002 
 Prevalence Odds Ratio (95% CI) 
for Periodontitis 
 Prevalence Odds Ratio (95% CI) 
for NAFLD 
 Crude Adjusted**  Crude Adjusted** 
Serum CRP* 1.27 (1.19, 1.37)  1.14(1.05, 1.24)  1.49 (1.37, 1.61) 1.26 (1.14, 1.39) 
Genetic scores*     
wGS CRP 1.08 (0.77, 1.52)  1.20 (0.82, 1.77) 
wGS IL-6 1.12 (0.71, 1.77)  0.53 (0.32, 0.89) 
wGS ESR 0.78 (0.37, 1.65)  1.60 (0.68, 3.75) 
wGS MCP 1.10 (0.79, 1.53)  1.08 (0.74, 1.57) 
*Estimate is for each unit increase in the respective genetic scores or log transformed CRP  
**Adjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption and diabetes 
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Table 11. Stratified analysis for the association between the proportion of periodontal sites with PD ≥4mm (0%, 
<30%, ≥30%) and Non-Alcoholic Fatty Liver Disease according to categories of the weighted genetic CRP score 
and serum CRP levels, in the Study of Health in Pomerania, 1997-2002 
 NAFLD Prevalence Odds Ratio (95% CI) 
 Cases Non-cases Crude Adjusted* 
wGSCRP ≤1.98 (N=1,222)     
No site (0%) 65 292 Ref. Ref. 
Moderate (<30%) 166 479 1.56 (1.13, 2.15) 1.08 (0.75, 1.57) 
Extensive (≥30%) 81 139 2.62 (1.78, 3.84) 1.14 (0.72, 1.80) 
wGSCRP >1.98 (N=1,259)     
No site (0%) 68 308 Ref. Ref. 
Moderate (<30%) 182 480 1.72 (1.26, 2.35) 1.33 (0.94, 1.89) 
Extensive (≥30%) 92 129 3.23 (2.22, 4.70) 1.65 (1.07, 2.55) 
Serum CRP <1mg/L (N=972)     
No site (0%) 29 313 Ref. Ref. 
Moderate (<30%) 89 402 2.40 (1.53, 3.73) 1.62 (1.00, 2.61) 
Extensive (≥30%) 46 93 5.34 (3.18, 8.97) 2.39 (1.32, 4.31) 
Serum CRP 1-3mg/L (N=887)     
No site (0%) 48 190 Ref. Ref. 
Moderate (<30%) 151 337 1.77 (1.23, 2.57) 1.37 (0.90, 2.08) 
Extensive (≥30%) 58 103 2.23 (1.42, 3.50) 0.97 (0.57, 1.66) 
Serum CRP >3mg/L (N=622)     
No site (0%) 56 97 Ref. Ref. 
Moderate (<30%) 108 220 0.85 (0.57, 1.27) 0.70 (0.45, 1.10) 
Extensive (≥30%) 69 72 1.66 (1.04, 2.65) 1.12 (0.65, 1.93) 
*Adjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption and diabetes 
CAL-clinical attachment level 
CRP-C-reactive protein 
wGSCRP- weighted genetic score for CRP 
**Interaction p-value for the genetic CRP score=0.6 
***Interaction p-value for serum CRP levels=0.01 
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Table 12. Stratified analysis investigating the relationship between CDC-AAP periodontitis and Non-Alcoholic 
Fatty Liver Disease according to categories of the genetic CRP score and serum CRP groups, in the Study of Health 
in Pomerania, 1997-2002 
 NAFLD Prevalence Odds Ratio (95% CI) 
 Cases Non-cases Crude Adjusted* 
wGSCRP ≤1.98 (N=1,220)     
None/mild 91 463 Ref. Ref. 
Moderate/Severe 221 445 2.53 (1.92, 3.33) 1.26 (0.90, 1.76) 
wGSCRP >1.98 (N=1,259)     
None/mild 112 467 Ref. Ref. 
Moderate/ Severe 230 450 2.13 (1.64, 2.77) 1.09 (0.80, 1.50) 
Serum CRP <1mg/L (N=971)     
None/mild 49 462 Ref. Ref. 
Moderate/ Severe 115 345 3.14 (2.19, 4.52) 1.43 (0.93, 2.19) 
Serum CRP 1-3mg/L (N=887)     
None/mild 82 305 Ref. Ref. 
Moderate/ Severe 175 325 2.00 (1.48, 2.72) 1.05 (0.72, 1.52) 
Serum CRP >3mg/L (N=621)     
None/mild 72 163 Ref. Ref. 
Moderate/severe 161 225 1.62 (1.15, 2.28) 0.86 (0.56, 1.32) 
*Adjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption and diabetes 
CRP-C-reactive protein 
wGSCRP- weighted genetic score for CRP 
**Interaction p-value for genetic CRP score=0.8 
***Interaction p-value for serum CRP group=0.014 
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Figure 13. Mean serum CPR level (right vertical axis) shown as solid black line for categories of the weighted 
CRP risk score. The shaded bars show the distribution of the weighted CRP risk score in the study population 
(left vertical axis) 
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Figure 14. Predicted probability of NAFLD according to tertile of the weighted genetic CRP score for study 
participants with no site (square), <30% of sites (circle) and ≥30% of sites (diamond) with PD ≥4mm 
 
 
Figure 15. Predicted probability of NAFLD according to serum CRP groups- low (CRP <1mg/L), intermediate 
(CRP 1-3mg/L) and high (CRP >3mg/L) for study participants with no site (square), <30% of sites (circle) and 
≥30% of sites (diamond) with PD ≥4mm 
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Figure 16. Predicted probability of NAFLD by tertile of the weighted genetic CRP score for study participants with 
(grey) and without (black) CDC-AAP moderate-severe periodontitis 
Figure 17. Predicted probability of NAFLD by serum CRP groups- low (CRP <1mg/L), average (CRP 1-3mg/L) and 
high (CRP >3mg/L) for study participants with (grey) and without (black) CDC-AAP moderate-severe periodontitis 
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11.8 Supplementary material 
Supplementary Figure Legend 
 
Figure 18. Associations between known CRP SNPs and log transformed serum CRP levels measured in 
the Study of Health in Pomerania (SHIP) 
 
Figure 19. Associations between known CRP SNPs and periodontitis (proportion of sites with PD ≥4mm) 
in the Study of Health in Pomerania (SHIP) 
 
Figure 20. Associations between known CRP SNPs and periodontitis (proportion of sites with CAL 
≥3mm) in the Study of Health in Pomerania (SHIP) 
 
Figure 21. Associations between known CRP SNPs and CDC-AAP moderate-severe periodontitis in the 
Study of Health in Pomerania (SHIP) 
 
Figure 22. Associations between known CRP SNPs and Non-alcoholic Fatty Liver Disease (NAFLD) in 
the Study of Health in Pomerania (SHIP) 
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Table 13. List of SNPs used in constructing the weighted genetic scores with their original source of publication and 
the corresponding information used in constructing the respective genetic scores 
SNP Chr. Position 
Coded 
Allele 
Beta SE P-value 
Closest 
Gene 
Study 
C-reactive Protein       
rs2794520 1 157945440 C 0.160 0.006 2.0x10-186 CRP 
Dehghan et al2011; 
Naitza et al 2012 
rs4420638 19 50114786 A 0.236 0.009 8.8x10-139 APOC1 Dehghan et al 2011 
rs1183910 12 119905190 G 0.149 0.006 2.1x10-124 HNF1A Dehghan et al 2011 
rs4420065 1 65934049 C 0.090 0.005 3.5x10-62 LEPR Dehghan et al 2011 
rs4129267 1 152692888 C 0.079 0.005 2.1x10-48 IL6R Dehghan et al2011;  
rs1260326 2 27584444 T 0.072 0.005 4.6x10-40 GCKR Dehghan et al 2011 
rs12239046 1 245668218 C 0.047 0.006 1.2x10-15 NLRP3 Dehghan et al 2011 
rs6734238 2 113557501 G 0.050 0.006 1.8x10-17 IL1F10 Dehghan et al 2011 
rs9987289 8 9220768 G 0.069 0.011 3.4x10-13 PPP1R3B Dehghan et al 2011 
rs10745954 12 102007224 A 0.039 0.006 1.6x10-11 ASCL1 Dehghan et al 2011 
rs1800961 20 42475778 C 0.088 0.015 2.2x10-9 HNF4A Dehghan et al 2011 
rs340029 15 58682257 T 0.032 0.006 4.1x10-9 RORA Dehghan et al 2011 
rs10521222 16 49716211 C 0.104 0.015 8.5x10-13 SALL1 Dehghan et al 2011 
rs12037222 1 39837548 A 0.045 0.007 6.4x10-11 PABPC4 Dehghan et al 2011 
rs13233571 7 72609167 A 0.054 0.009 3.6x10-9 BCL7B Dehghan et al 2011 
rs2847281 18 12811593 A 0.031 0.006 2.2×10-8 PTPN2 Dehghan et al 2011 
rs6901250 6 117220718 A 0.035 0.006 4.8×10-8 GPRC6A Dehghan et al 2011 
rs4705952 5 131867517 G 0.042 0.007 1.3×10-8 IRF1 Dehghan et al 2011 
rs12068753  157959161 A 0.213 0.035 1.2×10-9 DARC Naitza et al 2012 
Interleukin-6 (IL-6)       
rs643434 9 135132176 G 0.245 0.026 2.7×10-21 ABO Naitza et al 2012 
Erythrocyte Sedimentation Rate (ESR)      
rs12034598 1 205824138 G 0.143 0.022 9.3×10-11 CR1 Naitza et al 2012 
rs4910742 11 5263085 A 0.229 0.042 6.3×10-8  Naitza et al 2012 
Monocyte Chemoattractant Protein (MCP-1)     
rs12075 1 157441978 A 0.303 0.026 1.7×10-30 DARC Naitza et al 2012 
rs3026968 1 157414076 T 0.239 0.033 7.6×10-13 CADM3 Naitza et al 2012 
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Table 14. Distribution of baseline factors according to serum CRP groups among participants of the Study of Health 
in Pomerania, 1997-2002 
  Low 
(CRP <1mg/L) 
Intermediate  
(CRP 1-3mg/L) 
High 
(CRP >3mg/L) 
CRP, mg/l   0.53 (0.32, 0.75) 1.84 (1.30, 2.54) 5.83 (4.05, 8.67) 
Age, yrs.  43.0 (31.0, 56.0) 47.0 (35.0, 61.0) 52.0 (37.0, 63.0) 
Waist circumference (cm)  82.8 (74.0, 92.5) 89.2 (78.8, 99.1) 94.9 (84.2, 103) 
Alcohol*  4.65 (1.34, 7.71) 4.18 (1.31, 6.86) 3.35 (0.65, 5.33) 
Abdominal obesity**  150 (15.5) 284 (32.1) 313 (50.5) 
Physical activity  485 (50.2) 366 (41.4) 248 (40.1) 
Male gender   472 (48.6) 408 (46.0) 235 (37.8) 
Smoking     
Non-smoker  385 (39.8) 332 (37.6) 249 (40.2) 
Former  289 (29.9) 307 (34.7) 184 (29.7) 
Current  293 (30.3) 245 (27.7) 186 (30.1) 
Diabetes mellitus  125 (12.9) 191 (21.5) 149 (24.0) 
Data are presented as No. (%) or Median (lower quartile, upper quartile) 
*Number of standard drinks in the past 30 days 
**Sex-specific weight circumference defined as ≥88cm for women and ≥102cm for men (Grundy et al. 
2005) 
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Table 15. Stratified analysis for the association between the proportion of sites with CAL ≥3mm (0%, <30%, ≥30%) 
and Non-alcoholic Fatty Liver Disease according to categories of the weighted genetic CRP score and serum CRP 
levels, in the Study of Health in Pomerania, 1997-2002 
 NAFLD Prevalence Odds Ratio (95% CI) 
 Cases Non-cases Crude Adjusted* 
wGSCRP ≤1.98 (N=1,222)     
No site (0%) 9 112 Ref. Ref. 
Moderate (<30%) 52 297 2.18 (1.04, 4.57) 1.34 (0.62, 2.93) 
Extensive (≥30%) 251 501 6.24 (3.11, 12.5) 1.44 (0.65, 3.19) 
wGSCRP >1.98 (N=1,259)     
No site (0%) 5 92 Ref. Ref. 
Moderate (<30%) 77 316 4.48 (1.76, 11.4) 2.99 (1.13, 7.86) 
Extensive (≥30%) 260 509 9.40 (3.77, 23.4) 2.85 (1.06, 7.64) 
Serum CRP <1mg/L (N=972)     
No site (0%) 3 103 Ref. Ref. 
Moderate (<30%) 35 308 3.90 (1.18, 12.9) 2.43 (0.71, 8.31) 
Extensive (≥30%) 126 397 10.9 (3.40, 34.9) 2.58 (0.73, 9.10) 
Serum CRP 1-3mg/L (N=887)     
No site (0%) 7 66 Ref. Ref. 
Moderate (<30%) 55 202 2.57 (1.12, 5.91) 1.67 (0.67, 4.13) 
Extensive (≥30%) 195 362 5.08 (2.29, 11.3) 1.39 (0.55, 3.52) 
Serum CRP >3mg/L (N=622)     
No site (0%) 4 35 Ref. Ref. 
Moderate (<30%) 39 103 3.31 (1.11, 9.94) 2.02 (0.64, 6.34) 
Extensive (≥30%) 190 251 6.62 (2.31, 18.9) 2.22 (0.70, 7.03) 
*Adjusted for age, sex, waist circumference, smoking, physical activity, alcohol consumption and diabetes 
CAL-clinical attachment level 
CRP-C-reactive protein 
wGSCRP- weighted genetic score for CRP 
**Interaction p-value for the genetic CRP score=0.3 
***Interaction p-value for serum CRP levels=0.2 
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Figure 18. Associations between known CRP SNPs and log transformed serum CRP levels measured in the Study of 
Health in Pomerania (SHIP) 
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Figure 19. Associations between known CRP SNPs and periodontitis (proportion 
of sites with PD ≥4mm) in the Study of Health in Pomerania (SHIP) 
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Figure 20. Associations between known CRP SNPs and periodontitis 
(proportion of sites with CAL ≥3mm) in the Study of Health in Pomerania 
(SHIP) 
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Figure 21. Associations between known CRP SNPs and CDC-AAP moderate-severe periodontitis in the Study of 
Health in Pomerania (SHIP) 
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Figure 22. Associations between known CRP SNPs and Non-alcoholic Fatty Liver Disease (NAFLD) in the Study 
of Health in Pomerania (SHIP) 
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CHAPTER 12: DISCUSSION AND SUMMARY  
The premise for the oral diseases-systemic diseases relationship dates back to the early 20th 
century when Frank Billings (Billings 1912) introduced the focal infection theory. In his position paper 
Billings wrote “…ill-fitting crowns on teeth and much bridge work may harbor septic infection in the 
mouth and produce systemic disease, and when found be removed” (Billings 1912). This statement was 
broadly interpreted, resulting in widespread tooth extractions in an attempt to control systemic diseases. 
More than two decades and thousands of extractions later, this practice was abandoned (Easlick 1951), 
but not the premise that the state of health or disease of the mouth affects general health and wellbeing. 
About a half century after Billing’s paper, it was reported that patients presenting to the emergency 
department with a heart attack were disproportionately affected by oral diseases (Mattila et al. 1989). 
Since then, reports have emerged on associations between periodontitis and coronary heart diseases 
(DeStefano et al. 1993), diabetes, chronic kidney diseases, and adverse birth outcomes (Ide and 
Papapanou 2013; Ide et al. 2011). 
While biologically plausible given findings from experimental animal models, a causal 
explanation for these associations remains in question because few intervention studies have evaluated 
systemic health benefits of treating periodontal infections (Albert et al. 2011; Kapellas et al. 2014; 
Schwendicke et al. 2015). In particular, periodontitis is associated with adverse birth outcomes (Ide and 
Papapanou 2013) but periodontal treatment did not prevent adverse birth outcomes (Michalowicz et al. 
2013). Hence the ongoing debate about the perceived effect of periodontitis on systemic diseases. 
Common chronic diseases to which periodontitis is associated have multifactorial etiologies. 
Drawing as reference Rothman’s causal pie model (i.e. the sufficient-component cause model) (Rothman 
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et al. 2008), posits that every causal mechanism involves the joint action of numerous component causes, 
which can be genetic and/or environmental factors. Furthermore, for a given disease process more than 
one causal mechanism exist, of which the component causes might be different (Rothman et al. 2008). As 
a causal mechanism for a given disease, periodontitis represents a component cause and is unlikely to 
either be necessary and/or sufficient in every possible causal setting. Because more than one causal 
mechanism with different component causes can result in the same chronic health condition, and the 
likelihood that periodontitis may not be present in every causal network, treatment failure as some have 
reported, does not by itself prove that periodontal infection has no effect on chronic health conditions.  
This report explored in great depth the putative oral-systemic diseases relationship between 
periodontitis and non-alcoholic fatty liver disease. Evidence to date of an association between 
periodontitis and NAFLD comes from experimental animal models (Tomofuji et al. 2007; Yoneda et al. 
2012) and a cross-sectional clinic-based study (Yoneda et al. 2012). Constraining these studies were their 
small study size, cross-sectional nature, and choice of non-human investigation models. To our 
knowledge, this investigation is the first prospective investigation relating periodontitis to NAFLD. It is 
based on an 11-year follow-up of more than 2,600 adults, and utilized ‘gold standard’ methods in 
epidemiologic settings for assessing periodontitis and also NAFLD. The study findings were consistent 
with greater incidence rate of NAFLD among participants with a history of periodontitis. Progression of 
periodontitis i.e. worsening periodontitis, was also associated with greater incidence of NAFLD, however 
this finding was restricted only to participants with preexisting periodontitis at baseline.  
Various mechanisms may be at play. First, an underlying hyper-inflammatory trait (Shaddox et al. 
2010), that increases the risk of initiation and progression of periodontitis, and subsequently the 
occurrence of chronic low-grade systemic inflammation commonly associated with having periodontitis. 
Second, an increased permeability in gut epithelia induced by swallowed P. gingivalis, which likely 
promotes an alteration in the gut microbial composition (Arimatsu et al. 2014). Because the liver is 
constantly exposed to gut-derived factors through the portal vein, resident liver cells become activated by 
proinflammatory factors like lipopolysaccharides, with subsequent production of cytokines and reactive 
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oxygen species (ROS) that contribute to liver injury (Imajo et al. 2014). A likely source of gut-derived 
bacterial endotoxins is periodontal pathogen derived lipopolysaccharides given that on average, about 107 
copies of periodontal bacteria are found in a mL of saliva (Saygun et al. 2011). While this investigation 
lacked microbiologic data, the findings of increased NAFLD with worsening periodontitis suggest that 
progressive loss of periodontal attachment elicits systemic responses only when progression occurs at 
deep periodontal sites that are more likely anaerobic, and capable of eliciting systemic inflammation. 
Systemic markers of inflammation have been reported to be elevated in those suffering from 
periodontitis and NAFLD. Thus, it remains unclear whether these elevated inflammatory markers are 
mediators or modifiers of the association between these two conditions. Using as a marker of systemic 
inflammatory burden, the C-reactive protein, an acute phase reactant and a non-specific marker of 
inflammation, potential modification of the periodontitis-NAFLD association was investigated by 
categories of serum CRP and genetically determined CRP. Our results were consistent with a positive 
association between serum CRP and NAFLD as well as between serum CRP and periodontitis. In 
addition, serum CRP modified the association between periodontitis and NAFLD such that the higher 
prevalence odds of NAFLD among those with periodontitis was greater in those whose serum CRP levels 
indicated low inflammatory burden (CRP <1mg/L) and lowest in those with serum CRP indicative of high 
inflammatory burden (CRP >3mg/L). This relationship, opposite to our expectation, suggests that the 
effects of periodontitis on NAFLD may be conditioned by a systemic inflammatory response of which 
CRP is a marker. Alternatively, higher levels of serum CRP may indicate the presence of competing risk 
factors for NAFLD, or CRP generated in response to hepatic injury as a result of NAFLD. These results 
also suggest that periodontitis is associated with NAFLD to some degree independent of systemic 
inflammation as indexed by serum CRP, consistent with pathways involving an alteration in gut microbial 
composition by swallowed periodontal pathogens as previously described. 
The biological mechanisms underlying the observed association between periodontitis and 
NAFLD remain to be determined, and will mostly draw on experimental studies under well-controlled 
conditions. In the setting of a rising prevalence of NAFLD in both the U.S. and around the world, this 
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investigation addressed an important gap in literature by characterizing for the first time a longitudinal 
association between periodontitis and NAFLD. If replicated, these results would suggest that periodontitis 
represents a modifiable risk factor for NAFLD, a systemic condition with potentially serious adverse 
health outcomes. Replication and experimental characterization of this association are required to gauge 
the clinical and population-wide implications of periodontitis as a modifiable risk factor for NAFLD. 
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APPENDIX 1: FIGURES 
 
 
 
Figure 23. Microbial complexes identified in the oral biofilm (source: Socransky S.S.  Periodontol 2000; 2005) 
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Figure 24. Bidirectional relationship between periodontitis, diabetes mellitus and insulin resistance (source: 
Gurav A.N. Diabetes Metab J. 2012) 
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Figure 25. Graphical exploration of the relationship between selected covariates with Non-alcoholic Fatty Liver disease risk 
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Figure 26. Graphical exploration of the relationship between selected covariates and the risk of dropping out of study 
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Figure 27. Additional trace plots for imputed variables 
 
  
 129 
 
 
  
  
  
Figure 28. Additional kernel density plots of observed and imputed values for variables with missing observations at 
the first follow-up visit 
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Figure 29. Directed acyclic graph (DAG) for Mendelian randomization analysis of periodontitis suggestive loci 
(NIN) genotype, periodontitis and Non-alcoholic Fatty Liver disease (NAFLD) risk 
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Figure 30. Proportion with periodontitis (Standard error bars) according to tertile of the genetic CRP risk score for 
cases and non-cases of NAFLD 
 
 
 
 
Figure 31. Proportion with periodontitis (standard error bars) according to the genotype of IL-6 (rs643434) for cases 
and non-cases of NAFLD. IL-6 increasing allele is the G allele 
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Figure 32. Proportion with periodontitis (standard error bars) according to the NIN genotype (rs12883458) 
periodontitis suggestive loci for cases and non-cases of NAFLD 
 
 
 
 
Figure 33. Proportion with periodontitis (standard error bars) according to the NIN genotype (rs3783412) 
periodontitis suggestive loci for cases and non-cases of NAFLD 
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APPENDIX 2: TABLES 
Table 16. CDC-AAP clinical case classification for periodontitis for population based surveillance of periodontitis 
 CDC-AAP Periodontitis Case Classification 
Disease Category Clinical attachment level (CAL)  Probing pocket depth (PD) 
Severe periodontitis 
≥2 interproximal sites with CAL ≥ 
6mm (not on the same tooth) 
AND 
≥1 interproximal site with PD 
≥5mm 
Moderate 
periodontitis 
 
≥2 interproximal sites with CAL ≥ 
4mm (not on the same tooth) 
OR 
≥2 interproximal sites with PD 
≥5mm (not on the same tooth) 
 
Mild periodontitis  
 
≥2 interproximal sites with CAL ≥ 
3mm (not on the same tooth) 
AND 
≥2 interproximal sites with PD 
≥4mm (not on the same tooth) 
OR 
≥1 interproximal site with PD 
≥5mm 
No periodontitis Neither “severe”, “moderate” or “mild” periodontitis 
(Eke et al. 2012b; Page and Eke 2007) 
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Table 17. Predictive indices of Non-alcoholic Fatty Liver Disease severity 
 BARD BARG BAAT HAIR Other 
BMI √ √ √  √ 
Age √  √  √ 
AST:ALT ratio √ √   √ 
ALT   √ √  
Albumin     √ 
Platelets     √ 
Diabetes √     
HbA1C or 
hyperglycemia 
 √   √ 
Insulin resistance 
index 
   √  
Triglycerides   √   
hypertension    √  
BARD- BMI, Age, Ratio of AST: ALT, Diabetes (Angulo et al. 1999) 
BARG- BMI, Ratio of AST: ALT, HbA1C (Adams et al. 2005a) 
BAAT-  BMI, Age, ALT, Triglycerides (Ratziu et al. 2002)- presence of 0 or 1 excludes septal fibrosis 
HAIR- Hypertension, ALT, Insulin resistance (Dixon et al. 2001)- presence of 2 or 3 factors predicts NASH 
Other- (Angulo 2005) 
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Table 18. Identification criteria for the metabolic syndrome 
ATPIII (Expert Panel on 
Detection 2001) 
(International diabetes federation) 
definition (Federation. 2005) 
AHA/NHLBI 2005 
Waist circumference (central 
obesity) > 102 cm (>40 in) in 
men and > 88 cm (>35 in) in 
women 
 
Population specific waist 
circumference: 
Europeans: ≥94cm in men and ≥80 cm 
in Women  
Asians (including Japanese): ≥90cm in 
men and ≥80 cm in Women  
 
Waist circumference (central 
obesity) > 102 cm (>40 in) in 
men and > 88 cm (>35 in) in 
women 
 
Fasting blood glucose ≥110 
mg/dl 
 
Fasting blood glucose ≥100 mg/dl (5.6 
mmol/L) OR on drug treatment for 
elevated glucose  
 
Fasting blood glucose ≥110 
mg/dl (6.11mmol/L) OR on drug 
treatment for elevated glucose  
 
Triglycerides ≥150 mg/dl  
 
Triglycerides ≥150 mg/dl (1.7 mmol/) 
OR on drug treatment for elevated 
triglycerides 
Triglycerides ≥150 mg/dl (1.69 
mmol/L) 
OR on drug treatment for 
elevated triglycerides 
HDL-cholesterol <40 mg/dl in 
men and <50 mg/dl in women 
HDL-cholesterol <40 mg/dl (1.03 
mmol/L) in men and < 50 mg/dl (1.29 
mmol/L) in women OR specific 
treatment for this lipid abnormality 
HDL-cholesterol of <40mg/dl 
(1.03mmol/L) in men and <50 
mg/dl (1.29mmol/L) in women 
OR on drug treatment for 
reduced HDL-C 
Arterial systolic/diastolic blood 
pressure ≥130/85 mmHg  
 
Systolic/diastolic blood pressure 
≥130/≥85 mmHg  
OR treatment of previously diagnosed 
hypertension 
 
Systolic/diastolic blood pressure 
≥130/≥85 mmHg  
OR on antihypertensive drug 
treatment in a patient with a 
history of hypertension 
 
Adult treatment panel III, defines metabolic syndrome as present for 3 of these 5 conditions 
AHA/NHLBI- American heart association/ National, lung, blood and heart institute 
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Table 19. Subgroup analysis of the association between periodontitis and the incidence rate of NAFLD after a 
median 7.7 years of follow-up for participants of the Study of Health in Pomerania, 1997-2012 
Covariates CAL ≥3mm 
NAFLD 
Cases (N) 
Person-Years Rate**  IRR** (95% CI) p-value 
All groups No site 60 2,005.6 14.9 1.  
 edentulous 79 3,368.7 32.1 2.15 (1.16, 4.02)  
 ≥1 site 648 17,043.4 34.4 2.31 (1.54, 3.45)  
Sex      0.12 
Male No site 16 816.4 10.0 1.  
 edentulous 15 1,820.2 26.2 2.62 (0.86, 7.97)  
 ≥1 site 191 8,045.2 34.0 3.40 (1.52, 7.60)  
Female       
 No site 44 1,189.2 19.4   
 edentulous 64 1,548.5 43.6 2.25 (0.90, 5.63)  
 ≥1 site 457 8,998.2 34.6 1.78 (1.03, 3.10)  
Age (yrs.)      0.08 
20-50 No site 57 1,920.8 18.8 1.  
 edentulous 4 161.2 25.5 1.36 (0.39, 4.70)  
 ≥1 site 286 7,968.1 27.7 1.48 (0.88, 2.47)  
>50       
 No site 3 84.7 9.20 1.  
 edentulous 75 3,207.4 44.5 4.84 (1.83, 12.8)  
 ≥1 site 362 9,075.4 38.9 4.23 (1.67, 10.7)  
*Numbers of cases is the average from 40 rounds of multiple imputation 
**Confounding and censoring due to loss to follow-up adjusted estimates 
There was an inverted U relationship between age and risk of NAFLD with the peak at approximately 50 
years old. 
Rates are expressed per 1,000 person-years 
Subgroup p-value for statistical interaction were estimated using likelihood ratio tests 
 
  
  
 
Table 20. Relationship between baseline periodontitis status and NAFLD incidence among non-smoking participants of the Study of Health in Pomerania at 
baseline followed for a median 7.7 years 
 Proportion of sites with clinical attachment level (CAL) ≥3mm 
(n=1,002) 
 Proportion of sites with Probing pocket depth ≥4mm 
(n=1,002) 
 Rate IRR (95% C.I) P 
Value 
IRD (95% C.I) P 
Value 
 Rate IRR (95% C.I) P 
Value 
IRD (95% C.I) P 
Value 
Unadjusted            
Edentulous 24.5 0.81 (0.36, 1.83) .6 -5.61 (-23.2, 12.0) .5  24.5 0.69 (0.34, 1.39) .3 -10.8 (-25.6, 3.89) .2 
No site 30.1 1 [Reference] NA 0 [Reference] NA  35.4 1 [Reference] NA 0 [Reference] NA 
<30% of sites 37.0 1.23 (0.73, 2.08) .4 6.90 (-7.72, 21.5) .4  38.8 1.10 (0.80, 1.50) .6 3.39 (-6.59, 13.4) .5 
≥30% of sites 40.0 1.33 (0.79, 2.23) .3 9.84 (-9.24, 28.9) .3  40.5 1.15 (0.67, 1.95) .6 5.14 (-12.9, 23.1) .6 
Adjusted a            
Edentulous 26.9 1.09 (0.32, 3.72) .5 2.22 (-18.1, 22.6) .8  26.0 0.72 (0.23, 2.27) .5 -10.4 (-27.5, 6.83) .2 
No site 24.7 1 [Reference] NA 0 [Reference]   36.3 1 [Reference] NA 0 [Reference]  
<30% of sites 27.6 1.12 (0.60, 2.07) .8 2.92 (-11.3, 17.2) .7  35.9 0.99 (0.71, 1.37) .9 -0.42 (-10.4, 9.61) .9 
≥30% of sites 33.2 1.35 (0.75, 2.42) .1 -8.53 (-5.52, 22.6) .2  36.2 1.00 (0.56, 178) .9 -0.14 (-17.2, -16.9) .9 
Adjusted b            
Edentulous 27.9 1.50 (0.48, 4.73) .5 9.36 (-9.90, 28.6) .3  25.9 0.83 (0.31, 2.19) .7 -5.30 (-22.1, 11.5) .5 
No site 18.6 1 [Reference] NA 0 [Reference]   31.2 1 [Reference] NA 0 [Reference]  
<30% of sites 20.5 1.11 (0.53, 2.31) .8 1.96 (-10.0, 13.9) .7  41.1 1.32 (0.74, 2.34) .3 9.89 (0.37, 19.4) .04 
≥30% of sites 32.2 1.74 (0.85, 3.55) .1 13.7 (1.61, 25.7) .03  33.7 1.08 (0.57, 2.06) .8 2.47 (-7.04, 12.0) .6 
Adjusted c            
Edentulous 27.9 1.42 (0.42, 4.82) .6 8.23 (-11.3, 27.8) .4  24.5 0.76 (0.25, 2.28) .9 -7.72 (-24.1, 8.64) .4 
No site 19.7 1 [Reference] NA 0 [Reference]   32.2 1 [Reference] NA 0 [Reference]  
<30% of sites 21.9 1.11 (0.56, 2.21) .7 2.26 (-10.2, 14.7) .7  41.0 1.27 (0.69, 2.34) .05 8.81 (-0.78, 18.4) .07 
≥30% of sites 33.8 1.72 (0.92, 3.21) .09 14.1 (1.51, 26.7) .03  29.8 0.93 (0.45, 1.91) .3 -2.41 (-18.3, 13.5) .8 
All estimates were averages from 40 rounds of multiple imputation combined using Rubin’s rule and the variance a function of the within and between 
completed dataset variances. 
IRR-Incidence rate ratio; IRD-incidence rate difference 
Rates and IRD are expressed per 1,000 person-years 
Adjustment variables:  age, sex, waist circumference, BMI, physical activity, alcohol consumption, education, smoking and diabetes 
a Adjusted for confounders only, using Inverse probability of exposure weights 
b Adjusted for confounders and censoring due to loss-to-follow-up (LTFU) 
c Adjusted for confounders and censoring from any reason (including LTFU, end of follow-up, excessive alcohol consumption, hepatitis diagnosis in past year, 
use of hepatotoxic medications) 
1
3
7 
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Table 21. Gene abbreviations and name 
ABO 
alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-
galactosyltransferase 
APOC1 apolipoprotein C1 
ASCL1 achaete-scute family bHLH transcription factor 1 
BCL7B BCL tumor suppressor 7B 
CADM3 cell adhesion molecule 3 
CR1 complement C3b/C4b receptor 1 (Knops blood group) 
CRP C-reactive protein 
DARC atypical chemokine receptor 1 (Duffy blood group) 
GCKR glucokinase regulator 
GPRC6A G protein-coupled receptor class C group 6-member A 
HNF1A HNF1 homeobox A 
HNF4A hepatocyte nuclear factor 4 alpha 
IL1F10 interleukin 1 family member 10 (theta) 
IL6R interleukin 6 receptors 
IRF1 interferon regulatory factor 1 
LEPR interferon regulatory factor 1 
NLRP3 NLR family pyrin domain containing 3 
PABPC4 poly(A) binding protein cytoplasmic 4 
PPP1R3B protein phosphatase 1 regulatory subunit 3B 
PTPN2 protein tyrosine phosphatase, non-receptor type 2 
RORA RAR related orphan receptor A 
SALL1 spalt like transcription factor 1 
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Table 22. Investigating Periodontitis suggestive SNPs as instrumental variables with the odds of NAFLD among 
baseline participants of the SHIP, 1997-2002 
   Odds ratio (95% CI) 
   Periodontitis  NAFLD 
SNPs/risk allele RAF Gene* Moderate Severe   
rs3783412 /G** 0.49 NIN 1.09 (0.96, 1.24) 1.17 (1.00, 1.36)  1.07 (0.94, 1.22) 
GA/AA   1.07 (0.87, 1.32) 0.99 (0.77, 1.29)  0.97 (0.78, 1.20) 
GG/AA   1.19 (0.92, 1.54) 1.36 (1.01, 1.83)  1.15 (0.90, 1.48) 
       
rs12883458 /C** 0.09 NIN 0.74 (0.58, 0.93) 0.99 (0.76, 1.28)  0.84 (0.65, 1.07) 
CT/TT   0.72 (0.57, 0.93) 0.92 (0.69, 1.22)  0.81 (0.63, 1.04) 
CC/TT   0.62 (0.19, 2.08) 1.74 (0.60, 5.05)  1.04 (0.39, 2.93) 
*chromosome 14q21 
**Odds ratio is interpreted as the odds for each additional increase in the risk allele and assumes an additive 
genetic model. RAF- risk allele frequency 
Both SNPS are from the NIN gene region. rs12883458 in the NIN region was first identified by Divaris et al 
2013 (Divaris et al. 2013) and replicated by Shaffer et al 2014 (Shaffer et al. 2014) with another SNP 
rs3783412. These SNPs are suggestive loci for periodontitis as they did not reach the genome-wide significant 
threshold of 5 x10-8 
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Table 23. Distribution of potential confounders by periodontitis suggestive loci (NIN) genotype (rs12883458 and 
rs3783412) among baseline participants of the SHIP, 1997-2002  
 rs12883458 
(%) 
 rs3783412 
(%) 
 
 CC CT TT P value GG GA AA P value 
All (No.) 18 400 2,061 0.7* 572 1,246 661 0.6* 
Age mean (SD) 51.6 45.5 47.5 0.03 47.0 47.1 47.4 0.9 
Male sex 44.4 45.0 45.0 0.9 45.5 44.4 45.7 0.8 
Abdominal obesity 33.3 26.8 30.8 0.3 29.2 28.9 33.3 0.1 
Current smokers 22.2 30.0 29.3 0.9 30.0 29.3 28.8 0.9 
Physical activity 50.0 46.1 44.2 0.7 43.8 46.0 42.4 0.3 
Diabetes 16.7 17.3 19.1 0.3 20.5 17.2 20.3 0.2 
p-values are from t-tests for difference in means for continuous variable (age) or from chi-sq. test for 
differences in proportions for categorical variables 
*Test for Hardy-Weinberg equilibrium 
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